Yale University

EliScholar – A Digital Platform for Scholarly Publishing at Yale
Yale Graduate School of Arts and Sciences Dissertations
Fall 10-1-2021

Regulation of TIM-3 by Phosphatidylserine
Courtney McCaul Smith
Yale University Graduate School of Arts and Sciences, courtneymsmith15@hotmail.com

Follow this and additional works at: https://elischolar.library.yale.edu/gsas_dissertations

Recommended Citation
Smith, Courtney McCaul, "Regulation of TIM-3 by Phosphatidylserine" (2021). Yale Graduate School of
Arts and Sciences Dissertations. 415.
https://elischolar.library.yale.edu/gsas_dissertations/415

This Dissertation is brought to you for free and open access by EliScholar – A Digital Platform for Scholarly
Publishing at Yale. It has been accepted for inclusion in Yale Graduate School of Arts and Sciences Dissertations
by an authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more
information, please contact elischolar@yale.edu.

Abstract
Regulation of TIM-3 by Phosphatidylserine
Courtney McCaul Smith
2021
TIM-3, or T cell, immunoglobulin, and mucin domain-containing protein-3, is a
transmembrane glycoprotein expressed by several types of immune cells, including T
cells, making it an important regulator of the immune response. However, the biology of
TIM-3 is complicated, as it has been shown to variously promote and inhibit the function
of T cells and other immune cells. Understanding the contexts in which TIM-3 serves
these dual roles has remained difficult, as the ligands that regulate the activity of this
receptor are still unclear. Several molecules have been proposed to regulate TIM-3,
including phosphatidylserine (PS), galectin-9, carcinoembryonic antigen-related cell
adhesion molecules 1 (CEACAM1), and high motility group box 1 (HMGB1). The
majority of the literature has focused on galectin-9, a bivalent glycan-binding molecule
with additional binding partners, making it unclear if galectin-9 has TIM-3-specific
effects. Phosphatidylserine, on the other hand, is of particular interest, despite its lack of
attention in the literature. The TIM family are known as PS receptors with important
roles in recognizing and clearing apoptotic cells. Previous studies confirm the ability of
TIM-3 to bind PS, but additional studies on its ability to modulate TIM-3 function,
beyond phagocytosing apoptotic cells, are lacking.
The main goal of my dissertation was to determine how ligand regulation, in
particular, PS-binding, contributes to TIM-3 function. I also investigated how galectin-9
might impact the interaction between these components. In the first aim of my work, I
explored the ability of TIM-3 to bind membranes containing PS. I utilized surface

plasmon resonance, an approach that mimics the lipid context TIM-3 might encounter in
a cellular setting, to investigate the lipid binding of human TIM-3 and its relatives. I
found that TIM-3 bound to PS-containing membranes with low micromolar affinity,
weaker than its family members, but in range with other receptor-ligand pairs involved in
regulating the immune response. I also demonstrated the importance of calcium and
contacts with the hydrophobic PS acyl tail for TIM-3–PS binding. Using mutated variants
of galectin-9, I showed that a potential role of this bivalent lectin is to crosslink TIM-3 to
enhance its avidity for PS. In the second aim of my thesis, I asked how the TIM-3–PS
interaction modulated T cell activity. In line with other reports in the literature, I found
that TIM-3 promoted activity in the Jurkat T cell model across several readouts, including
transcriptional activation and cytokine release. Interestingly, I observed that PS was
exposed in Jurkat cell culture, which is not unexpected as cells in culture undergo
apoptosis and activation, two processes in which PS can be exposed on the plasma
membrane outer leaflet. Importantly, I demonstrated that the TIM-3 extracellular, ligandbinding region, and in particular, the ability to bind PS, contributed to TIM-3’s effect of
promoting T cell activity in this model. Reducing PS binding with mutations or antibody
blockade specifically reduced the ability of TIM-3 to promote T cell activity. Together,
these findings support a role for PS as a ligand of TIM-3 that regulates the impact of this
receptor on T cell signaling, thus enhancing our understanding of the regulation of TIM-3
by its ligand PS. Furthermore, they suggest that multiple ligands might simultaneously
modulate TIM-3 to determine the nature of its effect. As therapies targeting TIM-3 move
towards the clinic with the goal of enhancing anti-tumor immunity, it will be important to

understand whether and how each ligand of TIM-3 modulates its activity in different
immune cells to ensure optimal targeting of this unique immune-regulatory receptor.
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CHAPTER 1. Introduction
1.1. T cells in immunity and disease
1.1.1. The role of T cells in adaptive immunity
The immune system plays an important role in protecting the human body from disease,
constantly surveilling our body for foreign threats. Both the innate and adaptive immune
responses contribute to this key role. While the innate immune system is broad and fastacting, allowing our bodies to respond quickly to foreign pathogens, the adaptive
immune response is specific and develops memory, helping to protect us against future
exposure to any pathogen that we have already encountered. Cell surface receptors play
an essential role in both of these processes, helping to sense particular patterns of foreign
pathogens in the case of the toll-like receptors in the innate immune response1, for
example. Other receptors, like the B cell receptor (BCR), undergo massive
diversification early in our life to permit recognition of an enormous variety of foreign
peptides not expressed by our own bodies2. Still other surface receptors help to sense the
broader environment in the body, including soluble or membrane-bound signals, that
allow immune cells to communicate with each other to enhance the immune response or
dampen its activity3,4. Together, recognition of these many signals is essential in the fine
tuning of our immune response to ensure that it is active enough to clear foreign
substances, but not so active that it damages our own tissues.
Reacting to specific pathogens is a key function of the adaptive immune response,
which includes both B cells and T cells. B cells are responsible for producing antibodies
that can neutralize specific pathogens. T cells are capable of directly killing pathogeninfected cells, and can also release signals to direct the function of other immune cells.
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During differentiation, T cells form subsets with specific functions. CD8+ T cells, also
known as cytotoxic T lymphocytes, are capable of directly killing cells that display
foreign antigens5. Expression of the co-receptor CD4, on the other hand, marks another
major T cell subset known as helper T cells for their ability to promote the activity of
other immune cells. CD4+ T cells include Th1 cells, which release cytokines that help
activate CD8+ T cells and macrophages to clear intracellular pathogens, as well as Th2
cells, which release cytokines to promote clearance of larger, extracellular pathogens6.
Although they display distinct downstream effector functions, both CD4+ and
CD8+ T cells are activated in a similar manner. The T cell receptor (TCR) is the key
determinant of cell activation for both of these T cell subsets. Like the BCR, the TCR
undergoes immense diversification during development to allow recognition of a variety
of foreign antigens that we might encounter throughout our lifetime2. Peptide antigens
must be presented by major histocompatibility complex (MHC) molecules to be
recognized as the ligand for the TCR. When this occurs, TCR signaling activates T cells,
allowing them to undergo clonal expansion and differentiation to effector T cells7
(Figure 1.1). As their name suggests, effector T cells gain new functional capabilities,
including expression of cytokines, or cytotoxic molecules in the case of CD8+ T cells.
These differentiated effector cells continue to carry out their function until the antigen
source is cleared, at which point the loss of antigen initiates programmed cell death to
prevent inappropriate immune activity that might lead to tissue damage8,9. Not all cells
die off, however, as a small population of cells that retain self-renewal capacity in the
absence of antigen (called memory T cells) continue to persist in the body. These cells do
not actively carry out effector functions and are quiescent in the absence of stimulation,
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Figure 1.1) Progression of T cell differentiation following activation
Schematic showing the differentiation of effector T cells. Naïve T cells containing distinct
and diverse T cell receptor (TCR) clones circulate through the body, patrolling for their
cognate antigen. Peptide antigens are presented by major histocompatibility complex
(MHC) molecules on the surface of antigen presenting cells (APC) to the TCR on naïve T
cells. Engagement of TCR and co-stimulatory molecules leads to clonal expansion and
gaining of effector T cell function. Shown in the inset, differentiated effector T cells carry
out cytotoxic activity with cytokines IFN-γ and TNF-α and cytotoxic molecules perforin
(PFN) and granzyme B (GzmB). As cells containing the cognate antigen are killed and
cleared, loss of antigen presentation (above second arrow) leads to contraction of the
effector cells. Self-propagating memory cells persist in the pool of circulating lymphocytes
in the absence of antigen. This image was created using BioRender.
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but can quickly mount a response if and when the body encounters that particular antigen
again.

1.1.2. T cell receptor signaling
Between engagement of the TCR by peptide-bound MHC (pMHC) and the resulting
activation of the T cell, a complex and coordinated signaling cascade is engaged to
promote the cellular changes resulting in activation. This cascade is initiated by Lck, a
tyrosine kinase that is recruited to the intracellular regions of the TCR co-receptors, CD4
or CD8 in their respective T cell subsets7. Activated Lck phosphorylates tyrosines in the
immunoreceptor tyrosine-based activation motifs (ITAMs) of the TCR CD3γ, δ, ε, and z
chains, which recruit the tyrosine kinase Zap70 (Figure 1.2). Zap70 is then activated by
Lck, and continues this signaling cascade by phosphorylating the adaptor protein LAT.
Additional signaling molecules are recruited to phospho-LAT to promote their respective
signal transduction. These molecules include the adaptor Grb2 and the guanine
nucleotide exchange factor SOS1 that activate RAS/MAPK signaling, phospholipase C
γ1 (PLCγ1) that promotes intracellular calcium signaling, and the adaptor proteins
GADS and SLP-76 that promote cytoskeletal rearrangement. As a consequence of this
signal transduction cascade, several transcription factors are activated, including NF-κB,
NFAT, and AP-1. Activation of these molecules leads to transcriptional changes that
promote expression of cytokines (including IL-2), cell cycle components, and cytotoxic
molecules, in the case of CD8+ cells. Ultimately, these transcriptional programs permit
the changes in T cell activity that give rise to the clonal expansion and cytokine release
of effector T cells.
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Figure 1.2) The T cell receptor (TCR) signaling cascade
Schematic summary of the T cell receptor signaling cascade. The inset shows an overview
of the components involved in the interaction between an antigen presenting cell (APC)
and a T cell. The peptide-MHC complex, expressed by the APC, is recognized by the TCR
on the T cell. Interactions between the pMHC and TCR with sufficient dwell time allow
signal propagation. The kinase Lck initiates the signaling cascade and phosphorylates
tyrosines in the intracellular CD3z chains of the TCR complex. The kinase Zap70 is
recruited to phospho-CD3, where it is activated by Lck. Zap70 then phosphorylates LAT,
a key adaptor protein that serves as a hub for additional signaling molecules in this cascade,
including PLCγ1, Grb2/SOS1, and GADS/SLP-76. These molecules promote activation of
calcium and RAS/MAP kinase signaling, as well as cytoskeletal rearrangement.
Downstream of these signals, transcription factors NF-κB, AP-1, and NFAT are activated
and translocate to the nucleus to promote transcription of genes for T cell activity, including
IL-2, granzymes (Gzm), perforins (PFN), and cell cycle components. This figure was
created using BioRender
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The signaling components involved in the TCR cascade were identified
throughout the 1980s and 1990s, and the Jurkat T cell line played a central role in these
studies. Jurkat T cells are a human leukemic T cell line. They were first identified by
Steven Gillis, James Watson, and John Hansen as a transformed T cell line that released
the cytokine and marker of T cell activation IL-2 following their stimulation10.
Consistent with findings in primary T cells11, Jurkat T cells displayed maximal IL-2
secretion with ligation of both the TCR and the co-receptor CD28. Additional studies
using the parental Jurkat cell line identified several key factors of the TCR signaling
cascade, including that TCR engagement led to protein phosphorylation and calcium
flux12-14. Furthermore, Jurkat cells were essential in the characterization of Lck, Zap70,
and LAT and their roles in TCR signaling15-17. In summary, Jurkat T cells preserve
signaling changes observed in primary T cells, such as IL-2 secretion, changes in
phosphorylation of TCR components, and changes in activity of transcription factors
involved in T cell signaling, such as NF-κB, making them a useful tool in studying T
cells and TCR signaling.
It is important to note that Jurkat cells are deficient for phosphatase and tensin
homolog (PTEN) and SH2 domain-containing inositol 5’-phosphatase (SHIP), two lipid
phosphatases18. Loss of PTEN in particular results in constitutive activation of Akt
downstream of phosphatidylinositol 3-kinase (PI3K), as PTEN is unavailable to
dephosphorylate the PtdIns(3,4,5)P3 produced by PI3K. However, loss of SHIP and
PTEN do not prevent Jurkat cells from responding to T cell stimulation by ligands of the
CD3 component of the TCR and CD28, as described above. The Jurkat T cell line has
therefore remained an important and useful tool for studying TCR signaling since its
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discovery in the 1980s, as they are an immortalized cell line with less variability than
primary T cells10.

1.1.3. T cell co-signaling receptors
Though the TCR complex is the primary driver of signaling in T cells, as described
above, additional cell surface receptors are capable of modulating this signaling pathway.
These co-signaling molecules can have either stimulatory or inhibitory effects on T cell
signaling and activity4 (Figure 1.3). The canonical co-stimulatory receptor is CD28.
CD28 is a single-pass transmembrane receptor expressed by T cells as a disulfide linked
dimer11. The ligands of CD28 are CD80 and CD86, which are expressed on activated
antigen-presenting cells, along with the pMHC complex. As mentioned above, CD28 is
an important second signal in T cell activation, as engagement of both the TCR and
CD28 yields an enhanced response compared to TCR engagement alone11. Similar to the
CD3 chains of the TCR, CD28 is capable of recruiting signaling molecules in its
cytoplasmic region. Phosphorylation of tyrosines in these ITAMs recruits PI3K, and
additional proline-rich motifs recruit other signaling molecules, including Grb2 and
GADS (Figure 1.3A). The overlap of these components with many TCR signaling
molecules highlights the ability of CD28 to augment the TCR cascade. CD28 is not the
only co-stimulatory molecule, however. Additional co-stimulatory receptors include
ICOS, 4-1BB, and OX40, and these receptors respond to distinct ligands to also promote
T cell activation4,19.
In addition to these co-stimulatory receptors, T cells express co-receptors with
inhibitory functions, termed co-inhibitory receptors. Similar to co-stimulatory molecules,
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Figure 1.3) Co-receptors modulate TCR signaling
Schematic of T cell co-receptors and their role in TCR signaling. The final outcome on T
cell signaling will be determined by the net engagement of co-stimulatory and co-inhibitory
receptors on the T cell (blue) by their ligands on antigen presenting cells (purple)4.
BioRender was used to create this figure.
(A) The co-stimulatory receptor CD28 is engaged by its ligands CD80 or CD86. Upon
phosphorylation of tyrosines in the cytoplasmic region of CD28, signaling molecules,
including Grb2 and PI3K, are recruited. CD28 engagement thus enhances T cell activation.
(B) Co-inhibitory receptors, such as CTLA-4 and PD-1, reduce T cell activation. CTLA-4
competes with CD28 for binding to ligands CD80 and CD86. PD-1 recruits phosphatases
through the ITIM and ITSM in its cytoplasmic tail. In particular, Shp-2 has been shown to
preferentially reduce phosphorylation of CD28. CTLA-4 can also localize phosphatases
through its cytoplasmic tail.
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T cells express many distinct co-inhibitory receptors that recognize their ligands to
reduce T cell activity4,19. One of these receptors, cytotoxic T-lymphocyte associated
protein-4 (CTLA-4), directly antagonizes the function of CD28 (Figure 1.3B). The
ligands of CD28, CD80 and CD86, are also recognized by CTLA-4. In fact, CTLA-4
displays stronger affinity for these ligands, and thus competes with CD28 to inhibit the T
cell response20. Although CTLA-4 does not contain a canonical immunoreceptor
tyrosine-based inhibitory motif (ITIM) in its cytoplasmic tail, it is reported to bind Src
homology region 2 domain-containing protein phosphatase (Shp-2) and protein
phosphatase 2 (PP2A), that can reduce phosphorylation induced by TCR ligation20. In
addition to CTLA-4, another canonical co-inhibitory receptor is PD-1, or programmed
cell death protein-1 (Figure 1.3B). PD-1 has two ligands that are distinct from those of
CD28/CTLA-4: PD-L1 and PD-L2. PD-1 is expressed on the cell surface following
engagement of the TCR, and thus can be considered a marker of T cell activation. The
cytoplasmic tail of PD-1 contains an ITIM and an immunoreceptor tyrosine-based switch
motif (ITSM) that are capable of recruiting protein tyrosine phosphatases Shp-1 and Shp2 that can counteract the kinase signaling cascade that is initiated upon TCR ligation21.
Therefore, the expression of PD-1 upon T cell activation serves as an important
checkpoint, ensuring that the cell has appropriate and sufficient secondary stimulatory
signals (through CD28 and other receptors) to overcome the negative effect of PD-1 and
activate effector functions. Of note, Jurkat cells have also proven useful in studying the
inhibitory mechanisms of PD-1, indicating the utility of Jurkat T cells in understanding
how co-receptors modulate T cell activity and TCR signaling22-24.
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1.1.4. Kinetic proofreading
As a T cell searches for the cognate pMHC for its TCR, it will encounter many antigens
presented by MHC molecules. However, a T cell must respond with strong specificity
and selectivity only for foreign peptide antigens, and not self-antigens, in order to avoid
incorrect immune response against the body, which could result in autoimmune and
inflammatory conditions. As proposed by McKeithan (1995), kinetic proofreading best
explains the ability of T cells to discriminate self- from non-self-antigens in order to
control their immune response25,26. In this model, peptide-MHC complexes that engage
with the TCR for long dwell times, or duration of interaction, are needed to permit
necessary modifications (i.e. phosphorylation) needed for signal propagation to
accumulate – as constant phosphatase activity works against the protein phosphorylation
induced by TCR engagement. Indeed, optogenetic experimental approaches using light
pulsing to control the duration of engagement of the TCR support the model of kinetic
proofreading, estimating a 5-10 second half-life as a threshold needed for propagation of
major signals downstream of the TCR27,28. Jurkat cells served as a model system in these
studies, where Zap70 recruitment and calcium flux were used to measure T cell activity.
Another key component of this model is the formation of signaling clusters, as an
additional step for kinetic proofreading. When a T cell interacts with an antigen
presenting cell displaying its cognate antigen, an intercellular junction called an immune
synapse is formed. In these synapses, the cellular adhesion molecule ICAM-1 helps to
confine cell surface receptors involved in T cell signaling, while also excluding
inhibitory phosphatases, like CD4529. The TCR and pMHC form smaller complexes
within the larger immune synapse. Clustering also occurs in intracellular components,
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where, for example, the multivalent nature of the signaling component Grb2 binding to
both LAT and SOS1 promotes their oligomerization that can promote propagation of
signals from the TCR30. Dwell time of ligand interaction is also linked to receptor
clustering, as ligands with longer dwell times have been shown to promote TCR
clustering and increased receptor phopshorylation31. Phosphorylation of TCR
components can also be modified by co-stimulatory and co-inhibitory receptors, which
can be clustered within the immune synapse22,29,32. These co-receptors track kinases and
phosphatases into signaling complexes through their cytoplasmic regions, as described
above. Therefore, the activity of any given T cell is determined by the sum of the TCR
engagement and the presence of any co-stimulatory and/or co-inhibitory receptors
engaged in that cell – with the result likely to be kinetically defined.

1.1.5. T cell dysfunction in disease
The biological processes described above control T cell activation and ensure that an
immune response occurs only in the presence of foreign antigens. In some cases,
however, aberrant immune responses can occur as a result of hyper- or hypoactivation. In
the former, T cells can become inappropriately activated in the absence of antigen,
resulting in auto-immune diseases33. A common approach to combating and treating
these diseases is blocking co-stimulatory signaling. This therapeutic strategy removes the
second signal that permits effective T cell activation. For example, the soluble region of
CTLA-4 linked to a portion of human immunoglobulin (CTLA-4-Fc) is a therapeutic
strategy for autoimmune diseases including rheumatoid arthritis and psoriasis33. CTLA4-Fc competes for ligand binding with CD28, thus blocking its stimulatory effect and
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decreasing aberrant T cell activity. Therapies targeting additional co-stimulatory
receptors and their ligands, including CD40/CD40L, OX40, and ICOS/ICOSL, are
currently under investigation in other disease contexts involving hyperactivity of T
cells33.
Conversely, some disease contexts include a hypoactive and dysfunctional
immune response, requiring the opposite therapeutic intervention – increased immune
activation. In a typical immune response, effector T cells will successfully clear the
antigen source, undergo cell death, and leave only memory T cells that self-propagate in
the absence of antigen (Figure 1.1). However, when the source of antigen fails to be
cleared by the immune system, such as in chronic viral infections or in cancer, a distinct
and dysfunctional population of T cells, called exhausted T cells, forms as a result of this
chronic stimulation (Figure 1.4). Exhausted T cells were first identified in the
lymphocytic choriomeningitis virus (LCMV) model of chronic infection34,35. Decreased
proliferation, reduced effector functions, and increased expression of co-inhibitory
receptors are classic features of exhausted T cells36,37. Tumor cells can similarly act as a
chronic source of antigen, and indeed, exhausted T cells are observed in mouse tumor
models and in cancer patients38,39. Additional work has shown that exhausted T cells
display distinct epigenetic, transcriptional, and metabolic profiles compared to functional
effector cells and memory cells40-43.
Expression of inhibitory receptors by exhausted T cells suggested a potential
therapeutic intervention: blocking the inhibitory signals from these receptors to reactivate
the defective immune response19,44. Indeed, antibody blockade of the interaction between
PD-1 and its ligand, PD-L1, is capable of reactivating the immune response in the
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Figure 1.4) T cells become exhausted and dysfunctional upon chronic stimulation
Under conditions of acute stimulation, effector T cells form, which maintain effector
functions, including cytokine release and proliferation. Effector T cells express coinhibitory receptors as a homeostatic response to T cell activation. Exhausted T cells
develop under chronic stimulation, such as in chronic viral infection and in cancer.
Compared to functional effector T cells, exhausted T cells have reduced proliferative
capacity and ability to release cytokines. Increased expression of inhibitory receptors is a
key feature of exhausted T cells. This image was created with BioRender.
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LCMV model45 and also in cancer models46, prompting exploration of PD-1/PD-L1
blockade in the clinic. This strategy is often referred to as immune checkpoint blockade
(ICB), as blocking this inhibitory receptor relieves a suppressive checkpoint of T cell
activity. In the clinic, therapeutic blockade of the PD-1/PD-L1 axis has shown great
promise in treating cancer. Some patients observe durable response to PD-1 blockade,
which can be observed for years44,47, representing an important paradigm shift in cancer
treatment. However, the majority of patients do not respond to this approach, and those
that do can develop resistance19,48. Therefore, both academia and industry alike have
endeavored to identify new targets that might enhance immune responses to cancer. As
exhausted T cells express multiple co-signaling receptors in addition to PD-137,41,
targeting these additional molecules to promote enhanced anti-tumor immune activity is
one strategy to expand the arsenal of ICB therapies for cancer patients. One such target is
TIM-3, which is a unique and complex co-receptor in the immune system.

1.2. T cell, immunoglobulin, and mucin domain-containing protein-3 (TIM-3)
1.2.1. The TIM receptor family
T cell, immunoglobulin, and mucin domain-containing protein-3 (TIM-3) is a member of
the TIM protein family found in animals and other vertebrates. The TIM family was first
identified in a gene locus that was protective against airway hyperreactivity in a mouse
model of asthma49. The murine TIM family includes 8 genes, 4 of which are confirmed to
be expressed as proteins in mice (TIM-1, TIM-2, TIM-3, and TIM-4)50. In humans, 3
TIMs have been identified: TIM-1, TIM-3, and TIM-4, named for their homology with
the murine TIMs50.
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The domain architecture is similar across the TIM family. TIM-3 and its family
members TIM-4 and TIM-1 are type 1 transmembrane glycoproteins. They contain an Nterminal signal sequence, immunoglobulin-like V-type (IgV) and mucin domains in their
extracellular region, followed by a single-pass transmembrane helix and a short
cytoplasmic tail (Figure 1.5A). The TIMs have similar amino acid sequences in their
IgV domains, but are more divergent in their mucin domains and cytoplasmic regions51
(Figure 1.5B). TIM-3, like other family members, contains several N- and O-linked
glycosylation sites in its extracellular region52. The cytoplasmic domain of human TIM-3
is 77 residues long, which is 11 longer than the cytoplasmic region of murine TIM-3. Six
tyrosines in the TIM-3 C-tail are conserved in both human and murine homologs53.
Unlike other co-receptors in the immune system, however, these tyrosines do not fall into
a characterized immunoreceptor tyrosine-based inhibitory or activating motif
(ITIM/ITAM), known to recruit phosphatases or kinases upon phosphorylation to
modulate immune cell signaling54,55. Even though they are not located within such a
canonical motif, at least two tyrosines, Y244 and Y251 in humans (Y265, Y272 by
immature numbering) and Y237 and Y244 (Y256, Y263 by immature numbering) in
mice, are reported to be important for the function of TIM-3, as their mutation or deletion
reduces phosphorylation and function of TIM-356-59. These tyrosines are also conserved
in TIM-1 (Y335 and Y341 in mature, human TIM-1), but are not found in TIM-4, which
has only two tyrosines at distinct sites in its C-tail.
The TIM proteins are expressed on various cells in the immune system, where
they play important roles in regulating the immune response. Cells in both the innate and
adaptive immune system express TIM-3, including T cells, natural killer (NK) cells,
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Figure 1.5) TIM family members share a similar domain architecture
(A) Schematic of the domain architecture of the human TIM family members, including
TIM-3 (red), TIM-1 (teal), and TIM-4 (green). All TIMs contain an N-terminal signal
sequence (SS), an immunoglobulin-like V-type domain (IgV), a mucin domain, a
transmembrane helix (TM), and a C-terminal cytoplasmic tail (Cyto). The amino acid
numbers corresponding to the start of each region of the protein are listed in black.
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(B) Sequence alignment of the amino acid sequences of human TIM-3, TIM-1, and TIM4, performed using Clustal Omega Multiple Sequence Alignment (https://www.ebi.ac.uk/
Tools/msa/clustalo/)51. Amino acid numbers corresponding to the immature peptide
sequence are found on the far right. Dots underneath the sequence alignment denote
sequence similarity, while stars indicate sequence identity. Cysteines that form the three
disulfide bonds in the TIM IgV domain are highlighted in green. The residues involved in
cation coordination are highlighted in yellow and are conserved across these TIMs.
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dendritic cells (DCs), macrophages, and monocytes. The function of TIM-3 is complex
and incompletely understood. On T cells, TIM-3 has been shown to be capable of costimulating and co-inhibiting T cell activity depending on the study, although the
determinants of its activity remain unclear. A detailed discussion of TIM-3 function can
be found in Section 1.2.3, below. TIM-1 is also called Hepatitis A virus cellular receptor
1 (HAVCR1) or kidney injury molecule-1 (KIM-1), named for its roles in mediating
entry of Hepatitis A virus and in responses to kidney injury60,61. TIM-1 is expressed on
effector T cells, regulatory T cells, mast cells, and macrophages in the immune system,
as well as kidney cells following ischemic injury62. In the Jurkat T cell model, ectopic
expression of TIM-1 enhances T cell activity, and the cytoplasmic region of TIM-1 is
required for this effect63. Interestingly, TIM-1, like its family member TIM-3, also
appears to be capable of co-inhibitory activity in addition to its co-stimulatory role.
Unlike TIM-3, however, the factors contributing to the direction of TIM-1’s effect are
known. Changes in both antibody avidity and antibody epitope have been shown to
switch the direction in which TIM-1 modulates T cell function, supporting a role for
ligand binding of the TIM-1 extracellular domain in determining its effect 64,65. TIM-4,
on the other hand, is distinct from its family members in that is not expressed on T cells
and is found exclusively on antigen presenting cells66. TIM-4 plays a key role in these
phagocytic cells, recognizing apoptotic cells via their elevated expression of
phosphatidylserine (PS)67 to facilitate their clearance68,69. Although TIM-4 was the first
member of the TIM family identified as a PS receptor, TIM-1 and TIM-3 have
subsequently been shown to bind PS as well68,70-72, suggesting that the TIMs constitute a
family of PS receptors.
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1.2.2. Structure of TIM-3 and its family members
Previous studies have solved the crystal structures of the immunoglobulin-like V-type
(IgV) domain of TIM-3, TIM-4, and TIM-1. The canonical immunoglobulin fold is made
up of two β-sheets, connected by a single disulfide bond73. The IgV domain of the TIM
family is unique, in that it contains four noncanonical cysteines that are conserved across
the family and form two additional disulfide bonds (Figure 1.5B). These unique
disulfide bonds fold the loop connecting the C and C’ β-strands (CC’ loop) up, towards
the N-terminal region of the protein. As a consequence, a unique pocket is formed
between the CC’ loop and the FG loop. Crystal structures of the TIM family demonstrate
that this pocket is observed in TIM-3, TIM-4, and TIM-174-76 (Figure 1.6). This pocket
has been termed the MILIBS, for metal ion-dependent ligand binding site. Indeed, a
cation (sodium or calcium) has been resolved in the unliganded structures of TIM-4 and
TIM-375,77, though additional structures of TIM-3 and TIM-1 show that the pocket does
not necessarily require a metal ion74,76. Two residues, an asparagine and an aspartate
(N98/D99 in mature human TIM-3, N119/D120 by immature numbering), along with
several backbone residues are particularly important for coordinating the cation in the
MILIBS.
Additional work identified the ligand bound in the TIM family MILIBS. Cocrystal structures of TIM-4 and TIM-3 with a soluble, short chain form of
phosphatidylserine (dicaproylphosphatidylserine, DCPS) show that the conserved
MILIBS is indeed the binding site for PS72,75 (Figure 1.6A,B). The cation bound in this
pocket helps to coordinate the negatively charged PS head group in the pocket.
Furthermore, hydrophobic residues in the FG and CC’ loops appear to make contact with
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Figure 1.6) Crystal structures of TIM family members support their role as a family
of PS receptors
(A) The co-crystal structure of the murine TIM-4 IgV domain in complex with 1,2dicaproyl-sn-glycero-3-phosphatidylserine (black) and calcium (gray) (Santiago, et al.,
2007, PDB: 3BIB). The FG and CC’ loops sandwich the short chain PS in the MILIBS
binding pocket.
(B) The crystal structure of the human TIM-3 IgV domain (Zhang, et al., 2020, PDB:
6TXZ) overlaid on the co-crystal structure of the murine TIM-3 IgV domain in complex
with calcium (gray) and 1,2-dicaproyl-sn-glycero-3-phosphatidylserine (black) (DeKruyff,
et al., 2010, PDB: 3KAA). Hydrophobic residues of the FG and CC’ loops are labeled and
shown for both murine and human TIM-3 in purple and red, respectively.
(C) The crystal structure of the murine TIM-1 IgV domain (Santiago et al., 2007, PDB:
2OR8). The co-crystal structure of TIM-1 and PS has not yet been solved, but TIM-1 also
contains a MILIBS pocket where PS binding is thought to occur.
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the DCPS acyl chains, although the specific residues in these loops are not absolutely
conserved between the TIMs. In murine TIM-3, these residues are L99/M100 (mature
numbering) in the FG loop and W41 in the CC’ loop (Figure 1.6B). These residues are
analogous to I96/M97 and F40 (mature numbering) in the human TIM-3 FG and CC’
loops. Although the co-crystal structure of PS and TIM-1 has not yet been determined,
TIM-1 does also contain the MILIBS pocket between its FG and CC’ loops (Figure
1.6C), and is presumed to bind PS in the same way as its family members. Therefore, the
MILIBS is a conserved structural feature that contributes to the function of the TIM
proteins as PS receptors.
Each of the TIM structures determined thus far contains only the IgV domain of
TIM-3. Although the mucin domain is indeed conserved in all members of the TIM
family, its length, as well as its glycosylation state, varies across the family66. The mucin
domain is predicted to be elongated, but no shape or structural information exists for this
region of the TIM family.

1.2.3. Expression of TIM-3
TIM-3 was first identified in 2002 by Monney and colleagues, observed in an attempt to
identify cell surface markers that distinguish CD4+ Th1 cells from CD4+ Th2 cells –
which have distinct functions in the adaptive immune response to intracellular pathogens
and extracellular helminthic infections, respectively53. Screening of monoclonal
antibodies that selectively labeled CD4+ Th1 cells and CD8+ Tc1 cells and not CD4+ Th2
cells or CD8+ Tc2 cells and gene-expression cloning led to the identification of TIM-3 as
the target of these antibodies. TIM-3 expression was found to increase in response to
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stimulation of murine T cells under Th1 polarizing conditions53,78. Similarly, human
CD4+ and CD8+ T cells increase expression of TIM-3 following stimulation with
antibodies targeting the TCR CD3 chain and the CD28 co-receptor (αCD3/αCD28) alone
or when treated with common γ-chain cytokines (IL-2, IL-7, IL-15, and IL-21) alone79,80.
TIM-3 expression is not limited to T cells, however, and is also expressed on dendritic
cells81,82, mast cells83,84, macrophages71, regulatory T cells85, and NK cells86-88. The
expression of TIM-3 across these various cell types indicates a broad role of TIM-3 as an
immune regulatory receptor, function in both the innate and adaptive immune responses.

1.2.4. Functional studies of TIM-3
Efforts to understand TIM-3 function initially focused on its role in modulating T cell
function, given its original discovery as a marker of Th1 cells. In this context, treatment
with anti-TIM-3 antibody led to worsening of the Th1-dependent experimental
autoimmune encephalomyelitis (EAE), a mouse model for multiple sclerosis53. AntiTIM-3 was thus proposed to prevent an inhibitory effect of TIM-3 on Th1 cells, allowing
their unrestrained activity that led to more severe EAE in mice. Additional studies aimed
to inhibit TIM-3 function by using anti-TIM-3 or soluble TIM-3-Ig fusion (to act as a
sink for the still unknown TIM-3 ligands) in mouse models of transplant tolerance,
peripheral tolerance, and nonobsese diabetes78,89. In each case, mice treated with antiTIM-3 or TIM-3-Ig displayed a hyperactive immune response, suggesting that these
treatments were preventing TIM-3 from inhibiting the immune response and supporting
its role as an inhibitory co-receptor.

22

Development of TIM-3 knockout (KO) mice supported the notion that these
pharmacological approaches were blocking the effects of TIM-3. As seen with anti-TIM3, TIM-3-/- mice also failed to induce tolerance in a transplantation model78. TIM-3-/mice developed normally and did not display baseline autoimmunity or
lymphoproliferation, suggesting that any inhibitory role for TIM-3 must occur at later
stages of the immune response. Although complete loss of TIM-3 has not been
documented in humans, recent findings have shown that germline point mutations in
TIM-3 are a common feature in patients with subcutaneous panniculitis-like T cell
lymphoma (SPTCL), observed in ~60-80% of cases90-92. In this non-Hodgkin lymphoma,
some patients experience a hyperactive immune condition called hemophagocytic
lymphohistiocytosis (HLH) in the course of their disease. Missense mutations in TIM-3
identified in SPTLC patients, including Y61C and I76M (mature peptide numbering) in
the extracellular IgV domain, result in protein misfolding and loss of TIM-3 expression
at the cell surface90. In general, patients with germline TIM-3 mutations were more likely
to have severe HLH92, suggesting that these loss of function mutations in TIM-3 prevent
it from inhibiting the immune system, leading to a hyperactive response. However, a
very important consideration in all of these studies is that TIM-3 blockade, whether
through pharmacological inhibition, murine knockout, or human germline mutation,
occurs at the organismal level, across the multiple different cell types in which TIM-3 is
known to be expressed. These studies, therefore, can certainly suggest a global inhibitory
effect of TIM-3 on immune responses, but effects on any specific cell type cannot be
inferred from these data alone.
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Additional studies have therefore been performed to investigate the specific role
of TIM-3 in T cells. The human Jurkat T cell line, used in identifying key components of
TCR signaling, including Zap70 and Lck and co-receptors like PD-110,22,23, was also used
to investigate the role of TIM-3. Intriguingly, expression of TIM-3 in this system has
been shown to alternatively promote and inhibit T cell signaling in different published
studies. Lee and colleagues (2011) transfected murine TIM-3 in Jurkat T cells and
generated stable cell lines by antibiotic selection of single colonies57. They observed that
cells expressing TIM-3 displayed increased transcriptional activity of NFAT/AP-1 and
NF-κB, along with increased phosphorylation of PLC-γ1, ERK, and S6, following T cell
activation with αCD3/αCD2857. Further studies using this system demonstrated that the
ability of TIM-3 to increase T cell signaling involved both MEK/ERK and PI3K/Akt
activation93. A similar approach was used by Tomkowicz and colleagues (2015), where a
plasmid containing human TIM-3 was introduced into a Jurkat reporter line (NFκB/Jurkat/GFP Transcriptional Reporter cells, System Biosciences Inc.) by
electroporation, and cells were sorted for TIM-3-expressing cells after antibiotic
selection59. However, in this case, cells expressing TIM-3 instead displayed reduced
NFAT and NF-κB activity, decreased expression of CD69 (a marker of T cell activation),
and diminished secretion of cytokines such as IL-2 and IFN-α upon stimulation with
bead-bound αCD3/αCD28. A third group (Lee and colleagues, distinct from the Lee
group described above) found that Jurkat cells stably selected for human TIM-3
expression following lentivirus transduction also displayed reduced IL-2 secretion and
NFAT activity following stimulation with phorbol myristate acetate (PMA) and A23187,
a calcium ionophore58. The human and murine orthologs have very strong sequence
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similarity (~60%)53, and are unlikely to demonstrate opposing effects when expressed in
Jurkat cells. Thus, it remains a puzzle as to how expression of TIM-3 could yield these
distinct effects when the cell lines used, along with the methods for introducing TIM-3
and stimulating T cell activity, are so similar.
Beyond this work in the Jurkat T cell line, studies of primary T cells have also
suggested stimulatory or inhibitory roles of TIM-3. In particular, many studies have
focused on the expression of TIM-3 on exhausted T cells in chronic viral infections and
in cancer. In the classic chronic viral infection mouse model of lymphocytic
choriomeningitis virus (LCMV), TIM-3 is expressed in combination with PD-1 on
exhausted, virus-specific T cells94. In this context, cells expressing both TIM-3 and PD-1
display decreased proliferative capacity and cytokine production compared to PD-1+TIM3- cells. Likewise, TIM-3 and PD-1 are co-expressed on exhausted T cells in murine
cancer models and also in human tumor infiltrating lymphocytes (TILs)95-97. Tumorspecific exhausted T cells that express both PD-1 and TIM-3 also displayed decreased
proliferation and cytokine release compared to exhausted cells that expressed only PD195-97. Furthermore, TIM-3 is found to be expressed on T cells following PD-1 blockade
in both murine cancer models and human tumor samples, suggesting TIM-3 might
promote acquired resistance to PD-1 blockade98,99. In several studies, combination
blockade of PD-1 and TIM-3 enhanced cytokine production and proliferation of
dysfunctional T cells, and in mouse models, combination treatment reduced tumor
growth better than either monotherapy96-99. In some mouse tumor models, anti-TIM-3
alone was capable of reducing tumor growth, and this appeared to depend on T cells100.
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These findings, among others, have motivated ongoing efforts to explore the utility of
targeting TIM-3 to reactivate the immune response against cancer.
Across these studies, however, it is unclear if expression of TIM-3 is a cause or
consequence of T cell exhaustion. In fact, Avery et al. (2018) demonstrated that TIM-3 is
neither required nor sufficient for T cell exhaustion, as TIM-3 KO mice were still
susceptible to chronic LCMV infection and formed exhausted T cells, marked by
decreased IFN-γ and TNF-α and enhanced expression of the exhausted-associated
transcription factor Eomes in PD-1+ cells101. Furthermore, enforced expression of TIM-3
did not drive T cell exhaustion, as mice with constitutive expression of TIM-3 in CD4+ T
cells had increased levels of Eomes expression and similar levels of cytokine production
compared with wild-type mice in chronic LCMV infection101. Rather, TIM-3 expression
enhanced the formation of short-lived effector T cells101. Other studies show a more
direct stimulatory role of TIM-3 in T cells. For example, TIM-3 is expressed on activated
T cells responding to Listeria monocytogenes infection in mice102. TIM-3 KO impaired
the response to infection, and further, transfer of TIM-3-/- CD8+ T cells to a wild-type
host also impaired response to infection, suggesting that TIM-3 on the CD8+ T cells was
important for promoting T cell response to infection102 – another stimulatory effect. This
range of activity observed for TIM-3 is not limited to T cells, as the activity of both NK
cells and DCs are also reported variously to be enhanced82,86,103 or inhibited87,88,104,105 by
TIM-3 expression.
Together, these studies on TIM-3 highlight the complex nature of the biology of
this co-receptor. This immune regulatory receptor is expressed on multiple immune cell
types, and its expression on these cells is modulated in different disease states. In at least
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some (if not all) of these cells, TIM-3 appears to be capable of a range of functional
effects. A key unanswered question in the field of TIM-3 is what particular contexts are
responsible for its range of functions. Answering this question has remained a challenge,
in part, due to the lack of clarity of exactly which molecules serve as ligands and regulate
the function of TIM-3.

1.3. Ligands of TIM-3
To date, several molecules have been proposed as ligands for TIM-3, including
phosphatidylserine (PS), galectin-9, carcinoembryonic antigen-related cellular adhesion
molecule 1 (CEACAM1), and high motility group box 1 (HMGB1) (Figure 1.7). Each
molecule, along with the available evidence for their role as a ligand for TIM-3, is
described below.

1.3.1. Phosphatidylserine (PS)
Phosphatidylserine is a key component of the mammalian plasma membrane and makes
up approximately 8-12% of the total membrane phospholipids67,106. Although it is a
relatively minor component of membranes, PS plays an essential role in several
biological processes. PS is asymmetric in its distribution in the bilayer, found
predominantly in inner leaflet of the plasma membrane – indeed almost exclusively in
many cases. Transmembrane aminophospholipid transporters known as flippases utilize
ATP to preserve this asymmetry, moving PS from the extracellular face of the membrane
to the intracellular face after vesicular delivery. PS can also be flipped across the bilayer
by another class of transporters that are bidirectional and operate independently of ATP,
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Figure 1.7) Several molecules are proposed as ligands for TIM-3
Schematic of TIM-3 and its proposed ligands. Phosphatidylserine (yellow) is a component
of the plasma membrane that becomes exposed on the cell surface on apoptotic cells and
activated T cells. Galectin-9 is a carbohydrate binding protein with several roles in
regulating the immune response. Galectin-9 contains two carbohydrate recognition
domains (teal and blue), and thus is a bivalent ligand. CEACAM1 (pink) is another T cell
co-receptor, which may help to stabilize TIM-3 expression. HMGB1 (green) is a sensor for
cytosolic DNA and regulator of innate immunity, which may be released to the
extracellular milieu in certain contexts, such as during apoptosis. BioRender was used to
create this image.
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called scramblases. At steady state, flippases expend energy to maintain PS on the inner
leaflet, preventing its exposure on the extracellular surface of the plasma membrane
under most conditions. In several biological processes, including apoptosis, coagulation,
and cell activation, this asymmetry is reduced, and some PS becomes exposed on the cell
surface – at different levels in distinct circumstances67. In the coagulation cascade, PS
exposure permits the binding and activation of clotting factors. PS exposure on apoptotic
cells acts as an “eat me” signal, and receptors on phagocytes (including the TIM-3 family
member TIM-4) utilize their ability to bind PS to clear these dying cells. In both of these
processes, intracellular calcium flux activates a class of scramblases that randomizes PS
exposure across the plasma membrane67. PS also becomes exposed on the surface of
activated immune cells, including T cells, NK cells, and mast cells88,107,108. In the case of
T cells, activated cells expose an intermediate level of PS on their cell surface compared
to the levels seen on apoptotic cells. Furthermore, the loss of membrane asymmetry
appeared to result from inhibition of flippases returning PS to the inner leaflet, rather
than calcium-based activation of scramblases107.
The first evidence that TIM-3 might bind a component of the plasma membrane
came from screening cell lines for binding of the soluble TIM-3 IgV or complete
extracellular region in search of TIM-3 ligands. TIM-3 was found to bind to a number of
cells, such as the human Jurkat T cell line, the murine RMA-S lymphoma and NIH 3T3
fibroblast cell lines, the Chinese hamster ovary (CHO) cell line, and human T cells,
dendritic cells, macrophages, and B cells74,78,89. The ability of TIM-3 to bind to this
variety of cells from different species indicates that the ligand recognized by TIM-3
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might be evolutionarily conserved, suggesting a conserved cellular component, rather
than a protein (which is likely to be more divergent).
Indeed, after the identification of TIM-4 as a receptor for phosphatidylserine68,69,
TIM-3 was also determined to bind PS. Nakayama and colleagues (2009) showed that,
much like its relative, TIM-3 is capable of binding PS-expressing apoptotic cells and,
furthermore, can mediate phagocytosis of apoptotic cells when expressed on
macrophages or HEK293 cells71. ELISA-based binding studies confirmed that PS is
indeed at least one the molecules recognized by TIM-3 on the apoptotic cell surface71,72.
A co-crystal structure of murine TIM-3 and DCPS (a form of PS with a short acyl chain)
demonstrated that, as with its family member TIM-4, PS binds in the TIM-3 MILIBS
pocket that is unique to the TIM IgV fold72. Mutating either the asparagine/aspartate pair
that coordinates the metal cation in the pocket, or the hydrophobic residues in the FG and
CC’ loops reduced the PS binding of murine TIM-3, indicating the importance of both
regions for PS binding71,72.
Of the immune cells that express TIM-3, only some of these are capable of
clearing apoptotic cells. Recent work suggests that PS binding can elicit functional
consequences via TIM-3 beyond phagocytosis. Tan and colleagues (2020) showed that
NK cells expressing TIM-3 displayed reduced activity in the presence of PS88. T cells
expressing TIM-3 are capable of binding apoptotic cells, but do not phagocytose them, as
these cells do not have the machinery for phagocytosis72. However, beyond this binding
capacity, the consequence of the interaction between PS and TIM-3 on T cells remains
unknown, and this is a major area of focus in my thesis.
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1.3.2. Galectin-9
Despite the strong structural and biochemical evidence for PS as a ligand for TIM-3, the
primary focus in the field has nonetheless remained on galectin-9 as a TIM-3 ligand.
Galectin-9 is a member of the lectin family of oligosaccharide-binding proteins109.
Lectins have a conserved domain, termed the carbohydrate recognition domain (CRD)
through which they bind β-galactosides, for example in N-linked glycosylated proteins.
Unlike the prototype lectins, which form noncovalent dimers, galectin-9 contains two
CRDs connected by a linker peptide, so is bivalent. The galectin family has diverse roles
in proliferation, differentiation, cell death, and immunomodulation110. Like many of the
galectins, galectin-9 has been shown to promote cell death in T cells, and also functions
as an eosinophil attractant110,111. Both CRDs of galectin-9 appear to be required for its
function in these processes, as, for example, the isolated N-terminal CRD or C-terminal
CRD of galectin-9 failed to induce cell death in Jurkat cells110.
As TIM-3 is a glycoprotein with predicted N-glycans, it is feasible that galectin-9
binds TIM-3 by carbohydrate recognition. Indeed, precipitation of TIM-3 binding
partners in murine lymphoma TK-1 cells and mass spectrometry analysis identified
galectin-9 as a binding partner of TIM-352. Binding of galectin-9 to TIM-3 has been
shown to be mediated through N-glycans, as addition of lactose or deglycosylation by the
peptide-N-glycosidase F (PNGaseF) reduces the association between TIM-3 and
galectin-9. Furthermore, one CRD appears to be sufficient for galectin-9 to bind PS, as
only mutating either of the N- or C-terminal CRDs permitted binding of TIM-3 to cells
expressing galectin-9 – which was only reduced upon combined mutations in both
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CRDs. Unlike PS, however, galectin-9 is not a shared ligand amongst the TIM family, as
TIM-4 did not bind cells expressing galectin-9.
As mentioned above, galectin-9, like many other galectins, is capable of inducing
T cell death. After identifying TIM-3 as a binding partner for galectin-9, this T cell
inhibitory activity of galectin-9 was proposed to occur through TIM-3. Galectin-9 was
shown to preferentially kill Th1 cells – for which TIM-3 is a marker – over Th2 cells,
where TIM-3 is not expressed52. Additional approaches observed changes in the function
of NK cells expressing TIM-3 following addition of galectin-986 or loss of effect of
galectin-9 in TIM-3 knockout mice112. However, a key issue in these approaches is the
ability of galectin-9 to bind many additional glycosylated molecules that are also
involved in regulating the immune response, such as IgE, CD44, the IgM-BCR, disulfide
isomerase, and others113-116. Indeed, galectin-9 has been shown to elicit T cell death
independent of TIM-3, including in cells that lack TIM-3117,118. Thus, although galectin-9
may bind TIM-3, and even be able to modulate its function, it seems clear that galectin-9
also has TIM-3-independent functions. Therefore, it is difficult for studies utilizing only
galectin-9 to absolutely ascertain that any effects observed occur through TIM-3 rather
than through the many other interactions displayed by this lectin.
One interesting possibility that could explain TIM-3-dependent effects of
galectin-9 could involve it modulating the ability of TIM-3 to bind other ligands such as
PS. Several groups have suggested this idea, but it has not yet been tested directly66,119.
One consequence of galectin-9 induced cell death of T cells is apoptosis, and thus
enhanced PS exposure110,118. In this case, galectin-9 might indirectly modulate TIM-3
function by increasing the availability of the TIM-3 ligand. Alternately, the bivalent
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nature of galectin-9 could cross link glycosylated TIM-3 molecules together to modify
the avidity of the interaction between TIM-3 and PS. Previous work has indeed shown
the ability of galectin-9 to crosslink TIM-3 with CD45 or PD-1120,121. Consequently, it
might be possible for galectin-9 to crosslink TIM-3 molecules together, thus enhancing
their avidity for PS. I aimed to explore this possibility as part of my thesis work.

1.3.3. Carcinoembryonic antigen-related cellular adhesion molecule 1 (CEACAM1)
Carcinoembryonic antigen-related cellular adhesion molecule 1, or CEACAM1, is a
transmembrane receptor, comprised of four N-terminal immunoglobulin-like domains, a
transmembrane helix, and a C-terminal cytoplasmic domain. The cytoplasmic tail of
CEACAM1 has a long and short isoform that control its effect on T cell function. The
long isoform of CEACAM1 contains ITIMs and is capable of co-inhibiting T cell
activity, while the short isoform is reported to co-stimulate T cells122. Activated T cells
from CEACAM1-/- mice displayed reduced expression of TIM-3, suggesting a possible
interaction between these molecules123. Immunoprecipitation and NMR studies further
supported a direct interaction between TIM-3 and CEACAM1, where CEACAM1 is
thought to act in cis with TIM-3 to yield its inhibitory effect124. However, additional
studies suggested that CEACAM1 expression in cis or in trans did not enhance the
expression or effect of TIM-3 on T cell activity125. Therefore, additional work is needed
to understand the nature and importance of this putative interaction.
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1.3.4. High motility group box 1 (HMGB1)
High motility group box 1, or HMGB1, is an alarmin, or cytoplasmic sensor of DNA, that
can engage the innate immune system if genetic material is detected outside the nucleus,
indicating the presence of a pathogen. ELISA-based studies support a role for the
extracellular domain of TIM-3 in binding HMGB1, with functional consequences on
tumor-infiltrating dendritic cells126. However, additional studies are also needed to
improve our understanding of the potential interaction between TIM-3 and HMGB1, and
its impact on DCs and other cell types where TIM-3 is expressed, such as T cells.

1.4. Objectives
TIM-3, a receptor involved in immune regulation, is unique, particularly in its role as a
co-receptor in T cells. Since its discovery, both co-stimulatory and co-inhibitory roles
have been reported for TIM-3. This dual function is also observed in other cell types,
including DCs and NK cells. TIM-3 is not alone in its ability to impart both stimulatory
and inhibitory effects of T cells. The TIM family member TIM-1 is reported to have both
co-stimulatory and co-inhibitory roles, too. Unlike TIM-1, however, the determinants that
regulate TIM-3 activity remain unclear. Thus, an important, but still unanswered question
in the field is how TIM-3 can both enhance and reduce T cell activity, and what
circumstances permit these orthogonal effects.
The lack of clarity surrounding the ligands of TIM-3 further compounds the
unanswered questions about TIM-3 function. Multiple molecules have been suggested as
ligands for TIM-3. Among these, phosphatidylserine (PS) is of particular interest, given
the function of the TIM family as PS receptors. Furthermore, PS is only TIM-3 ligand for
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which structural information exists regarding the receptor-ligand interaction. However,
beyond studies of TIM-3–PS in phagocytosis, the impact of a TIM-3–PS interaction on
cellular signaling and function has remained unclear. Furthermore, how multiple ligands
of TIM-3 might modulate its activity in combination is also unknown. These are key
questions I aimed to address in my thesis.
In Chapter 2, I aimed to investigate the PS-binding of human TIM-3. In particular,
I utilized surface plasmon resonance to study the lipid binding of TIM-3 in a system that
preserves the lipid state and membrane composition close to what is observed in vivo.
Using SPR, I compared the PS-binding capacity of TIM-3 with that of its family
members, TIM-1 and TIM-4. I also used competition studies and mutated variants of
TIM-3 to explore the contributions of different regions of TIM-3 to its PS binding.
Lastly, I also performed biochemical studies to ask how galectin-9 might impact the
ability of TIM-3 to bind PS.
In Chapter 3, I aimed to apply the findings from the PS binding studies to a
cellular model system. I first generated a cellular system where I observed changes in
signaling that depend on expression of TIM-3. I explored how TIM-3 might enact these
changes. I then investigated the importance of PS in regulating the activity of TIM-3,
using chimeric receptors, mutated variants of TIM-3, and pharmacological blockade.
Lastly, I asked how galectin-9 might impact TIM-3 function in T cells.
Overall, the goal of my thesis is to expand our understanding of the regulation of
TIM-3 by the ligand PS. I am interested in understanding whether the interaction of PS
and TIM-3 is capable of eliciting a change in cell function and signaling, beyond a simple
attachment to a PS-containing surface. Many questions remain about the function of

35

TIM-3, which are of particular interest given the current status of TIM-3 as a therapeutic
target in immune checkpoint blockade. Several companies are developing antibodies
against TIM-3 – making mechanistic understanding all the more urgent. However, TIM-3
is expressed in several immune cell types, where its function remains unclear –
promoting immune activity in some contexts but inhibiting it in others. Understanding
how TIM-3 regulates activity of particular cells, and the cumulative outcome of these
effects on the immune response will be important for optimizing use of TIM-3-targeting
antibodies as/if they move into the clinic. As antibody blockade targets the ligandbinding region of TIM-3, understanding the impact of the proposed TIM-3 ligands on the
function of this immune modulatory receptor will help inform the most effective use of
anti-TIM-3 therapies.
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CHAPTER 2. Biochemical analysis of phosphatidylserine binding by
TIM-3
Parts of this chapter are modified excerpts from Smith, C.M., et al., Biochemical Journal,
2021.
2.1. Introduction
Members of the TIM family share strong sequence similarity (~60%) in their
extracellular, ligand-binding region (Figure 2.1). Crystallographic (Figure 1.6) and
binding studies70-72 support the ability of TIM-3 to bind PS, like its family
members68,69,75. However, the functional consequence of PS binding in TIM-3-expressing
cells, beyond promoting macrophage phagocytosis of apoptotic cells71,72, remains
unclear. One potential reason why the effect of this receptor-ligand pair on immune cell
function has not been better explored is the lack of biochemical information about their
interaction. To date, ELISA studies have primarily been used to analyze binding of TIM3 (and other TIMs) to PS68,69,71,72,75. ELISAs can be useful for qualitative assessment of
lipid binding, but likely do not capture the physiological lipid state that the TIMs would
encounter in vivo. The solid-state presentation of pure individual lipid types in an ELISA
does not recapitulate the fluidity of a cell membrane or lipid bilayer127. Therefore,
additional approaches are needed to determine a relevant measure of interaction between
TIM-3 and PS to inform future studies on the impact of this interaction in cells.
Understanding the interaction between TIM-3 and PS is also important for
understanding how other proposed ligands of TIM-3, particularly galectin-9, might come
into play. Several groups have recently suggested the potential of TIM-3 to interact with
multiple ligands simultaneously119,128. This is an interesting idea, which could explain
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Figure 2.1) Alignment of human TIM extracellular regions
Sequence alignment of the soluble regions of human TIM-3, TIM-1, and TIM-4, performed
using
Clustal
Omega
Multiple
Sequence
Alignment
(https://www.ebi.ac.uk/Tools/msa/clustalo/)51. The extracellular region of each protein was
determined from the reviewed entry on Uniprot. The six cysteines making up the one
canonical and two noncanonical disulfide bonds of the TIM family are highlighted in green.
The FG and CC’ loops that make up the outer edge of the MILIBS, or PS-binding pocket,
are marked with a blue line. Hydrophobic residues at the edge of the MILIBS involved in
PS binding are highlighted in teal. Charged residues that participate in calcium
coordination (either confirmed from structural studies or predicted from sequence
similarity) are highlighted in yellow. TIM-3 residues that were mutated and displayed
reduced PS binding are boxed in dark red. The C-terminal residue used in each expression
construct is marked with an arrowhead, and the residue is colored in teal for sTIM-1, red
for sTIM-3, and green for sTIM-4. Predicted glycosylated residues for human TIM-3 are
highlighted in magenta.
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some of the differences in activity observed for TIM-3 in the immune system5759,78,89,101,102

. Combinatorial ligand binding adds complexity to the already complicated

activity of TIM-3. A first step in understanding the impact of a combination of ligands on
TIM-3 activity is to understand the nature of their individual interactions. With a defined
interaction between TIM-3 and PS, additional ligands can be added to the system to
determine how their presence modulates the interaction between TIM-3 and PS.
In this Chapter, I aimed to investigate the binding of TIM-3 to PS-containing
membranes in a physiologic context and to explore the impact of galectin-9 on the
interaction between TIM-3 and PS. The studies described here utilized surface plasmon
resonance (SPR), which has been used to investigate the interaction of proteins and
phosphoinositides, among other protein-lipid interactions129, to explore the interaction of
TIM-3 (and its family members) with PS. Additionally, I analyzed the ability of galectin9 to crosslink TIM-3 and the resulting impact on TIM-3–PS binding. This analysis details
the interaction between TIM-3 and PS, as well as the impact of the bivalent galectin-9 on
this interaction, and is useful for informing the cellular studies described in Chapter 3 and
future work on this receptor-ligand pair.

2.2. Materials and Methods
2.2.1. Cloning and constructs
pCDEF3-hTIM-3 was a gift from Dr. Lawrence Kane (Addgene plasmid# 49212), and
contained the natural TIM-3 variant L119, which was corrected to R119 by site-directed
mutagenesis. Plasmids containing human TIM-1 (cat# RC217039) and human TIM-4
(cat# RC203848) were obtained from Origene. For expression of isolated extracellular
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regions, cDNA fragments encoding the human TIM-3 IgV domain (natural signal
sequence + S1-R119) and the extracellular regions (ECRs) of human sTIM-3 (natural
signal sequence + S1-R179), human sTIM-1 (natural signal sequence + S1-R227), and
human sTIM-4 (natural signal sequence + E1-K283) were sub-cloned into the
pcDNA3.1(+) vector using Gibson assembly130, introducing a C-terminal hexa-histidine
tag. The TIM-3F40A and TIM-3I96A/M97A variants were generated by QuikChange sitedirected mutagenesis (Agilent) in pcDNA3.1 (+) for ECR protein expression. The
plasmid containing the human galectin-9 with modified linker for increased solubility
and stability (ssGal9)131 was obtained from the Riken BioResource Research Center
(cat# RDB15282). QuikChange site-directed mutagenesis (Agilent) was also used to
generate the ssGal9R65D and ssGal9R200D variants, which was completed by Alice Li, an
undergraduate researcher in the lab. All plasmids were sequence validated before use.

2.2.2. sTIM-1, sTIM-3, and sTIM-4 purification
As specified in the Expi293 Expression System manual, Expi293F cells were cultured to
reach a density of 4.5-5.5 x 106 cells/ml on the day of transfection and were seeded at
3 x 106 cells/ml. A transfection mixture containing DNA vector (1 µg per ml of culture to
be infected), Expifectamine reagent (ThermoFisher Scientific), and Opti-MEM (Gibco)
was then incubated at room temperature for 10 min and subsequently added to the
culture. Cells were returned to the humidified incubator at 37˚C, 8% CO2 with shaking.
Expi293 enhancers (ThermoFisher Scientific) were added 18-22 h after transfection, and
the culture was harvested 4-6 days later by centrifugation (1,000 RPM). Culture
supernatant was collected and diafiltered against 4 times the culture volume with 10 mM
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HEPES pH 8, 150 mM NaCl (TIM Buffer 1). Nickel affinity chromatography was
performed on the diafiltered supernatant with Ni-NTA agarose (Qiagen), with
approximately 0.5 ml Ni-NTA resin per 100 ml of culture. The Ni-NTA resin was
washed with 20 column volumes (CVs) of TIM Buffer 1 containing 10 mM imidazole.
TIM proteins eluted from the Ni-NTA resin in TIM Buffer 1 containing 50-150 mM
imidazole (approximately 5 CV of 50, 100, and 150 mM imidazole). Protein-containing
fractions (determined by SDS-PAGE) were pooled, diluted to 50 mM NaCl, filtered
(0.22 µm), and injected onto a Fractogel TMAE column (EMD Millipore) equilibrated in
25 mM HEPES pH 8 with 50 mM NaCl. Protein was eluted using a gradient from 50 to
700 mM NaCl. Peak fractions (~150 mM NaCl) were collected, concentrated using a
10 kDa MWCO centrifugal filter (EMD Millipore), filtered (0.22 µm), and applied to a
Superose 12 10/300 column (Cytiva Life Sciences) for gel filtration in TIM Buffer 2
(10 mM HEPES pH 7.6, 150 mM NaCl). Peak fractions were collected, concentrated
using a 10 kDa MWCO centrifugal filter (EMD Millipore) and filtered (0.22 µm). SDSPAGE was performed to confirm protein size and purity. Protein concentration was
determined by 280 nm absorbance using a NanoDrop spectrophotometer (ThermoFisher
Scientific) with calculated extinction coefficients.

2.2.3. Unilamellar vesicle preparation
Lipids were purchased from Avanti Polar Lipids in chloroform solution, including
dioleoylphosphatidylcholine (DOPC), dioleoylphosphatidylserine (DOPS),
dioleoylphosphatidic acid (DOPA), and dioleoylphosphatidylethanolamine (DOPE).
Lipid solutions were combined at the appropriate molar ratios in a glass vial. Chloroform
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was removed by drying under a stream of nitrogen gas, and the lipid mixture was dried
fully under vacuum for at least 1 h. Lipid mixtures were rehydrated with 10 mM HEPES
pH 7.6, 150 mM NaCl, vortexed to mix, and subjected to at least 10 freeze-thaw cycles,
where the suspension was frozen in liquid nitrogen and thawed in a warm sonicating
water bath, to generate unilamellar vesicles. Vesicle suspensions were stored at -20˚C.
Before use, thawed sonicated vesicles were extruded using a 100 nm filter membrane in
an Avanti Mini Extruder.

2.2.4. Surface plasmon resonance
Surface plasmon resonance (SPR) analyses of protein-lipid interactions were performed
using a Biacore 3000 instrument essentially as described129,132. Lipid vesicles containing
DOPC or the specified percentage (mole/mole) of lipid in a DOPC background were
immobilized by flowing lipid vesicles across a Pioneer L1 sensorchip (Cytiva) in TIM
Buffer 2. After immobilization, purified proteins were flowed across the chip at varying
concentrations in the presence or absence of 1 mM CaCl2. Protein samples were injected
at 10 µl/min, for 5 min total. After injection was complete, the lipid surface was
regenerated with 0.1 M NaOH before the next injection. Some experiments also included
1 mM EDTA to chelate calcium ions, while others used 1 mM of other divalent cations,
including nickel, zinc, magnesium, and manganese, in place of calcium. Competition
experiments utilized O-phospho-L-serine (L-PS; Sigma-Aldrich cat# P0878), Ophospho-D-serine (D-PS; Cayman Chemical Company cat# 17602), or 1,2-dihexanoylsn-glycero-3-phosphoserine (DHPS; Echelon Biosciences Inc., cat# L3106), 100 µM
each, to compete for binding with the surface-bound PS. Resonance units at equilibrium
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detected by the Biacore 3000 were corrected for background (DOPC) binding on a
separate sensorchip surface and were plotted against protein concentration. Curves were
fit using the equation: RUmax = Bmax x [TIM]/ (Kd + [TIM]), and apparent Kd was
estimated from these curves using GraphPad Prism.
SPR experiments assessing the impact of ssGal9 on TIM-3–PS binding were
performed as above. Lipid vesicles containing DOPC or 20% DOPS/80% DOPC
(mole/mole) were immobilized on separate channels of a Pioneer L1 sensorchip. ssGal9
constructs (WT, R65D, or R200D) at varying concentrations from 0.05 to 1.5 µM were
incubated with 6 µM sTIM-3 and 1 mM CaCl2 prior to injection over the lipid surfaces.
Resonance units (RUs) at equilibrium, after 4 min, 50 s of the 5 min injection, were
recorded. The RUs from the DOPC channel were subtracted from the DOPS channel and
plotted as a function of ssGal9 concentration. To determine the off rate, the dissociation
phase was isolated from the sensorgrams of sTIM-3 alone (6 µM), sTIM-3 (6 µM) with
ssGal9WT (0.75 µM), sTIM-3 (6 µM) with ssGal9R65D (0.75 µM), and sTIM-3 (6 µM)
with ssGal9R200D (0.75 µM). The dissociation curves were then fit with a one-phase,
exponential decay curve (RU=(RU0 – NS) * exp(-koff*t) + NS, where RU0 is the RU
value at the start of the dissociation phase, NS is the non-specific binding at infinite
times, koff is the rate constant, and t is time in seconds) in Prism, and the off-rate was
estimated from the koff constant determined with the fit.

2.2.5. PNGase F treatment
Purified TIM-3 extracellular domain (sTIM-3) was deglycosylated with PNGase F
(NEB, cat#P0704). PNGase F is capable of removing N-linked oligosaccharides,
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specifically between the asparagine and the innermost GlcNAc residue of complex
oligosaccharides on glycoproteins. TIM-3 (4 µg) was first denatured with SDS and DTT
at 100˚C for 10 min, followed by treatment with PNGase F in the presence of NP-40 for
14 h at 37˚C. Deglycosylation was analyzed by running reactions on SDS-PAGE and
staining with Coomassie Blue. A downward shift in the protein band on the gel indicated
successful deglycosylation, as proteins lose molecular mass after deglycosylation and
move further through the gel.

2.2.6. ssGal9 purification
ssGal9, a variant of galectin-9 with an optimized linker sequence for increased solubility
and stability, was purified following a protocol adapted from Itoh, et al. Glycobiology
(2013) and Nishi, Glycoforum (2020)131,133. BL21(DE3) RIPL Codon Plus E. coli cells
were transformed with the ssGal9 plasmid131 (Riken, cat# RDB15282) and selected with
ampicillin (100 µg/ml), spectinomycin (50 µg/ml), and chloramphenicol (25 µg/ml).
2xYT media (220 ml; 16 g tryptone, 5 g NaCl, 10 g yeast extract per liter) cultures were
inoculated with a starter culture, expanded from a single antibiotic-selected colony in LB
media (10 g tryptone, 10 g NaCl, 5 g yeast extract per liter) containing ampicillin
(100 µg/ml). Cultures were grown at 37˚C, shaking at 200 RPM until OD600 reached 0.60.7. Cultures were then induced with a final concentration 0.1 mM isopropyl-bthiogalactopyranoside (IPTG) at 20˚C for 16 h (after cooling). Following induction, cells
were pelleted by centrifugation (6,000 x g, 10 min) and resuspended in ssGal9 Lysis
Buffer (36 ml; 10 mM Tris-HCl pH 7.5, 500 mM NaCl, 1 mM phenylmethylsulfonyl
fluoride (PMSF)). Cells were lysed by sonication, 6 to 8 cycles of 1 min (1 s on, 1 s off)
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at 20% amplitude on ice with 1 min rest between cycles. After sonication, 10%
(weight/volume) Triton X-100 (4 ml) was added to the lysate to give a final Triton X-100
concentration of 1%. The lysate with Triton X-100 was then mixed for 30 min at 4˚C
with gentle stirring. Lysate was clarified by centrifugation (18,000 x g, 30 min, 4˚C) and
mixed with lactose-agarose resin (2 ml of a 50% slurry; Sigma-Aldrich, cat# L7634) for
1 h at 4˚C. The lysate-resin mixture was then packed in a Kontes column by gravity flow
to remove unbound material. The resin was then washed with 20 CVs of ssGal9 Lactose
Binding Buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl), and ssGal9 was eluted with 4
CVs of ssGal9 Lactose Binding Buffer containing 200 mM lactose. Eluted fractions were
analyzed by SDS-PAGE with Coomassie Blue staining. Peak fractions were combined
and dialyzed against PBS (500 ml for 4-5 h, 1 l for 16 h, and 500 ml for 4-5 h) in 12-15
kDa MWCO dialysis tubing. The small amount of precipitated material was removed by
centrifugation (25,000 x g, 20 min, 4˚C) and the supernatant filtered (0.22 µm) and
stored at 4˚C. Protein concentrations were determined by 280 nm absorbance using a
NanoDrop spectrophotometer (ThermoFisher Scientific) with calculated extinction
coefficients. The same purification strategy was used for ssGal9R65D and ssGal9R200D
variants.

2.2.7. ssGal9-TIM-3 crosslinking
Purified soluble TIM-3 (sTIM-3; 4 µM) was incubated with varying concentrations of
purified galectin-9 (ssGal9; 0.4, 2, 4 µM) in TIM Buffer 2 with- and without
disuccinimidyl suberate (DSS; 300 µM) for 30 min at room temperature. DSS stock in
dimethyl sulfoxide (DMSO) was diluted 10-fold in TIM Buffer 2 and DMSO (1:1
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mixture) for use in the reaction. Reactions were quenched with 4 x PierceÔ LDS Sample
Buffer (Thermo Fisher Scientific, cat# 84788) at 98˚C for 2 min. Samples were analyzed
by SDS-PAGE (NuPAGE 4-12% Bis-Tris, ThermoFisher Scientific, cat#NP0322) and
Coomassie Blue staining and also by Western blot.

2.3. Results
2.3.1. TIM-3 binds PS-containing membranes with low micromolar affinity
In considering approaches to explore the interaction of human TIM-3 (along with its
relatives TIM-4 and TIM-1) with PS, I aimed to utilize methods that would more closely
resemble the conditions these proteins would encounter when recognizing PS in vivo
than have been used in published studies. I therefore selected the Expi293 mammalian
cell system for recombinant expression and purified the complete soluble extracellular
region of the human TIMs (sTIM-n). sTIM-3 expressed in the mammalian Expi293 cells
maintained glycosylation (see Section 2.3.7), which is expected in vivo. Additionally, the
sTIM constructs did not contain Fc-fusion or other fusion partners to artificially dimerize
the receptor, as in some previous studies69,71,72. Using nickel affinity chromatography,
ion exchange chromatography, and size exclusion chromatography, soluble human TIM
ECRs (sTIM-1, sTIM-3, and sTIM-4) were purified to >90% purity, and were
monodisperse, suggesting that the protein produced was soluble and monodisperse, and
therefore suitable for lipid binding studies (Figure 2.2). Some preparations of sTIM-3
contained a shoulder on the left side of the peak, which could reflect a distinct
glycosylation state compared to the main peak. Of note, all sTIM constructs eluted from
the size exclusion column earlier than might be expected for a globular protein standard
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Figure 2.2) Expression of soluble extracellular regions (ECRs) of human TIM
proteins
(A) Representative elution profiles of the soluble, ECRs of the human TIMs – sTIM-1
(teal), sTIM-3 (red), and sTIM-4 (green) – from a Superose12 size exclusion column.
Elution profiles are overlaid with protein standards (gray), with molecular weight standards
for each peak indicated with an arrowhead below the elution volume on the x-axis. Note
that sTIM proteins elute between ~40 and 160 kDa, which is likely due to the extended
mucin domain in the extracellular region and glycosylation that increase the Stokes radius
of the protein beyond that predicted for a globular protein of the same molecular weight.
All purified proteins demonstrate monodispersity, indicating that protein samples are
homogeneous.
(B-D) Representative SDS-PAGE analysis of (B) sTIM-1, (C) sTIM-3, and (D) sTIM-4
fractions from size exclusion chromatography, demonstrating that the protein is
substantially pure.
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of the same molecular weight, which is not surprising given that the mucin domain of the
TIM family is long and unstructured, thus increasing the Stokes radius of the sTIM
proteins (Figure 2.2A).
To quantify the interaction of sTIMs with PS, I utilized surface plasmon
resonance (SPR). Compared to other methods, such as ELISA, SPR can mimic the lipid
membrane state and multi-lipid context observed in a cell membrane129, but does not
require as much protein as other direct binding techniques like isothermal titration
calorimetry (ITC). SPR has been successfully used to study binding of proteins to lipid
membranes containing PS132 and other phospholipids129,134. Further, when assessing the
lipid binding of PH domains, surface plasmon resonance yielded similar affinity
measurements as ITC studies129. A tryptophan shift assay, such as that used by Tietjen et
al. (2014), can also preserve the favorable properties of SPR. However, unlike murine
TIM-3, TIM-4, and TIM-1, human TIM-3 does not contain a tryptophan in the loops
surrounding the PS-binding pocket, making it unclear if changes in the environment of
other tryptophans would be significantly modified with lipid binding to observe a useful
shift in fluorescence signal. Therefore, SPR was used to study the interaction of PS and
TIM-3, TIM-4, and TIM-1, as described129,132. Briefly, vesicles containing different
percentages of dioleoylphosphatidylserine (DOPS) in a dioleoylphosphatidylcholine
(DOPC) background were immobilized on a Pioneer L1 sensorchip, and sTIM-3, sTIM1, and sTIM-4 were then injected across the surface. The maximal resonance units (RU)
observed at steady state equilibrium were subtracted from a background surface
(containing only DOPC) and plotted as a function of the concentration of sTIM to
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determine an apparent equilibrium dissociation constant (Kd, app) using a one site, specific
binding fit.
Using SPR, all human soluble TIM extracellular regions were determined to bind
to membranes containing PS in the presence of calcium, mimicking the environment in
which the TIMs might recognize their lipid ligand in vivo135. Sensorgrams (which display
the change in RU as protein is flowed over the immobilized lipid surface) demonstrated a
rapid increase in RU upon injection to PS-containing surfaces (Figure 2.3A-C, ~75 s)
and rapid dissociation at the end of the injection (~375 s), suggesting that the protein
bound to the lipid, remained well-behaved, and did not aggregate on the chip. All sTIMs
reached equilibrium during the 300 s (5 min) injection period. With this approach, sTIM3 displayed the weakest PS binding amongst the TIM family (Figure 2.3D, Table 2.1),
with a Kd, app = 9.7 ± 4.2 µM for membranes containing 20% DOPS/80% DOPC
(mole/mole). sTIM-4 bound surfaces of 20% PS with a Kd, app = 0.77 ± 0.32 µM, while
sTIM-1 bound membranes of 20%PS/80%PC (mole/mole) with a Kd,
app

= 0.35 ± 0.05 µM.
Binding to membranes containing 10%DOPS/90%DOPC (mole/mole), also in the

presence of 1 mM CaCl2, was assessed for all TIMs (Figure 2.3E). sTIM-3 displayed an
approximately 2-fold weaker Kd, app (22.4 ± 12.6 µM) for membranes containing 10% PS
versus those with 20% PS. Both sTIM-1 and sTIM-4 displayed similar Kd, app for surfaces
containing 10% and 20% PS (Table 2.1), suggesting that TIM-3 binding is more
dependent on PS density in the target membranes. Previous studies of murine TIM-4
demonstrated sensitivity of binding to PS density, with a Hill coefficient of ~2.570. The
observed enhanced binding of mTIM-4 to surfaces with increased PS density required
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Figure 2.3) sTIM-1, sTIM-3, and sTIM-4 bind membranes containing
phosphatidylserine
(A-C) Representative, reference (PC)-subtracted sensorgrams of (A) sTIM-1, (B) sTIM-3,
and (C) sTIM-4 binding to 20% PS/80% PC (mole/mole) surfaces in the presence of 1 mM
CaCl2. A rapid increase in binding signal is observed at the start of each injection (~75 s),
which plateaus and rapidly returns to baseline at the end of the 300 s injection. Legend to
the right indicates [sTIM] for each injection.
(D,E) Graphs of equilibrium response units (RUs) for sTIM-3 (red), sTIM-1 (teal), and
sTIM-4 (green) injected at different concentrations onto membranes with (D) 20% PS or
(E) 10% PS in the presence of 1 mM CaCl2, measured by SPR. Maximum response units
(RU) are plotted for each protein concentration. Curves are fit with one site, specific
binding curve to estimate Kd, app values shown for each representative curve (20% PS: nsTIM1=6, nsTIM-3=11, nsTIM-4=5; 10%: nsTIM-1=1, nsTIM-3=6, and nsTIM-4=2).
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Table 2.1) SPR data for TIM family members binding to PS-containing membranes
with 1 mM CaCl2.
% PS

20%

10%

Sample

CaCl2 (mM)

Kd, app ± SD (µM)

N

sTIM-1

1

0.35 ± 0.05

6

sTIM-3

1

9.7 ± 4.2

11

sTIM-4

1

0.77 ± 0.32

5

sTIM-1

1

0.49

1

sTIM-3

1

22.4 ± 12.6

6

sTIM-4

1

0.69 ± 0.05

2
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four basic surface-exposed residues70. However, only two of these four residues are
conserved in human TIM-4 (R48 and K102 in mature murine TIM-4, R46 and K100 in
mature human TIM-4), which might explain why little difference is seen for the Kd, app
measured for human TIM-4 here with membranes containing 10 and 20% PS.
The 12-27-fold weaker PS binding of sTIM-3 compared to sTIM-1 and sTIM-4
observed here is supported by previous studies using ELISA or tryptophan shift assays7072

. In those previous assays, murine TIM-3 was reported to bind to PS-containing

membranes with affinity in the nanomolar range however71,72 – several orders of
magnitude stronger than the affinity range reported here. This difference may result from
changes between the human and mouse protein or (more likely) differences in the
approach used to measure affinity. ELISA and SPR quantify distinct phenomena, and
very different affinity values can be recorded for a multi-valent lipid-binding system
such as this one when comparing a direct binding method like SPR with ELISA129,136.
The Lemmon lab has reported similar phenomena for other phospholipid-binding
domains129, where ELISA assays report anomalously high affinities, whereas SPR
experiments of the sort described here return Kd, app values that agree across multiple
methods. Nonetheless, the trends in relative PS-binding affinity are consistent across
studies, with TIM-3 demonstrating weaker PS binding at both 10% and 20% PS
compared with its family members. Previous work also showed that substitution of the
murine TIM-3 CC’ loops, which make up one edge of the PS binding site, with those of
human TIM-3 reduced binding72 – consistent with hTIM-3 having a lower affinity for PS
than mTIM-3.
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2.3.2. sTIMs display reduced binding to PS-containing membranes in the absence of
calcium
As shown in Figure 1.6, the PS binding pocket of the TIM family has been established
with X-ray crystal structures. This pocket was first coined the MILIBS, for metal iondependent ligand binding site, when the co-crystal structure of TIM-4 and PS was
solved, and reflects the importance of a metal cation in the pocket coordinating the
negatively charged PS head group75. Additional binding studies support the importance
of calcium for TIM-4–PS binding70,75,137. The co-crystal structure of murine TIM-3 and
PS also supports the importance of a cation coordinating PS in the pocket for other TIM
family members72. Calcium does not appear to be required for the IgV domain to
maintain its fold, as murine TIM-3 and TIM-1 have been crystalized without density for
calcium or another cation detected74,76. However, calcium seems to be capable of binding
the MILIBS even in the absence of PS, as seen for the human TIM-3 IgV domain
structure77.
The TIMs are not unique in their use of calcium in their PS pocket, as several
classes of PS binding proteins also utilize calcium for lipid binding106. Intracellularly,
calcium flux upon signal activation can provide a temporal control for PS binding for
some proteins, like some members of the annexin family. Other members of this broad
family, such as annexin V, are extracellular and retain their calcium-dependent PS
binding138 to play roles in clearing PS-exposing apoptotic cells. Recognition of apoptotic
cells is a key function for the TAM family of receptor tyrosine kinases, too. The ligands
for the TAM receptors contain Gla domains that, like annexins, display calciumdependent PS binding137 to surface-exposed PS to aid in clearance of apoptotic cells139.
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In addition to calcium-dependent PS binding, these domains also utilize less specific
hydrophobic interactions with the membrane surface for their lipid binding106.
To determine if, like some other extracellular PS-binding domains, calcium is
important for PS binding of the TIM family, SPR was used to determine the dissociation
constants for sTIM-1, -3, and -4 in the absence of calcium. As described above, lipid
vesicles containing 20% PS (mole/mole) in a PC background were immobilized on an L1
sensorchip, and soluble TIM protein was flowed over the surface, this time in the
absence of calcium. In the case of each TIM, the absence of calcium reduced PS binding
(Figure 2.4A-C, Table 2.2). sTIM-3 displayed approximately 2-fold weaker binding to
PS membranes in the absence of calcium (Kd, app, 0 mM Ca2+ = 20.4 ± 10.5 µM vs.
Kd,

app, 1 mM Ca2+

= 9.7 ± 4.2 µM). Both sTIM-1 and sTIM-4 displayed approximately 10-

fold weaker binding in the absence of calcium, as previously suggested70,75,137. sTIM-4
bound membranes containing PS with a low micromolar affinity in the absence of
calcium (Kd, app, 0 mM Ca2+ = 7.21 ± 0.45 µM). The family member sTIM-1 also bound PScontaining membranes with low micromolar affinity without calcium
(Kd, app, 0 mM Ca2+ = 3.13 ± 0.31 µM). These findings are in line with previous work on
TIM-4, and support a role for calcium in PS binding for the entire TIM family, similar to
annexin and Gla domains, other PS-binding proteins.
Calcium can drive fusion of lipid vesicles in some contexts140. It was therefore
important to ensure that the levels of calcium used here did not impact the lipid surface
generated on the L1 sensorchip. Therefore, the PS binding of the bovine lactadherin (also
known as milk-fat globule EGF factor 8 protein) C2 domain was quantified in the
presence and absence of calcium. The lactadherin C2 domain binds PS independent of
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Figure 2.4) Calcium enhances PS binding of sTIM-1, -3, and -4
(A) Binding curve of sTIM-1 to 20% PS-containing membranes with- (solid teal curve) or
without (dashed teal curve) 1 mM CaCl2. Inclusion of 1 mM CaCl2 and 1 mM EDTA
(dotted gray curve) abrogates PS binding.
(B) sTIM-3 binds to 20% PS/80%PC (mole/mole) membranes in the presence (solid red
curve) or absence (dashed red curve) of 1 mM CaCl2. Addition of EDTA (1 mM) with Ca2+
(dotted gray curve) prevents PS binding.
(C) Representative binding curve of sTIM-4 to 20% DOPS membranes with (solid green
curve) or without (dashed green curve) CaCl2 (1 mM). Inclusion of 1 mM EDTA with 1
mM CaCl2 (dotted gray curve) reduces PS binding.
(D) Binding curves of the bovine lactadherin C2 (LactC2) domain binding to PS-containing
membranes (20% mole/mole) alone (solid purple curve), with 1 mM CaCl2 (dashed purple
curve) and with 1 mM CaCl2 and 1 mM EDTA (dotted gray curve), indicating no change
in binding with calcium or EDTA.
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Table 2.2) Comparison of sTIM binding 20% DOPS/80% DOPC surface in the
presence and absence of calcium.
Sample

CaCl2 (mM)

Kd, app ± SD (µM)

N

sTIM-1

0

3.1 ± 0.3

2

sTIM-1

1

0.35 ± 0.05

6

sTIM-3

0

20.4 ± 10.5

3

Fold
Increase
8.9

2.1
sTIM-3

1

9.7 ± 4.2

11

sTIM-4

0

7.2 ± 0.5

2
9.4

sTIM-4

1

0.77 ± 0.32
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calcium106; therefore, if addition of calcium does not modify the lipid surface generated
on the L1 sensorchip, lactadherin C2 binding with and without calcium should be
similar. As expected, binding of lactadherin C2 was not changed by the addition of 1
mM Ca2+ (Figure 2.4D). The effect of calcium observed for sTIM-3, sTIM-1, and sTIM4 therefore reflects a true difference in protein-lipid binding, rather than a change in the
lipid membrane in the presence of calcium.
To further assess the requirement of calcium for TIM–PS binding, PS binding was
assessed by SPR for TIM proteins incubated with calcium and EDTA. EDTA chelates
divalent cations, such as calcium. As shown in Figure 2.4A-C (dashed lines), inclusion
of EDTA abrogated the ability of sTIM-3, sTIM-1, and sTIM-4 to bind PS – arguing that
their PS binding relies on the residual divalent cation bound to the protein and/or lipid
bilayer, and is only lost when divalent ions are stripped by chelation – in contrast with
the lactadherin C2 domain. Further addition of Ca2+ enhances PS binding, while
chelation by EDTA prevents binding. The effect of EDTA on sTIM-4 was more
moderate compared its impact on sTIM-1 or sTIM-3, but nonetheless, still decreased PS
binding. As expected, EDTA did not impact the ability of the lactadherin C2 domain to
bind PS, as its PS-binding is calcium-independent.
In the absence of calcium, the difference in PS binding by the TIMs is reduced,
with only ~3-7-fold difference between sTIM-1/TIM-4 and sTIM-3, compared to the 1227-fold change in the presence of calcium. However, given that extracellular calcium
levels remain around 1-2 mM135,141, it is unclear if TIM–PS binding in the absence of
calcium will occur in vivo. One possibility that I considered is that additional, less
common biologically relevant cations could enhance PS binding by TIM-3 to different
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extents, perhaps bringing the PS binding of sTIM-3 closer to that of its family members.
To assess this possibility, PS binding of sTIM-3 was examined in the presence of
calcium, in addition to zinc, nickel, magnesium, and manganese (Figure 2.5). The
concentration of sTIM-3 was held constant below its Kd, app to assess the ability of these
cations to promote TIM-3 binding at a concentration below maximal binding. As
expected, addition of 1 mM calcium enhanced binding to PS-containing membranes by
~3-fold at this concentration of TIM-3. On the other hand, addition of 1 mM EDTA in
the presence of calcium reduced binding to about half of the binding observed for sTIM3 alone. Either 1 mM zinc or 1 mM nickel were capable of enhancing PS binding to
similar extents as calcium, by 3.4- and 3.1-fold, respectively. However, no change in
binding was seen in the presence of magnesium (1 mM) or manganese (1 mM). Zinc can
be mobilized intracellularly following T cell activation141, but the levels of extracellular
zinc, approximately 20,000-fold higher than intracellular levels, should remain mostly
consistent. Much less is known about the biological relevance of nickel, especially in the
immune system. Additionally, the extracellular concentration of calcium (~1-2 mM) is
about 100-fold greater than the extracellular concentration of zinc (~15 µM). Therefore,
the more abundant calcium ions are more likely to bind TIM-3 (and its family members)
to enhance PS binding. The decreased PS binding of TIM-3 compared to its family
members measured here is therefore not modified by addition of cations other than
calcium, and calcium is likely to be the most relevant divalent cation for TIM–PS
binding.
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Figure 2.5) Additional divalent cations enhance TIM-3–PS binding to a similar
extent as calcium
Binding of TIM-3 to a lipid surface containing 20% PS (mole/mole) in a PC background
was assessed for sTIM-3 alone or in the presence of various divalent cations, each at 1 mM.
Like calcium (red), both zinc (blue) and nickel (purple) enhanced binding of sTIM-3 to PScontaining surfaces. Addition of magnesium (yellow) or manganese (green) did not affect
sTIM-3–PS binding. Error bars represent ± standard deviation for n=2.
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2.3.3. The extended mucin domain of TIM-3 does not affect phosphatidylserine binding
In addition to their conserved IgV fold that contains the MILIBS where PS binds, as
described above, all TIM family members contain a mucin domain. The mucin domain is
an extended region between the IgV domain and transmembrane helix. Much of the
previous work in the TIM-3 field has utilized only the isolated IgV domain. The entire
TIM-3 extracellular domain was used to study binding of Fc-linked protein to PScontaining surfaces using ELISA71 and RMA-S lymphoma cells in competition with
mTIM-3 IgV tetramers74. However, the impact of the mucin domain on PS binding by
the IgV domain has not yet been directly assessed. Therefore, I expressed and purified
the TIM-3 IgV domain (sTIM-3IgV) in the mammalian Expi293F system for comparison
with sTIM-3 in lipid-binding studies.
sTIM-3IgV was flowed over 20% DOPS surfaces in a DOPC background in the
absence and presence of CaCl2, as described above for sTIM-3. Similar to sTIM-3
containing the complete extracellular region of TIM-3, sTIM-3IgV bound to PScontaining membranes with low micromolar affinity (Figure 2.6, Table 2.3). sTIM-3IgV
bound 20% PS with Kd, app = 10.0 µM in the presence of calcium (Figure 2.6A), similar
to the Kd, app value determined for sTIM-3 (9.7 ± 4.2 µM). Furthermore, sTIM-3IgV
displayed a similar 2-fold reduction in Kd, app in the absence of calcium (Figure 2.6B,
Kd, app = 26.2 ± 4.2 µM), like sTIM-3. Therefore, the mucin domain of TIM-3 does not
appear to modulate the ability of TIM-3 to bind PS. Perhaps, as previously suggested66,
the function of the mucin domain is indeed to extend the ligand binding domain of TIM3 away from the cell surface and towards potential ligand(s) on adjacent membranes.
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Figure 2.6) sTIM-3 and sTIM-3IgV bind PS-containing membranes with similar
affinities
(A) Curves comparing binding of sTIM-3 (solid red curve) and sTIM-3IgV (solid pink
curve) to 20% PS/80% PC (mole/mole) surface (in the presence of 1 mM CaCl2) by surface
plasmon resonance. Curves are fit with one-site, specific binding curves to estimate
Kd, app (nsTIM-3=11, nsTIM-3 IgV=1).
(B) Curves comparing binding of sTIM-3 (dashed red curve) and sTIM-3IgV (dashed pink
curve) to 20% DOPS in a DOPC background with no cation added. One-site specific
binding fits are used to fit data, with representative curves shown (nsTIM-3=3, nsTIM-3 IgV=2).
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Table 2.3) Comparison of sTIM-3 and sTIM-3IgV binding to 20% PS-containing
membranes.
Sample

CaCl2 (mM)

Kd, app ± SD (µM)

N

sTIM-3IgV

1

10.0

1

sTIM-3

1

9.7 ± 4.2

11

sTIM-3IgV

0

26.2 ± 14.7

2

sTIM-3

0

20.4 ± 10.5

3
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2.3.4. Hydrophobic interactions contribute to PS-containing membrane binding by TIMs
Some lipid binding proteins can display specificity for the particular lipid headgroup they
recognize, such as the PLCγ-PH domain, which specifically recognizes inositol (1,4,5)trisphosphate142,143. Other lipid binding proteins, however, utilize the lipid headgroup in
combination with hydrophobic interactions with the lipid surface or electrostatic
interactions to drive membrane association106. For example, the annexin and Gla PSbinding domains both utilize insertion into the hydrophobic membrane core, in addition
to calcium-mediated binding of the PS headgroup, to bind PS-containing surfaces.
Previous work on the murine TIM proteins suggests that a similar mode of lipid binding,
where both head group recognition and membrane interaction make important
contributions to the PS-binding ability of the TIM family. The model of PS binding
generated from the co-crystal structure of dicaproylphosphatidylserine (DCPS) and
murine TIM-3 suggests the insertion of the TIM-3 into the membrane, with residues from
the FC and CC’ loops at the edge of the PS binding pocket directly contacting the
glycerol and fatty acid regions of the phospholipid72. X-ray reflectivity studies on the
TIM-3 relative TIM-4 further support this model and suggest that the TIM FG and CC’
loops at the edge of the MILIBS insert into the membrane upon PS binding70.
To experimentally assess this proposed model of binding to PS-containing
membranes, a short acyl chain version of PS, dihexanoylphosphoserine (DHPS), along
with the L and D enantiomers of the PS headgroup, were used to compete with sTIM
binding to DOPS-containing membranes. Any differences in competition between PS
head groups and short chain PS may indicate the importance of hydrophobic interactions
in TIM–PS binding. For example, if the addition of soluble PS head groups alone
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substantially reduces binding of TIM-3 to a PS-containing surface, the headgroup itself is
likely to be important for the TIM-3–PS interaction. Alternately, if additional
competition occurs with the inclusion of a short acyl chain, hydrophobic interactions
likely also contribute to TIM-3–PS binding.
Competition assays showed that both the PS headgroups and DHPS were capable
of reducing binding of TIM-3 to membrane-bound PS, suggesting that later case is true
for TIM-3 (Figure 2.7). While addition of calcium enhanced sTIM-3 binding as
expected, addition of calcium and O-phospho-L-serine (L-PS) or O-phospho-D-serine
(D-PS) reduced binding to a 20% PS/80% PC surface by approximately 15% and 12%,
respectively (Figure 2.7A). sTIM-3–PS binding was reduced by ~60% in the presence of
DHPS, greater than either head group alone. In the absence of calcium, both the L-PS
and D-PS enantiomers were still capable of reducing PS-binding of sTIM-3IgV by 28%
and 32% respectively (Figure 2.7B), suggesting a lack of stereospecific recognition of
the PS headgroup. The enhanced competition of the PS headgroups in the absence of
calcium may result from overall weaker binding to the PS-surface, as demonstrated in
Section 2.3.2. Even without calcium present, DHPS reduced binding of sTIM-3IgV to the
20% PS surface to a greater extent than either headgroup enantiomer (~40%). Similar
results were obtained for sTIM-4, where inclusion of DHPS reduced binding to a
membrane of 20% PS/80% PC (mole/mole) by 40% compared to the L- and D-PS
enantiomers, which reduced membrane binding by only 15% each (Figure 2.7C).
Together, these data support the model previously proposed by X-ray crystal structures
of murine TIM-3 in complex with DCPS72 and X-ray reflectivity studies of murine TIM470. Additionally, the TIM family MILIBS pocket appears to have some flexibility, as
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Figure 2.7) Short acyl chain and headgroup PS compete for binding with 20% PScontaining membranes
(A) Binding of sTIM-3 (1 µM) to 20% PS/80% PC membranes in the absence (red open
bar) or presence (red filled bar) of 1 mM CaCl2. Addition of L-PS (blue shaded bar) or DPS (gray shaded bar) headgroups (100 µM) slightly decreased binding to PS-containing
surface. sTIM-3–PS binding was decreased to a greater extent by addition of short-chain
DHPS (purple filled bar, 100 µM). Each bar represents the reference-subtracted response
units for binding to the PS-containing surface, normalized to the sTIM-3 + CaCl2 sample,
with n=2. Error bars represent standard deviation.
(B) sTIM-3IgV (5 µM) binding to 20% PS-containing membranes (open pink) was reduced
in the presence of the PS headgroup, either the D (shaded blue) or L (shaded gray)
enantiomer (100 µM). Addition of DHPS (filled purple) further reduced PS-binding. Bars
represent reference-subtracted response units for PS-binding, normalized to sTIM-3IgV.
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(C) Binding of sTIM-4 (0.75 µM) to 20% DOPS/80%DOPC membranes with (green
shaded bar) or without (green open bar) CaCl2. Reference-subtracted response units for
PS-binding normalized to sTIM-4 + CaCl2 are displayed for samples with L-PS (100 µM,
blue shaded bar), D-PS (100 µM, gray shaded bar), or DHPS (100 µM, purple filled bar),
demonstrating the ability of these components to compete with sTIM-4–PS binding. Error
bars represent standard deviation for 2 replicates.
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both L and D enantiomers of PS display similar ability to reduce binding to the surfacebound PS. Moreover, the inclusion of a short acyl chain appears to allow DHPS to
display enhanced competition with surface bound PS, suggesting that interactions made
by the TIM family with the hydrophobic membrane core are also important for binding
to PS-containing membranes.

2.3.5. Mutating hydrophobic residues in the CC’ and FG loops of sTIM-3 reduces PS
binding
The data presented here, combined with previous studies of murine TIM-3, support the
ability of TIM-3 to bind phosphatidylserine. However, the biological importance of this
interaction remains unclear. One useful tool for probing the role of PS in TIM-3 function
would be an intact, well-folded, variant of TIM-3 with reduced or deficient PS binding
for use in cellular or even animal studies. Based on the competition data in Section 2.3.4,
one possible region that might reduce PS binding if mutated are the hydrophobic regions
in the CC’ and FG loops. One benefit of targeting these residues is that they are primarily
solvent exposed, and are therefore unlikely to result in protein misfolding when mutated
– always a concern in mutational loss-of-function studies. Moreover, mutational work
with murine TIM-3 supports the importance of these residues in PS-binding72. Binding
analysis of mutated variants of mTIM-3 determined that residues W41, L99, M100,
N101, and D102 (mature protein numbering) all contribute to the binding of mTIM-3 to
PS. Residues W41 and L99/M100 on the CC’ and FG loops respectively sandwich the
PS at the edge of its binding pocket (Figure 2.8A), while N101/D102 coordinate the
cation inside the MILIBS pocket that binds the negatively charged PS head group.
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Figure 2.8) TIM-3 CC’ and FG loop mutants display reduced PS binding
(A) The X-ray crystal structure of murine TIM-3 in complex with PS (DeKruyff, et al.
2010; PDB: 3KAA, blue) overlaid with that of human TIM-3 (Zhang, et al. 2020, PDB:
6TXZ, red). The inset figure shows the details of the PS-binding site, with a calcium ion in
gray that coordinates the negatively charged PS head group. The hydrophobic W41/S42
(F40 in human TIM-3) in the CC’ loop and the L99/M100 (I96/M97 in human TIM-3) in
the FG loop sandwich the PS in the binding pocket.
(B) Elution profile of wild-type sTIM-3 (sTIM-3WT; red, solid line) and mutated versions
of sTIM-3, sTIM-3F40A (dark red, dotted line) and sTIM-3I96A/M97A (dark red, dashed line)
from a Superose12 size exclusion chromatography column. Molecular weight standards
are shown in gray, with corresponding sizes below the x-axis. sTIM-3 mutants overlap with
the wild-type sTIM-3 elution profile, suggesting that protein samples were homogeneous
and soluble.
(C) Equilibrium binding curves of sTIM-3WT (solid, red), sTIM-3F40A (dotted, dark red),
and sTIM-3I96A/M97A (dashed, dark red) binding to 20% DOPS/80%DOPC with 1 mM
CaCl2. Binding curves were fit with one-site, specific curve fit, and are representative of
three independent experiments.
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Human TIM-3 has a slightly different CC’ loop, and the residue F40 is closest to the
W41 from murine TIM-3 (Figure 2.8A). The residues in the FG loop of hTIM-3 are a bit
closer to those of mTIM-3, with mTIM-3 residues L99/M100 corresponding to I96/M97
of hTIM-3. Therefore, two mutated variants of human sTIM-3 where hydrophobic
residues were replaced with alanine (F40A and I96A/M97A) were recombinantly
expressed and purified. Size exclusion traces confirmed that these constructs were wellexpressed, soluble, homogenous proteins (Figure 2.8B) that could be used in lipidbinding studies.
Using surface plasmon resonance, the binding of sTIM-3F40A and sTIM-3I96A/M97A
to membranes containing DOPS (20% mole/mole) was assessed and compared with
binding of wild-type sTIM-3, as described above. As shown in Figure 2.8C, both sTIM3F40A and sTIM-3I96A/M97A displayed significantly reduced binding compared to wild-type
sTIM-3. sTIM-3F40A reached only approximately 8% of the maximum binding observed
for wild-type sTIM-3, whereas sTIM-3I96A/M97A reached approximately 33% of the
maximum binding. The equilibrium dissociation constants for these mutated sTIM-3
variants were too high to measure accurately, appearing to exceed 200 µM. These data
further support the role of membrane insertion in TIM-3–PS binding and, importantly,
provide an important tool for assessing the role of PS in TIM-3 function in a cellular
context, which will be further discussed in Chapter 3.

2.3.6. Binding of TIMs to other anionic lipids
Since hydrophobic interactions with the membrane surface are important for TIM–PS
binding, I wondered whether TIM-3 (and other TIMs) might bind additional anionic
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phospholipids, differing in their headgroup but not in the acyl chain region. Previous
studies utilized lipid dot blots, where filter papers are blotted with various lipids and
stained with proteins, to assess the ability of TIM-4 and TIM-1 to bind other
phospholipids68,69. These studies demonstrated the ability of TIM-4 and TIM-1 to
recognize PS, but did not detect binding to other lipids. Additional ELISA studies also
did not observe binding of TIM-4 or TIM-1 to phosphoinositide (PI),
phosphatidylethanolamine (PE), or phosphatidylcholine (PC)68,69. Such studies have not
been performed for TIM-3, but crystallographic studies of TIM-4 and TIM-3 suggest that
they display similar methods of PS binding72,75.
Given the lack of stereospecificity with PS, it seemed reasonable to argue that
other anionic phospholipids could also bind the TIM MILIBS. The conserved aspartate
and asparagine side chains in the TIM FG loop coordinate the cation (mainly calcium) in
the MILIBS, which binds the negatively charged phosphate portion of the PS headgroup,
which is shared with other anionic phospholipids (Figure 2.9). In addition, the serine
component of the PS headgroup is pointed towards the solvent exposed area in the cocrystal structures of PS with either TIM-3 or TIM-4, which may leave flexibility for
binding of other phospholipids. Other PS-binding proteins, including lactadherin and
Gas6, bind additional anionic phospholipids beyond PS144,145, further prompting to me to
directly investigate the ability of the TIM family to bind additional phospholipids,
including phosphatidic acid (PA) and phosphatidylethanolamine (PE) (Figure 2.9).
Phosphatidic acid is another anionic component that makes up a small proportion of the
plasma membrane inner leaflet (~1-4%)106,146. PA can be generated from
phosphatidylcholine by phospholipase D hydrolysis, and can modulate localization and
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Figure 2.9) Structure of monounsaturated (18:1, Δ9-cis) phospholipids used to make
unilamellar vesicles
(A) Structure of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) with zero net charge.
DOPC is used to mimic neutral phospholipid background in the cell membrane.
(B) Structure of 1,2-dioleoyl-sn-glycero-3-phosphoserine (DOPC) with net charge of -1.
(C) Structure of 1,2-dioleoyl-sn-glycero-3-phosphate (DOPA) with -1 net charge.
(D) Structure of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) with no net
charge.
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activity of several enzymes, including Shp-1, the protein tyrosine phosphatase that plays
a key role in limiting T cell signaling146. PE is a zwitterionic phospholipid making up
approximately 20% of the plasma membrane147. Like PS and PA, PE is primarily found
on the inner leaflet of the plasma membrane, and PE can be transported to the outer
leaflet during apoptosis148.
As described for PS, lipid vesicles containing the phospholipids phosphatidic acid
(PA) or phosphatidylethanolamine (PE) were immobilized on an L1 sensorchip, along
with PS as a reference, to assess binding of sTIM-3, sTIM-1, and sTIM-4. Given that
calcium was required for strong TIM–PS binding, CaCl2 was included in all binding
reactions. All sTIMs displayed the ability to bind to surfaces containing 20% PA,
although binding saturated at lower levels than was observed for PS (Figure 2.10A-C).
As seen for PS binding, TIM-3 bound to PA-containing membranes with a reduced
affinity compared to its family members TIM-1 and TIM-4. sTIM-1 displayed a unique
activity amongst its family members in that it also bound significantly to surfaces
containing 20% PE (Figure 2.10A), giving signals similar to those seen for PA binding –
which was not observed for sTIM-3 or sTIM-4 (as expected based on previous ELISA
studies)68,71. Although some earlier ELISA studies did not suggest that TIM-1 binds
PE68, other studies have supported the ability of TIM-1 to bind PE and suggest that this
binding is important for TIM-1-mediated viral entry149. Indeed, TIM-1 was first
identified as a hepatitis A virus cellular receptor, as its gene name HAVCR1
suggests61,150. Binding to multiple phospholipid components may be important for the
function of TIM-1 in this context.
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Figure 2.10) TIM family members bind to PS- and PA-containing membranes, but
only TIM-1 binds membranes with PE
(A-C) sTIM binding to 20% DOPS/80% DOPC (circles), 20% DOPA/80% DOPC
(squares), or 20% DOPE/80% DOPC (diamonds) surface was determined in the presence
of 1 mM CaCl2 for sTIM-1 (teal), sTIM-3 (red), and sTIM-4 (green), with binding curves
representative of at least 2 independent experiments, except for TIM-4. Note that all sTIMs
bind PA significantly, but that sTIM-1 is unique in also binding substantially to PE (gray
line in C).
(D-E) sTIM binding to 20% DOPS/80% DOPC (circles) or 20% DOPS/5%DOPA/75%
DOPC (crosses) surface was determined in the presence of 1 mM CaCl2. For each sTIM
protein, adding 5% PA (mole/mole) detectably increases binding.
(F) sTIM-3 binding to 20% DOPS/5% PA/75% DOPC (stars) surface was determined in
the presence of 1 mM CaCl2, and found to exceed that seen for 25% DOPS/75% DOPC
(half-filled circles), indicating some preference for PA.
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Phosphatidylserine is a key signal during apoptosis, where calcium signaling
activates phospholipid scramblases to ablate the membrane asymmetry that is created by
flippases during cell homeostasis67. Additional anionic phospholipids, such as PA and PE
can also be exposed on the cell surface during cell death148,151, yielding a mixture of
phospholipids that might be bound by cell receptors, like the TIMs. To determine if the
presence of additional lipids might impact the TIM-PS interaction, binding of sTIM-1, 3, and -4 to surfaces containing 20% PS was compared with that of surfaces containing
20% PS plus 5% PA. Surprisingly, addition of 5% PA enhanced the lipid binding of all
sTIM proteins, with sTIM-3 displaying the most dramatic increase in binding (Figure
2.10D-F, Table 2.4). The dissociation constant of sTIM-3 for surfaces containing
20% PS + 5% PA (Kd, app = 3.5 ± 0.5 µM) was approximately 3-fold stronger than the
Kd, app for 20% PS alone. sTIM-3 also displayed greater binding to surfaces with 20% PS
+ 5% PA compared to 25% PS (Figure 2.10G), suggesting that the increase in binding is
not simply due to the presence of additional binding sites. There appears to be some
distinct preference for PA. However, this mixed lipid composition did not enhance the
affinity of sTIM-3 to the sub-micromolar level observed for sTIM-1 and sTIM-4.
In summary, all TIM proteins bind PS, along with PA. TIM-1 is unique amongst
this family in its ability to bind PE. The addition of PA can enhance TIM binding to PS
containing membranes beyond that which is seen for the same amount of PS, but TIM-3
still binds lipid surfaces more weakly than its family members TIM-1 and TIM-4.
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Table 2.4) SPR data for TIM family members binding to membranes with 20% PS +
5% PA.
Sample

CaCl2 (mM)

Kd, app ± SD (µM)

N

sTIM-1

1

0.35

1

sTIM-3

1

3.5 ± 0.5

2

sTIM-4

1

1.0

1
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2.3.7. Galectin-9 crosslinks TIM-3
Galectin-9, CEACAM1, and HMGB1 have all been proposed ligands for TIM-3 in
addition to PS, as discussed above. Of these, the HMGB1 binding site on TIM-3 is
unclear, and the CEACAM1 binding site is thought to overlap with the PS binding
pocket124. Galectin-9 binds to carbohydrates attached to TIM-3, so could bind at the
same time as other ligands, and might modulate TIM-3–PS binding, for example.
Galectin-9 is a tandem lectin that binds two glycans through its two separate
carbohydrate recognition domains (CRDs). The predominant hypothesis in the TIM-3
field is that galectin-9 binds TIM-3 to modulate its co-receptor role and cause it to inhibit
T cell function and promote cell death52,119,152. However, it is clear that galectin-9 binds
multiple additional targets beyond TIM-3113-116, and indeed several studies have shown
that galectin-9 can exert effects on T cells independent of TIM-3117,153, making it unclear
from the functional studies how galectin-9 might affect TIM-3 activity. Recent
interesting work has supported the ability of galectin-9 to crosslink TIM-3 with PD-1121,
which suggests that galectin-9 can bind to two protein molecules simultaneously –
associating with carbohydrates on each. In light of this work and our enhanced
understanding of the TIM-3 – PS interaction, I wondered if galectin-9 could crosslink
multiple TIM-3 molecules together to enhance the avidity of its PS binding – which
might increase the strength of TIM-3-mediated interactions with cells that have modest
PS levels on their surface.
To first determine if this model is feasible, I first used NetNGlyc Server
(https://services.healthtech.dtu.dk/service.php?NetNGlyc-1.0) and NetOGlyc Server
(https://services.healthtech.dtu.dk/service.php?NetOGlyc-4.0) to predict glycosylation
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sites in the extracellular region of TIM-3 based on its primary sequence. These prediction
programs identified two possible N-linked glycosylation sites (N78 and N151) and five
possible O-linked glycosylation sites (T114, T124, T132, S156 and T157) on human TIM-3
(Figure 2.1, highlighted in magenta). Of the two N-linked sites that galectin-9 might
bind, only one is in the IgV domain, where the PS binding site is located. Importantly,
this residue, N78, is on the opposite face from the PS binding pocket, and therefore could
permit binding of TIM-3 to both PS and galectin-9 without steric clashing. The
remaining N-glycan site could also permit binding of galectin-9 and PS without steric
hindrance, as it is located in the elongated mucin domain, away from the PS binding site.
With at least two glycans on TIM-3 for galectin-9 binding, galectin-9 may be able
to dimerize or even oligomerize TIM-3, if a single TIM-3 was bound by two galectin-9
molecules that were also bound to an additional TIM-3 molecule each. In this way,
galectin-9 could enhance the avidity of TIM-3 for PS. The sTIM-3 construct used here
was expressed and purified from mammalian Expi293 cells, and should contain
glycosylated residues that galectin-9 can interact with. To experimentally test for the
presence of glycans on the sTIM-3 construct used in these studies, I analyzed sTIM-3
treated with the bacterial amidase peptide-N-glycosidase F (PNGase F) by SDS-PAGE
and Coomassie blue staining. Treatment with PNGase F cleaves the bond between the
asparagine and N-linked glycans at the innermost N-acetylglucosamine residue, resulting
in loss of mass that should be observed in faster migration by SDS-PAGE. Indeed,
treatment of sTIM-3 with PNGase F resulted in the band corresponding to sTIM-3
running further on SDS-PAGE than untreated sTIM-3 (red arrow, Figure 2.11A),
suggesting that glycans were removed from the protein in the presence of PNGaseF.
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Figure 2.11) Galectin-9 crosslinks TIM-3
(A) SDS-PAGE analysis of sTIM-3 treated with PNGase F. Untreated sTIM-3 (red arrow,
left) runs between the 50 and 37 kDa markers (lane 2), and addition of PNGase F (gray
arrow) shifts the sTIM-3 band below the 37 kDa molecular weight marker (lane 3).
(B) SDS-PAGE analysis of recombinantly expressed ssGal9. Clarified E. coli cell lysate
was incubated with lactose affinity beads to capture ssGal9. Lactose bead flow throw (FT)
and wash fractions (W) did not contain ssGal9. ssGal9 was eluted with four 1 column
volume fractions containing 200 mM lactose (1-4) and that were >90% pure. ssGal9
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fractions were dialyzed to remove free lactose before use in crosslinking and surface
plasmon resonance experiments.
(C) SDS-PAGE analysis (Coomassie blue stained) of chemical crosslinking of sTIM-3 and
ssGal9. Protein samples of sTIM-3 alone (lane 1), ssGal9 alone (lane 2), or sTIM-3 with
ssGal9 were all incubated with DSS (300 µM, 37.5-75-fold molar excess) at 25˚C for
30 min before quenching the reaction and boiling samples. High molecular weight species
are observed only in the presence of sTIM-3 and ssGal9, supporting the ability of ssGal9
to crosslink sTIM-3.
(D) Western blot analysis of cross-linked samples in (C). Blotting with anti-TIM-3 shows
increasing intensity of sTIM-3 in larger molecular weight complexes with increasing
concentrations of ssGal9 (lanes 2-4), but not in the absence ssGal9 (lane 1).
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These data therefore suggest that, as expected, sTIM-3 contains N-glycan(s) that
galectin-9 can bind.
To test the ability of galectin-9 to bind and multimerize TIM-3 directly, sTIM-3
was mixed with galectin-9 in the presence of the crosslinking reagent disuccinimidyl
suberate (DSS). If galectin-9 does oligomerize TIM-3, DSS will covalently link these
molecules to form a larger molecular weight complex which will migrate more slowly on
SDS-PAGE. In these reactions, a variant of galectin-9 called ssGal9 was used in place of
full-length, long isoform galectin-9, as the full-length protein was insoluble in several
expression systems that I tested. ssGal9 is a stable, soluble version of galectin-9 with a
modified linker peptide to reduce susceptibility to proteolysis131. ssGal9 was
recombinantly expressed in E. coli and was purified using lactose affinity
chromatography (Figure 2.11B). SDS-PAGE analysis with Coomassie blue staining and
immunoblotting for TIM-3 were then used to analyze sTIM-3, ssGal9, and sTIM-3 with
ssGal9 in the presence of DSS. In the presence of DSS alone, sTIM-3 formed a single
species at approximately 40 kDa, consistent with the expected size for the glycosylated
sTIM-3 monomeric species (Figure 2.11C, lane 1; Figure 2.11D, lane 1). However, in
the presence of ssGal9 and DSS, sTIM-3 was detected in several higher molecular
weight species, which were more prominent with increasing concentrations of ssGal9
(Figure 2.11C, lane 3-5; Figure 2.11D, lane 2-4). The higher molecular weight species
were not seen when ssGal9 alone was treated with DSS (Figure 2.11C, lane 2) or when
sTIM-3 alone was treated with DSS (Figure 2.11C, lane 1 and Figure 2.11D, lane 1),
suggesting that both proteins were necessary to generate these larger protein complexes.
Interestingly, the higher molecular weight species appear to form a ladder. As TIM-3 has
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at least 2 glycosylation sites, these ladders could represent species with multiple galectin9 molecules bound to multiple sTIM-3 molecules, reminiscent of the LAT-Grb2-SOS
“mats” or assemblies that form through multivalent interactions between these
complexes30. Although the precise state of these complexes is difficult to determine,
these data nonetheless support the ability of galectin-9 to bind and crosslink TIM-3
through its glycosylated residues.

2.3.8. Galectin-9-linked TIM-3 displays enhanced avidity for PS-containing membranes
After confirming the ability of galectin-9 to crosslink TIM-3, I next aimed to determine
how this effect might modulate the ability of TIM-3 to bind PS. As described above, the
location of the predicted glycosylated residues and the known PS binding site could
permit TIM-3 to bind both galectin-9 and PS simultaneously. I therefore hypothesized
that the presence of ssGal9 should oligomerize sTIM-3 and might enhance its avidity for
PS-containing membranes. To evaluate this hypothesis, I used surface plasmon
resonance to compare binding of sTIM-3 alone and ssGal9-bound sTIM-3 to surfaces
containing PS. An ideal experiment to evaluate this hypothesis would be to compare the
Kd determined for sTIM-3 with that determined for sTIM-3 in the presence of ssGal9.
However, despite the improvement in the modified ssGal9 construct compared to the
full-length form, ssGal9 retains a solubility limit at approximately 10 µM, above which
the protein precipitates. Unfortunately, this solubility limit prevented me from achieving
the reaction conditions necessary to determine the affinity of ssGal9-bound sTIM-3 for
PS for comparison with the Kd, app determined for sTIM-3 alone.
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To overcome this limitation, PS binding was instead assessed at one concentration
of sTIM-3 with ssGal9 titrated into the solution. I reasoned that, if ssGal9 enhances the
avidity of TIM-3 for PS, addition of increasing amounts of ssGal9 into a constant
concentration of sTIM-3 should result in an increased binding response, or RUs. As
shown in Figure 2.12A, adding ssGal9 increased binding of sTIM-3 to PS-containing
membranes at all concentrations tested (compare dark blue point on the y-axis,
representing binding of sTIM-3 without ssGal9, to remaining blue points). Since the
response units are proportional to the mass bound to the chip, the increase in RU in the
presence of ssGal9 could represent increased avidity of sTIM-3 for PS, or increased mass
on the chip from ssGal9 binding sTIM-3. To evaluate these two possibilities, this
experiment was repeated with two mutated forms of ssGal9: R65D and R200D
(corresponding to R239 in full-length galectin-9). These mutations change the charge of
a key residue in the N or C terminal CRD111, and therefore should still permit binding to
glycans via their remaining functional CRD. Indeed, previous work found that a single
mutation in either CRD of Galectin-9 still permitted binding to TIM-352. However, these
mutants should have reduced or abrogated ability to crosslink sTIM-3, due to the
mutation in their other CRD. As shown in Figure 2.12A, addition of ssGal9R65D or
ssGal9R200D to sTIM-3 failed to enhance PS binding to the same degree as ssGal9WT
(compare dark green and gold curves to dark blue curve), suggesting that the increased
RU signal is due to increased PS binding by TIM-3, rather than additional mass from
ssGal9.
Another way to examine the effect of ssGal9 on the avidity of TIM-3 for PS is to
assess the off rates of sTIM-3 alone and sTIM-3 in the presence of ssGal9. If ssGal9 does
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Figure 2.12) Crosslinking by ssGal9 enhances sTIM-3 avidity for PS-containing
membranes
These experiments were performed in collaboration with Alice Li.
(A) Binding of sTIM-3 (6 µM) to 20% PS-containing membranes in the presence of 1 mM
CaCl2 and increasing concentrations of ssGal9WT (dark blue solid curve), ssGal9R200D (dark
green dotted curve), and ssGal9R65D (gold dashed curve) from 50 nM to 1.5 µM. Substantial
increase in PS binding is observed only in the presence of bivalent ssGal9, but not either
mutant. Error bars represent standard deviation for n=3 replicates.
(B) Representative reference-subtracted sensorgram of sTIM-3 alone (6 µM, red solid
curve) or in combination with ssGal9WT (0.75 µM, dark blue solid curve), ssGal9R200D (0.75
µM, dark green dotted curve), and ssGal9R65D (0.75 µM, gold dashed curve), binding to
immobilized lipid membranes containing 20% PS/80% PC. Injection begins around 75 s,
with the rapid increase in signal indicating binding to the PS-containing surface. At the end
of the 300 s injection, proteins dissociate from the surface, as highlighted in the gray inset.
Signal rapidly falls for sTIM-3 alone, sTIM-3 with ssGal9R200D, or with ssGal9R65D
reflecting rapid dissociation. Dissociation is much slower for sTIM-3 with ssGal9WT,
however. The dissociation curves are fit with a one phase exponential decay curve (black
lines) to estimate an off-rate, as shown in Table 2.5.
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increase the avidity of TIM-3 for PS, TIM-3 should display a significantly slower
dissociation from the PS surface, as at least two TIM-3 molecules will need to
completely dissociate from the membrane for the signal to decrease. Indeed, analysis of
the sensorgrams – traces of the change in RU throughout the injection of the protein
solution over the lipid surface – of sTIM-3 alone (red curve) compared to sTIM-3 with
ssGal9WT (dark blue curve) show that sTIM-3 dissociates from the PS-surface much more
slowly in the presence of ssGal9. Importantly, addition of ssGal9R65D (gold curve) or
ssGal9R200D (dark green curve) does not change the dissociation rate of sTIM-3 compared
to that of sTIM-3 alone (Figure 2.12B). By fitting these dissociation curves with a one
phase exponential decay function (Figure 2.12B, inset), the off-rate of each sample can
be estimated. As shown in Table 2.5, the presence of wild-type ssGal9, but not mutant
ssGal9, slowed the off-rate of sTIM-3 from the PS-membrane by approximately 10-fold.
These data therefore provide additional support for a model where galectin-9 crosslinks
sTIM-3 molecules together to enhance the avidity of sTIM-3 for PS. Furthermore, these
findings provide the first evidence that sTIM-3 can simultaneously bind multiple ligands,
which is likely to be important for regulating the activity of TIM-3 in cells. Interestingly,
this 10-fold slower off rate in the presence of ssGal9 would correspond with a 10-fold
stronger dissociation constant, which would bring sTIM-3 into the same affinity range as
the sub-micromolar dissociation constant observed for sTIM-1 and sTIM-4. In other
words, galectin-9 mediated oligomerization of TIM-3 could ‘convert’ it into a high
affinity PS binding protein similar to TIM-1 or -4, which could have important functional
consequences.
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Table 2.5) Off-rates of sTIM-3 with 1 mM CaCl2 from a 20% PS/80% PC
membrane in the presence of wild-type (WT) or mutant ssGal9 constructs,
determined from SPR sensorgrams.
Sample

koff (sec-1)

sTIM-3

0.30

sTIM-3 + ssGal9WT

0.032

sTIM-3 + ssGal9R65D

0.27

sTIM-3 + ssGal9R200D

0.23
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2.4. Discussion
As a first step in understanding how PS regulates TIM-3, I explored the PS-binding of
TIM-3 in relation to its family members and assessed the impact of galectin-9 on this
interaction. The SPR studies utilized here allowed determination of a dissociation
constant for TIM-3 and its family members. sTIM-3 bound PS-containing membranes
with a low micromolar affinity (9.7 ± 4.2 µM) in the presence of calcium, which is 12fold to 27-fold weaker than the dissociation constants determined for sTIM-4
(0.77 ± 0.32 µM) and sTIM-1 (0.35 ± 0.05 µM). PS-binding of sTIM-3, sTIM-1, and
sTIM-4, were all enhanced by calcium, and zinc and nickel cations were also able to
increase binding of TIM-3 to PS-containing membranes. Importantly, the Kd, app values
determined here for sTIM-3 and its ligand PS are similar to those determined for
recognition of the prototypical T cell co-receptors CD28 and PD-1 for their respective
ligands, CD80/86154 and PD-L1155, as well as other PS binding proteins, lipid-binding PH
domains, and other membrane-binding proteins106,132,156, suggesting they are in the range
of biologically relevant interactions.
Additional work described here also provide the first evidence that TIM-3 can
bind multiple ligands simultaneously, and that the presence of one TIM-3 ligand can
impact binding of another. Galectin-9 has been the focus of most of the TIM-3 literature,
despite some work suggesting that galectin-9 has TIM-3-independent functions117,153.
Here, I showed that galectin-9 can crosslink TIM-3 and enhance its avidity for PScontaining membranes, which might have important functional consequences. If TIM-3
can indeed bind multiple ligands in a cellular context, both levels of PS and galectin-9 in
culture might modulate the activity of TIM-3, making this system quite complex.
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Additional information about the nature of the complex formed when galectin-9, TIM-3,
and PS are present will be important for understanding how this system works.
A key limitation of the studies described here is the solubility limit of ssGal9. I
encountered protein precipitation following centrifugal concentration of the protein
sample, which, unfortunately, prevented preparation of samples needed to complete
several quantitative experiments of interest. If higher protein concentrations of ssGal9
could be obtained, two interesting experiments would be (1) to determine a full binding
curve of sTIM-3 to PS-containing membranes with ssGal9 and (2) Small-angle X-ray
scattering (SAXS) analysis of the sTIM-3/ssGal9 complex to assess its size, shape,
heterogeneity, and possibly stoichiometry. The first experiment would allow a
comparison of dissociation constants for TIM-3 and TIM-3 crosslinked by ssGal9 to
directly assess the effect of galectin-9 on PS binding. The second experiment would help
to elucidate the nature of the complex formed between TIM-3 and ssGal9, which has the
potential to form larger oligomeric complexes due to the bivalent nature of ssGal9 and
the presence of at least two predicted N-glycans on TIM-3 where ssGal9 could bind. I did
attempt this experiment with the maximal concentrations of TIM-3 and ssGal9 I could
achieve, but unfortunately, the scattering signal was too low to generate informative
results. If the concentration of ssGal9 could be increased, the findings from these
experiments could inform what types of complexes might be expected to form in cells,
and also what levels of each ligand might be needed to observe an effect on TIM-3
function.
While several questions regarding the impact of galectin-9 still remain
unanswered, the biochemical analysis of the interaction between TIM-3 and PS described
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here is useful in evaluating the role of this interaction on TIM-3 activity in cells, and
suggests a new model for its function. In addition to a defined measurement of interaction
between human TIM-3 and PS-containing membranes, residues involved in PS-binding
were also identified. Mutation of either F40 or I96/M97 to alanine significantly reduces
TIM-3–PS binding. Modulating PS levels in cells might be a difficult approach in
exploring the impact of this interaction on TIM-3 activity; therefore, variants of TIM-3
that are soluble but display substantially reduced PS binding, such as those identified
here, provide an alternate approach to exploring the impact of PS-binding on TIM-3
activity in cellular studies, which will be detailed in Chapter 3.
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CHAPTER 3. Investigation of the role of PS in TIM-3 function
Parts of this chapter are modified excerpts from Smith, C.M., et al., Biochemical Journal,
2021.
3.1. Introduction
Ligand engagement of co-stimulatory and co-inhibitory molecules regulates their activity,
and the sum of these interactions, in conjunction with TCR engagement by peptide-MHC,
determines the direction and magnitude of the T cell response4. The ligand requirements
for engaging and regulating TIM-3, however, remain incompletely understood. Although
the work described here and elsewhere70-72 have confirmed the ability of both human and
murine TIM-3 to bind phosphatidylserine (PS), the functional consequence of this
interaction in T cells remains completely unknown. T cells expressing TIM-3 have only
been shown to conjugate to apoptotic cells with PS exposed on their outer surface72; no
change in signaling or T cell activity as a consequence of TIM-3–PS binding has yet been
documented. In general, the effect of PS binding on TIM-3 function has been largely
overshadowed by studies of galectin-9, even though this glycan-binding molecule is
known to bind other receptors113-116 and displays many TIM-3-independent
effects117,153,157. One exception to this is recent work exploring the impact of TIM-3 and
PS in NK cells88, where treatment with PS resulted in increased TIM-3 phosphorylation
and modified NK cell function, suggesting that this receptor-ligand interaction is capable
of more than just conjugating cells together. Why might T cells need to sense PS via
TIM-3 and signal in response? TIM-3 could permit T cells to recognize and respond to
PS exposed on the surface of apoptotic cells, other activated T cells, or even tumor cells
in their environment, which all have elevated PS on their surfaces67,88,107,158. PS
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recognition might then have a role in promoting or braking the immune response,
depending on the circumstances.
In this Chapter, I aimed to investigate the requirement of ligand binding for the
effects of TIM-3 on T cell activity, and to determine whether PS is capable of serving as
a ligand that controls TIM-3 function in T cells. Specifically, I utilized a Jurkat cell
model system to identify the effects of TIM-3 on T cell activity, including a
transcriptional reporter of T cell signaling, changes in phosphorylation of components of
the TCR cascade, and analysis of cytokines released following T cell activation. I then
employed chimeric receptors, mutated variants of TIM-3, and blocking antibodies to ask
if PS binding is important for those functions of TIM-3. The findings described here
support a key role for PS in modulating the effect of TIM-3 on T cell activity, and
suggest tools that might be used to further explore the importance of this interaction in
primary cells and in vivo in future studies.

3.2. Materials and Methods
3.2.1. Cloning and constructs
pCDEF3-hTIM-3 was a gift from Dr. Lawrence Kane (Addgene plasmid #49212), and
contained the natural TIM-3 variant L119, which was corrected to R119 by site-directed
mutagenesis. Full length human TIM-3 (R119) was then sub-cloned into pcDNA3.1(+)
using Gibson assembly130. Human PD-1 in pENTR223159 was a generous gift from Dr.
Aaron Ring at Yale University. Plasmids containing human TIM-1 and human TIM-4
were obtained from Origene. The lentivirus transfer plasmid was a generous gift from the
laboratory of Dr. Mandar Muzumdar at Yale University and contained AmpR, PuroR
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under the simian virus 40 promoter, and the gene of interest under the phosphoglycerate
kinase promoter160. The lentivirus envelope and packaging plasmids pMD2.G and pCMV
delta R8.2 were gifts from Dr. Didier Trono (Addgene plasmids #12259 and #12263).
cDNA fragments encoding human TIM-3 and human PD-1 were sub-cloned into the
lentivirus transfer plasmid. TIM-1-3 (TIM-1 signal sequence+S1-G285 + TIM-3 I182-P280),
TIM-4-3 (TIM-4 signal sequence+E1-Q290 + TIM-3 I182-P280), and PD-1/TIM-3 chimerae
(PTT: PD-1 signal sequence+F1-V147 + TIM-3 I182-P280; PPT: PD-1 signal sequence+F1I168 + TIM-3 F203-P280) were constructed in the lentivirus transfer vector using Gibson
assembly. The TIM-3F40A and TIM-3I96A/M97A variants were generated by QuikChange
site-directed mutagenesis (Agilent) in the lentivirus transfer vector for cellular studies.
Sequencing was performed to validate all plasmids before use.

3.2.2. Cell culture
The NF-kB/Jurkat/GFPTM Transcriptional Reporter cell line was obtained from System
Biosciences, and was cultured in RPMI-1640 media supplemented with 10% FBS, 100
U/ml penicillin, and 100 µg/ml streptomycin at 37˚C with 5% CO2 in a humidified
environment. HEK293 LTV cells (Cell Biolabs Inc.) used to generate lentivirus were
cultured in DMEM supplemented with 10% FBS, 100 U/ml penicillin, and 100 µg/ml
streptomycin at 37˚C in 5% CO2 in a humidified environment. Human peripheral blood
mononuclear cells (PBMCs) were a generous gift from the laboratory of Dr. Susan
Kaech. PBMCs were cultured in RPMI-1640 media supplemented with 10% FBS, 2 mM
GlutaMAX (ThermoFisher Scientific), 50 µM beta-mercaptoethanol, 100 U/ml
penicillin, and 100 µg/ml streptomycin at 37˚C with 5% CO2 in a humidified
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environment. Raji B cells were obtained from American Type Culture Collection and
were cultured in RPMI-1640 media supplemented with 10% FCS, 100 U/ml penicillin,
and 100 µg/ml streptomycin at 37˚C with 5% CO2 in a humidified environment.

3.2.3. Lentivirus transduction
Lentiviruses were generated by co-transfecting HEK293 LTV cells with lentivirus
transfer, envelope, and packaging plasmids using the Mirus Bio TransIT-Lenti
Transfection Reagent, according to the manufacturer’s protocol. Briefly, HEK293 LTV
cells were cultured to 80-95% confluency. Plasmids were mixed with Opti-MEM and
TransIT-Lenti Transfection Reagent and were incubated at room temperature for 10 min
before being added to HEK293 LTV cells and incubating at 37˚C, 5% CO2. After 48 h,
virus-containing medium was collected and filtered through a 0.22 µm filter. Filtered
virus suspension was then added to Jurkat cells (2 x 105 cells), and cells were transduced
with lentivirus by spinfection (spinning at 800 x g for 30 min at 32°C)161 in sealed
aerosol containment lids. Three days after transfection, medium was replaced and cells
were selected with puromycin (1 µg/ml) for 2 days. After selection, medium was
replaced again and cells were allowed to recover. Following selection, receptor
expression was verified by flow cytometry. Cells were washed in FACS Buffer: 10%
FBS plus 0.1% NaN3 in phosphate-buffered saline (PBS) 0.22 µm filtered. Cells were
then stained with antibodies in the dark, including phycoerythrin-conjugated forms of
anti-TIM-3 (R & D Systems, catalog #FAB2365P), anti-PD-1 (BioLegend, catalog
#329905), anti-TIM-1 (BioLegend, catalog #353903), anti-TIM-4 (BioLegend, catalog
#354003), or with an unlabeled TIM-3 primary antibody (R & D Systems, catalog
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#AF2365) using a phycoerythrin-conjugated anti-goat secondary antibody for detection
(R & D Systems, catalog #F0107). Cells were rewashed and then analyzed on a
FACSMelody (Becton Dickinson), with a four-color set up (488 nm and 561 nm lasers
with 527/32, 700/54, 582/15, and 613/18 filter sets).

3.2.4. Western blotting analysis
NF-kB GFP reporter Jurkat cells were serum starved and stimulated with anti-CD3 clone
OKT3 (BioLegend, catalog #317326) and anti-CD28 clone CD28.2 (BioLegend, catalog
#302943). Additional treatments are stated in figure legends. Where wortmannin was
used (in Figure 3.7), cells were pre-treated with drug for 1 h before stimulation. Cells
were pelleted by centrifugation (800 x g for 1.5 min) in the last 1.5 min of stimulation.
Supernatant was removed, and cells were lysed in ice-cold Lysis Buffer (Cell Signaling
Technology) with freshly added cOmplete protease inhibitor (Roche) and PhosSTOP
phosphatase inhibitor (Roche). Lysates were clarified by centrifugation (10,000 x g for
10 min at 4˚C), and clarified lysate was isolated. Clarified lysates were mixed with
NuPAGE LDS Sample Buffer (Invitrogen) plus dithiothreitol (DTT) and were boiled for
8 min. Samples were then analyzed by SDS-PAGE using NuPAGE 4-12% Bis-Tris gels.
Gels were transferred to 0.22 µm nitrocellulose membranes using the Xcell Surelock
Electrophoresis system (ThermoFisher Scientific). To probe multiple proteins
simultaneously without requiring stripping and reprobing, a multistrip Western blotting
procedure was used162, in which horizontal strips are excised from the nitrocellulose
membrane corresponding to molecular weight guides to allow probing of one blot with
several antibodies. Membranes were blocked with 4% BSA in Tris-buffered saline plus
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Tween20, probed with primary antibody for 1 h to overnight, and then probed with HRPtagged secondary antibodies for 1 h. Antibodies used for Western blotting included antiZap70 pY319 (Cell Signaling Technology, catalog #2701), anti-LAT pY220 (Cell
Signaling Technology, catalog #3584), anti-PLCg pY783 (Cell Signaling Technology,
catalog #14008), anti-ERK1/2 pT202/pY204 (Cell Signaling Technology, catalog
#9106), anti-Grb2 (Cell Signaling Technology, catalog #3972), anti-CD28 pY218
(Sigma Aldrich, catalog #SAB4504133), anti-CD28 pY191 (Cell Signaling Technology,
catalog #16399), anti-Akt pT308 (Cell Signaling Technology, catalog #2965), anti-TIM3 (R & D Systems, catalog #AF2365), anti-TIM-3 (Abcam, catalog #ab241332), and
anti-PD-1 (Cell Signaling Technology, catalog #86163). Detection was by enhanced
chemiluminescence using SuperSignal Western Pico PLUS Chemiluminescent substrate
(ThermoFisher Scientific), with visualization and quantitation using a Kodak Image
Station (Kodak Scientific).

3.2.5. Widefield fluorescence microscopy: Detection of TIM-3
Jurkat reporter cells virally transduced to express TIM-3 were pelleted by centrifugation
(300 x g for 5 min) before washing with ice-cold PBS for three washes total. Cells were
fixed in 4% paraformaldehyde in PBS for 15 min at room temperature. Jurkat cells were
then cytospun onto microscope slides at 800 RPM for 5 min. On the slide, cells were
incubated in permeabilization buffer (0.1% Triton X-100 in PBS) for 7 min at room
temperature. Permeabilization buffer was gently aspirated from the slide. Cells were
washed with PBS before gentle aspiration and blocking with 1% BSA for 15 min at room
temperature. After gently aspirating the blocking solution, cells were incubated with
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staining buffer, anti-TIM-3—AlexaFluor® 647 (R & D Systems, #FAB2365R, 1:200 in
PBS), for 1 h in the dark. After incubation with primary antibody, solution was removed
by gentle aspiration, and cells were washed 3 times in PBS. Cells were then mounted
with ProLongTM Diamond Antifade Mountant with DAPI (ThermoFisher Scientific,
catalog #P36966) per the manufacturer’s instructions. Images were collected with a
Nikon Eclipse Ti2 widefield fluorescence microscope. Excitation was provided by a Sola
light engine with a DAPI or Cy5 filter cube set. Emission was collected by an sCMOS
pco.edge camera. Images were analyzed using FIJI software.

3.2.6. Expression of TIM-3 on peripheral blood mononuclear cells
After overnight recovery, thawed PBMCs were transferred to a 24-well plate coated with
1 µg/ml aCD3 (BioLegend, catalog #317326), and soluble aCD28 (1 µg/ml; BioLegend,
catalog #302943) was added to the culture to promote outgrowth of T cells. Cells were
maintained between 0.25 and 0.5 x 106 cells per cm2 with aCD3/aCD28 stimulation for
7 days to promote expression of TIM-3163. After 7 days, PBMCs were washed in FACS
Buffer (10% FBS plus 0.1% NaN3 in PBS 0.22 µm filtered). PBMCs were then stained
with phycoerythrin-Dazzle594-labeled anti-CD3 (Biolegend, catalog #317345), PerCPCyanine5.5TM-labeled anti-CD8 (Biolegend, catalog #301031), BB515-labeled anti-CD4
(BD Biosciences, catalog #564420), and phycoerythrin-labeled anti-TIM-3 (R & D
Systems, catalog #FAB2365P) in the dark. Cells were then washed again in FACS
Buffer before analysis on a FACSMelody. PBMCs were first subjected to doublet
discrimination before analyzing for expression of cell surface markers, as shown in
Figure 3.2.
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3.2.7. NF-κB GFP reporter assay
NF-kB GFP reporter Jurkat cells were resuspended in RPMI-1640 media with 0% FBS
and were serum starved for 4 h. After starvation, cells were counted and 5 x 105 cells
were plated in a V-bottom 96-well plate and stimulated with aCD3/aCD28 (1 µg/ml
each, or 0.5 µg/ml for aCD28), with additional treatments as stated in figure legends. In
experiments investigating effects of anti-TIM-3 (clone F38.2E2, ThermoFisher Scientific
#16-3109-85), cells were pre-treated with TIM-3 antibody for 1 h before stimulation with
aCD3/aCD28. Cells were returned to the incubator at 37˚C, 5% CO2 for 16 h. Cells were
then washed in FACS Buffer prior to analysis using the FACSMelody. Data were
analyzed using FlowJo software. GFP signal was quantified for single cells, as
determined through SSC-Height vs. SSC-Width and FSC-Height vs. FSC-Width gates.

3.2.8. IL-2 ELISA
NF-kB GFP reporter Jurkat cells were resuspended in RPMI-1640 media with 0% FBS
and were serum starved for 4 h. After starvation, cells were counted and 5 x 105 cells
were plated in a V-bottom 96-well plate. Cells were stimulated with 1 µg/ml aCD3
(BioLegend, catalog #317326) plus 0.5 or 1 µg/ml aCD28 (BioLegend, catalog
#302943), and returned to the incubator at 37˚C, 5% CO2, for 16 h. In experiments
analyzing the effect of anti-TIM-3 F38.2E2, cells were pre-treated with anti-TIM-3 for
1 h before stimulation with aCD3/aCD28 for 16 h. In experiments using Raji B cellbased stimulation, Raji B cells were loaded with 30 ng/ml Staphylococcal enterotoxin E
(Toxin Technology Inc., catalog #ET404) for 30 min at 37˚C and were washed in serumfree RPMI-1640 media to remove excess toxin. Jurkat NF-kB GFP reporter cells were
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serum starved in RPMI-1640 media with 0% FBS for 3 h. After starvation, 2 x 105 Jurkat
cells were mixed with 105 SEE-loaded Raji B cells per well in a 96-well U-bottom plate,
as described164. The plate was centrifuged for 1 min at 300 x g to initiate cell contact, and
plate was returned to incubator at 37˚C, 5% CO2, for 6 h. Following antibody or cellbased stimulation, media was collected for analysis of IL-2 secretion by ELISA (R & D
Systems, cat #D2050), following the IL-2 Quantikine ELISA manual. Experiments were
performed in technical duplicate and biological triplicate.

3.2.9. Luminex
As described above, Jurkat reporter cells were serum starved at 37˚C for 4 h in RPMI1640 with 0% FBS. For analysis of TCR components, 2.5 x 106 cells were resuspended
in fresh serum-free media after starvation. Cells were stimulated with a final
concentration of 1 µg/ml aCD3 and 1 µg/ml aCD28, as described above, for 0, 5, 20, 40,
or 60 min. With 2.5 min remaining in the stimulation, cells were pelleted by
centrifugation at 800 x g for 2 min. The supernatant was removed, and cells were
resuspended in 100 µl of ice-cold Lysis Buffer (Cell Signaling Technology) with
cOmplete protease inhibitor (Roche) and PhosSTOP phosphatase inhibitor (Roche)
added fresh. Lysates were mixed by vortexing, and then were centrifuged for 10 min at
10,000 x g at 4˚C. The supernatant (clarified lysate) was then recovered in a fresh tube
and stored at -80˚C until analysis. Thawed lysates were reclarified to remove any
precipitate that had formed. The Milliplex T-Cell Receptor Signaling Magnetic Bead Kit
7-plex (Millipore Sigma, #48-690MAG) was brought to room temperature and prepared
according to the manufacturer’s instructions. Briefly, the kit was first equilibrated in
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assay buffer. After decanting the buffer, each well was prepared with diluted beads and
sample buffer, standard controls, or cell lysates before overnight incubation with shaking
at 4˚C. After incubation, the liquid was decanted using a magnetic plate to recover the
beads. The plate was washed with assay buffer, and was then incubated with detection
antibodies, followed by streptavidin-phycoerythrin. The plate was then read on a
Luminex MAGPIX® System. The net median fluorescence intensity (MedFI) of for each
phosphospecific antibody in each sample was recorded and averaged for three technical
replicates. Averaged net MedFI values were then normalized to the beta-tubulin signal
and reported.
For analysis of TNF-a, cells were starved for 4 h in serum-free RPMI-1640
media. Following starvation, 5 x 105 cells were resuspended in 0.35 ml fresh serum-free
medium, and then were plated in a V-bottom 96-well plate. Cells were then stimulated
with 1 µg/ml aCD3 and 1 µg/ml aCD28 overnight at 37˚C. The next day, the 96-well
plate containing the stimulated cells was centrifuged (300 x g, 5 min), and supernatants
from each sample were isolated for analysis. Components of the HCYTOMAG-60K
Human Cytokine kit, including beads for detecting TNF-a (Millipore Sigma), were
warmed to room temperature and were prepared according to the manufacturer’s
instructions, including standards with known TNF-a concentrations. After adding assay
buffer and standards or cell medium, plates were incubated for 2 h at room temperature
with shaking. Plates were washed, using a magnetic plate to recover the beads. After
incubation with detection antibodies and streptavidin-phycoerythrin, beads were washed
and plate was analyzed on the Luminex MAGPIX® System. Using the Luminex analysis
software, standard curves were created and fit with a log5P curve, which was used to
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determine the concentration of TNF-a in each sample. Every sample contained three
biological repeats with two technical repeats of each.

3.2.10. Analysis of CD28 expression
Expression of CD28 on the cell surface of the Jurkat reporter cells was analyzed by flow
cytometry. Jurkat cells were washed in ice-cold FACS Buffer for three total washes.
Cells were stained with anti-CD28 labeled with PerCP-Cyanine™5.5 (Biolegend catalog
#302922) for 1 h on ice in the dark. Cells were washed three times again in ice-cold
FACS Buffer, and then were analyzed on a BD FACSMelody. FlowJo software was used
for data analysis, and gating on SSC-Height vs. SSC-Width and FSC-Height vs. FSCWidth was used to identify singlets for analysis of PerCP-Cyanine5.5 signal.

3.2.11. Unilamellar vesicle preparation
Lipid vesicles were prepared as described in Section 2.2.3.

3.2.12. Annexin V cell staining: Flow cytometry
PerCP-CyanineTM5.5 or FITC-labeled annexin V were obtained from BioLegend (catalog
#640936 and 640905). As specified by the manufacturer, cells were washed twice with
ice-cold PBS and then resuspended in 10 mM HEPES pH 7.5, 140 mM NaCl, 2.5 mM
CaCl2 (binding buffer). Annexin V-PerCP-Cyanine5.5 or -FITC was added to each
sample and incubated for 15 min in the dark. Additional binding buffer was added to
each sample, followed by analysis using FACSMelody (Becton Dickinson) and FlowJo
software.
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3.2.13. Annexin V cell staining: Widefield fluorescence microscopy
AlexaFluor® 647-labeled annexin V was obtained from Biolegend (catalog #640911).
As detailed above, Jurkat NF-kB GFP reporter cells were washed twice with ice-cold
PBS and resuspended in annexin V binding buffer (10 mM HEPES pH 7.5, 140 mM
NaCl, 2.5 mM CaCl2). Annexin V-AlexaFluor® 647 was added to cells and incubated
for 15 min in the dark. Cells were then fixed in 4% paraformaldehyde in PBS with 2.5
mM CaCl2 for 15 min. Annexin V-stained cells were cytospun onto microscope slides at
800 RPM for 5 min. Cells were mounted to the slide with ProLongTM Diamond Antifade
Mountant with DAPI (ThermoFisher Scientific, catalog #P36966) per the manufacturer’s
instructions. Images were collected with a Nikon Eclipse Ti2 widefield fluorescence
microscope using a Nikon Plan Apo λ 40x 0.95 N.A. objective. Excitation was provided
by a Sola light engine with DAPI or Cy5 filter cube sets. Emission was collected by an
sCMOS pco.edge camera. Images were analyzed with FIJI software.

3.2.14. Quantification and statistical analysis
All experiments were completed with at least three biological repeats unless noted
otherwise. For transcriptional reporter experiments, each independent experiment
included three technical repeats. In addition to mean fluorescence intensity (MFI), the
percent of GFP-positive cells and the median fluorescence intensity of GFP-positive cells
were quantitated for transcriptional reporter experiments, to ascertain whether analysis
method influenced interpretation. In all cases, the result was the same as seen when
assessing mean fluorescence intensity as done in the figures – lending confidence to our
analysis and its qualitative conclusions. All quantitated values are represented as mean
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values ± standard deviation. Statistical analysis was performed with two-tailed, unpaired
Student’s t-tests.

3.3. Results
3.3.1. Establishing a model to study TIM-3 function
Before exploring the effect of PS on TIM-3 activity, I first aimed to develop a system
where I could define a cellular outcome that was TIM-3 dependent. TIM-3 is expressed
on T cells53,78,89, and is of particular interest as a therapeutic target due to its expression
on exhausted T cells in cancer and in chronic viral infection95-97,128. I therefore focused
on exploring the effect of TIM-3 (and its ligand PS) on T cell function.
The human Jurkat T cell line has been used for many decades to establish much of
what is currently known about T cell signaling10. Jurkat T cells have also been used to
investigate the function of T cell co-receptors, such as PD-122. I therefore selected the
Jurkat T cell line as a model system for studies on TIM-3. Specifically, I utilized an NFκB/Jurkat/GFP™ T cell line (System Biosciences Inc.) for my experiments, which have
been engineered to stably express a GFP reporter downstream of NF-κB response
elements. The NF-κB transcription factor is downstream of TCR activation7, and
expression of the GFP reporter in these cells therefore serves as a marker of T cell
activity. Importantly, these Jurkat cells do not express detectable levels of TIM-3 on the
cell surface or in the lysate of the cells at baseline or after stimulation (Figure 3.1A,B). I
therefore ectopically expressed the wild-type, full-length TIM-3 in these Jurkat cells.
After attempting several approaches including lipid-based transduction and
electroporation of DNA and RNA, I found lentivirus transduction to be a reproducible
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Figure 3.1) Lentiviral transduction of TIM-3 and PD-1 in NF-κB/Jurkat/GFP cells
(A) Flow cytometry analysis of TIM-3 expression in parental Jurkat NF-κB reporter cells
(black) and virally transduced Jurkat reporter cells (red), indicating successful introduction
of TIM-3 and lack of endogenous expression.
(B) Analysis of TIM-3 in parental (left lanes) and TIM-3+ (right lanes) Jurkat cells by
Western blotting, indicating expression of TIM-3 only after viral transduction.
(C) Widefield fluorescence microscopy analysis of TIM-3 expression after staining with
AlexaFluor 647-labeled anti-TIM-3, shown in pink in the left and right panels. DAPI
staining for detection of the nucleus is shown in blue in the middle and right panels.
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(D) Analysis of PD-1 in parental Jurkat reporter cells (black) and those transduced to
express PD-1 by lentivirus (blue) by flow cytometry.
(E) Western blot analysis of PD-1 expression in parental Jurkat reporter cells (left lanes)
and in those transduced to express PD-1 by lentivirus (right lanes).
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method of introducing TIM-3 into the Jurkat NF-κB reporter cells. After viral
transduction and selection, TIM-3 was detected at the cell surface by flow cytometry
(Figure 3.1A) and in whole cell lysate by Western blot (Figure 3.1B). Furthermore,
TIM-3 was also detected by widefield fluorescence microscopy, where it localized at the
edges of the cell, away from the nucleus (Figure 3.1C). I also introduced PD-1 into the
Jurkat reporter cells through similar lentivirus transduction (Figure 3.1D,E) as a
negative control for signaling experiments, to rule out any non-specific effects due to
lentiviral transduction.
I next asked how the levels of TIM-3 expressed in this virally-transduced model
compared to levels of TIM-3 seen in primary T cells, to ensure that the TIM-3 levels in
the transduced Jurkat cells were biologically reasonable. Previous work reported the
expression of TIM-3 on T cells derived from peripheral blood mononuclear cells
(PBMCs) after several days of stimulation with antibodies targeting the CD3 chain of the
TCR and the co-stimulatory receptor CD28 (aCD3/aCD28)80. Following this approach, I
stimulated human PBMCs in cultures with aCD3/aCD28 for 7 days and analyzed TIM-3
expression by flow cytometry. After gating the forward and side scatter for single cells
(Figure 3.2A), I analyzed the bulk “PBMC” population for expression of T cell markers
to confirm that the stimulation approach enriched for T cells in the culture. As expected,
the vast majority of the cells expressed CD3 (Figure 3.2B,C). About half of the cells
expressed the co-receptor CD8, while the other half expressed CD4, and their expression
was mutually exclusive (Figure 3.2B-D). When analyzing expression of TIM-3 by flow
cytometry, both the CD3+CD8+ and CD3+CD4+ cell populations expressed TIM-3, with
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Figure 3.2) Comparison of TIM-3 expression on T cells from PBMCs and Jurkat
reporter cells
(A) Gating strategy to select singlets for analysis of PBMCs. Forward and side scatter was
plotted for each event to identify the bulk population of cells. This gate was further
analyzed to select singlets based on side scatter height and width, and then forward scatter
height and width. The final population of events that was used for analysis of receptor
expression was termed “PBMC”.
(B) Following stimulation with aCD3/aCD28, expression of CD3 and CD8 on PBMCs
was quantified by flow cytometry, with the majority of cells expressing CD3.
(C) CD3 and CD4 expression on PBMCs were quantified by flow cytometry after
aCD3/aCD28 stimulation.
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(D) Expression of CD4 and CD8 on PBMCs was mutually exclusive, with about 50% of
cells expressing each co-receptor.
(E) Flow cytometry analysis of TIM-3 expression on bulk PBMC population (blue,
dashed), CD3+CD8+ PBMCs (green, dashed), and CD3+CD4+ PBMCs (yellow, dashed).
Expression of TIM-3 in all PBMC populations overlapped with levels of TIM-3 expressed
following lentiviral transduction in Jurkat reporter cells (red, solid). Unstained PBMCs and
TIM-3+ Jurkat cells are shown in blue shaded and pink shaded curves.
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expression at slightly higher levels in CD8+ T cells. Importantly, the expression of TIM-3
in these human primary T cells overlapped with the levels of virally-transduced
expression of TIM-3 in the Jurkat reporter cells (Figure 3.2E). These findings therefore
suggest that the levels of TIM-3 obtained in the Jurkat model system are in a similar
range as those seen in primary cells.

3.3.2. TIM-3 promotes T cell activity
I next aimed to assess how expression of TIM-3 modulates T cell function in this Jurkat
reporter system. Since a key goal of my thesis research is to understand how PS
modulates TIM-3’s co-receptor/signaling activity, defining a TIM-3-dependent
functional effect in the Jurkat model system was an essential part of addressing this
objective. Previous work in the field has reported that TIM-3 can variously inhibit or
promote T cell activity in Jurkat T cell lines57-59, suggesting that either might be observed
in this system.
Jurkat cells were activated with aCD3/aCD28 to mimic antigen binding.
Compared to unstimulated cells, treatment with aCD3/aCD28 resulted in robust
expression of the GFP reporter downstream of TCR signaling, as expected (Figure
3.3A,B). However, stimulated NF-kB reporter activity was consistently and significantly
increased in cells transduced with TIM-3, whereas they were indistinguishable from
parental cells when left unstimulated. GFP reporter expression was increased by about
50% in stimulated TIM-3+ cells compared to stimulated parental cells (Figure 3.3A,B).
Importantly, this was observed only for cells transduced with TIM-3, as expression of
PD-1 did not enhance NF-κB reporter activity (Figure 3.3B). As a second readout of

107

Figure 3.3) Cells expressing TIM-3 display enhanced T cell activation
(A) Representative histogram of GFP reporter expression downstream of NF-κB activation
with aCD3/aCD28 (1 µg/ml each) in parental (black) or TIM-3+ (red) cells. Gray and pink
shaded curves represent unstimulated parental and TIM-3+ cells, respectively.
(B) Quantification of the GFP mean fluorescence intensity (MFI) of parental, TIM-3+, and
PD-1+ Jurkat reporter cells with- and without stimulation. Bars represent mean ± standard
deviation for 4 biological repeats (2 for PD-1+ cells). An unpaired, two-tailed Student’s ttest was used to determine the p-value comparing parental and TIM-3+ cells.
(C,D) Analysis of IL-2 secretion into the Jurkat cell media following activation with (C) 1
µg/ml aCD3 and 1 µg/ml aCD28 for 16 h or (D) SEE-activated Raji B cells for 6 h. Bars
represent mean ± standard deviation (n=3). Levels of IL-2 secreted by parental (black) and
TIM-3 (red) Jurkat reporter cells were compared with an unpaired, two-tailed Student’s ttest.
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T cell activity, I also compared expression of IL-2, a cytokine and marker of T cell
activation10, in parental and TIM-3+ Jurkat reporter cells. Upon stimulation with
aCD3/aCD28, TIM-3-expressing Jurkat also displayed increased IL-2 production
compared to parental cells (Figure 3.3C), supporting the findings from the NF-κB
reporter assay.
The use of aCD3/aCD28 to mimic antigen binding is a common approach for
activating T cells57,59, but does not fully recapitulate the formation of the immune
synapses, where TCRs cluster with other signaling molecules when stimulated by antigen
presenting cells in vivo29. I therefore also stimulated the Jurkat reporter cells with
activated Raji B cells as antigen presenting cells (APCs)22,23 to ask whether the
stimulatory effect of TIM-3 observed upon aCD3/aCD28 activation was also observed
in a system where immunological synapses form. Just as observed with antibody-based
stimulation, after stimulation with SEE-activated Raji cells, TIM-3+ cells displayed
significantly elevated secretion of IL-2 compared to parental Jurkat cells (Figure 3.3D).
Therefore, the ability of TIM-3 to promote T cell activity, as quantified here through a
transcriptional reporter and enhanced IL-2 production, appears to reflect a TIM-3dependent effect on T cell activity that occurs with either method of TCR stimulation.
These data are consistent with other reports in the literature that, in some contexts, TIM3 functions as a co-stimulatory molecule57,93,101.
Co-stimulation of CD28 contributes to T cell activation in both APC- and
antibody-based activation11, and I wondered if this was necessary for the observed TIM3-dependent increase in T cell activity. I therefore compared expression of the NF-κB
reporter after stimulation by aCD3 alone with aCD3/aCD28 stimulation. TIM-3
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maintained the ability to promote T cell activity when stimulated by aCD3 alone (Figure
3.4A,B). Adding aCD28 further enhanced expression of the GFP reporter downstream of
T cell activation for both parental and TIM-3+ cells as expected11,165, however, as seen by
comparing the curves in Figure 3.4A and C. Importantly, addition of aCD28 costimulation did enhance the fold increase in NF-κB activation caused by TIM-3
expression (Figure 3.4C,D), possibly suggesting that TIM-3 synergizes with CD28 to
promote T cell activity.

3.3.3. Jurkat cells expressing TIM-3 display increased phosphorylation of CD28 but not
other components of the TCR signaling cascade
To further explore how TIM-3 might enhance T cell activity, I analyzed phosphorylation
of several components of the TCR signaling cascade following stimulation with
aCD3/aCD28. Using Western blotting, I observed, as expected, that components of the
TCR cascade, including Zap70, PLCγ1, ERK, and LAT display an increase in
phosphorylation after 5 min of stimulation, which then decreased at the 20- and 60-min
time points. However, TIM-3 did not appear to alter either the amplitude or duration of
this phosphorylation (Figure 3.5A). Some blots did suggest elevated phosphorylation of
LAT and Zap70 in TIM-3+ cells, but the changes were not statistically significant across
several replicates (Figure 3.5B-E). I expanded this analysis to assess phosphorylation of
additional TCR signaling components by Luminex, which recognizes proteins – or in this
case, phosphoproteins – of interest with antibodies linked to colored beads to allow
quantification of multiple proteins simultaneously. As seen in the Western blotting
experiments, phosphorylation of several components of the TCR cascade was increased
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Figure 3.4) TIM-3 promotes T cell activity upon T cell stimulation with aCD3 or
aCD3/CD28
(A,B) Representative histograms of NF-κB-driven GFP expression in parental (black) or
TIM-3+ (red) Jurkat cells after activation with (A) 1 µg/ml aCD3 alone or (B) 1 µg/ml
aCD3 and 0.5 µg/ml aCD28.
(C,D) Quantification of GFP mean fluorescence intensity of parental (black) and TIM-3+
(red) Jurkat reporter cells following stimulation with (C) 1 µg/ml aCD3 or (D) 1 µg/ml
aCD3 and 0.5 µg/ml aCD28. Values were normalized to the parental GFP MFI for each
stimulation. Error bars represent standard deviation for two biological repeats in one
independent experiment.
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Figure 3.5) Expression of TIM-3 does not modulate phosphorylation of downstream
components of the T cell receptor cascade
(A) Western blotting analysis was used to analyze changes in specific phosphosites of TCR
components following stimulation with aCD3/aCD28 (1 µg/ml each) in TIM-3+ Jurkat
reporter cells (left lanes) and parental Jurkat reporter cells (right lanes). Grb2 was used as
a loading control, as described by Aksamitiene and colleagues (2015).
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(B-E) Band intensities for (B) phospho-Zap70 (Y319), (C) phospho-PLCγ1 (Y783), (D)
phospho-ERK (T202/Y204), and (E) phospho-LAT (Y220) were quantified using Kodak
ImageStation software, and were normalized to the band intensity for Grb2 and the 5-min
parental time point. Data represent mean ± SD for n=3 (n=2 for PD-1). Data points for
ERK represent mean of n=2 for parental and TIM-3+ cells, and n=1 for PD-1+ cells.
Statistical analysis was performed with an unpaired, two-tailed Student’s t-test, with no
statistical difference observed at any time point when comparing values for TIM-3+ cells
and parental cells, or PD-1+ cells and parental cells.
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following stimulation, peaking at about 5 min and declining at the 20-, 40-, and 60- min
time points (Figure 3.6). In general, however, phosphorylation time courses of parental
Jurkat cells and TIM-3+ cells were very similar. Phosphorylation levels of the CD3ε
chain of the TCR, of Zap70, and of CREB were all similar between TIM-3 and parental
cells (Figure 3.6A-C). In this analysis, LAT and ERK phosphorylation were slightly
decreased in TIM-3+ reporter cells compared to parental cells, but not to the same extent
as PD-1+ cells (Figure 3.6D,E), and the difference did not appear significant.
One important difference that was uncovered in my analysis of phosphorylation
of signaling proteins was seen with phosphorylation of CD28, the classic TCR costimulatory molecule. CD28 phosphorylation was recently suggested to be influenced by
PD-1, as a result of phosphatase recruitment to the C-tail of PD-1 – leading to
preferential dephosphorylation of CD28 and consequently reduced T cell signaling22.
Western blot analysis showed that CD28 phosphorylation was detected at both tyrosine
191 and 218, which, as expected11, rose from baseline following 5 minutes of
stimulation, and declined at the later time points (Figure 3.7A,B). Interestingly, TIM-3transduced Jurkat reporter cells displayed enhanced phosphorylation of CD28 at both
tyrosine 191 and tyrosine 218 after 5 minutes of stimulation when compared to parental
cells at the same timepoint (Figure 3.7 A,B). TIM-3+ cells also displayed a modest, but
significant increase in phosphorylation of pCD28Y191 at 20 and 60 min (Figure 3.7C),
which was not observed for pCD28Y218 (Figure 3.7D). Importantly, parental and TIM-3+
Jurkat reporter cells express similar levels of CD28 protein at the cell surface (Figure
3.7E), suggesting that the increase in phosphorylation seen was not simply due to an
increased total amount of CD28 protein. Phosphorylation of the three C-terminal
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Figure 3.6) TIM-3-expressing Jurkat reporter cells do not display enhanced
phosphorylation of CD3 or downstream components
Luminex analysis was used to analyze changes in phosphorylation of (A) phospho-CD3ε
(pan tyrosine), (B) phospho-CREB (S133), (C) phospho-Zap70 (pan tyrosine), (D)
phospho-LAT (pan tyrosine), and (E) phospho-ERK (T185/Y187) after starvation and
stimulation with aCD3/aCD28 (1 µg/ml each) for 0, 5, 20, 40, or 60 min. Average net
MedFI for each phosphosite were normalized to beta-tubulin as a loading control. Data
points represent n=1 for each time point for parental (black), TIM-3+ (red), and PD-1+
(blue) Jurkat reporter cells.
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Figure 3.7) Cells expressing TIM-3 display enhanced phosphorylation of CD28
(A,B) Western blotting analysis of CD28 phosphorylation at (A) Y191 and (B) Y218 in
TIM-3+ (left lanes) and parental (right lanes) Jurkat NF-κB reporter cells after 4 h starvation
and stimulation with aCD3/aCD28 (1 µg/ml each). Band intensity was quantified with the
Kodak ImageStation software, and normalized to Grb2 as a loading control. Relative band
intensities at the 5-min time point were plotted in the right panel, where bars indicate mean
and error bars indicate standard deviation for (A) npY191=6 and (B) npY218=7. Statistical
analysis used unpaired, two-tailed Student’s t-test to determine a p value.
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(C,D) Quantitation of band intensity for phospho-CD28 (C) Y191 and (D) Y218 in parental
(black) and TIM-3+ (red) Jurkat reporter cells following stimulation for 5, 20, and 60 min.
Data points and error bars represent mean values ± standard deviation for n=5 complete
time courses for each phosphosite. Statistical analysis used an unpaired, two-tailed
Student’s t-test to compare values for parental and TIM-3+ cells at each timepoint.
(E) Flow cytometry analysis of surface CD28 expression. Histogram shows fluorescence
of CD28, detected by a PerCP-Cyanine5.5 labeled antibody for parental Jurkat NF-κB
reporter cells (black curve) and cells expressing TIM-3 (red curve), with unlabeled parental
cells (gray shaded curve) as a control.
(F) Wortmannin (final concentration = 0.2 µM) was used to inhibit PI3K and assess the
phosphorylation of CD28 in Jurkat NF-κB reporter cells. Parental, TIM-3, or PD-1 cells
were untreated or were stimulated with aCD3/aCD28 (1 µg/ml each) for 5 min, with or
without wortmannin. Decreased phosphorylation of AKT (T308), indicates PI3K was
inhibited, but no change in CD28 phosphorylation was observed.
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tyrosines of CD28 (Y206, Y209, and Y218, numbering of immature amino acid
sequence) is required for T cells to secrete IL-2166, and pCD28Y218 has been shown to be
important for NF-κB activation167, providing a possible explanation for how TIM-3
might enhance T cell activity.
CD28 phosphorylation at Y191, on the other hand, is primarily linked to
recruitment of phosphatidylinositol 3-kinase (PI3K)11, which could also promote NF-κB
activation7. In Jurkat cells, however, loss of the phosphatase and tensin homolog (PTEN)
results in hyperactivation of PI3K, which could reduce the requirement of activation by
recruitment to CD28. Wortmannin, a PI3K inhibitor, was therefore used to ensure that
elevated phosphorylation of CD28 did not depend on this enhanced activity of PI3K.
Upon treatment with wortmannin, Akt phosphorylation was abrogated (Figure 3.7F),
indicating that PI3K was successfully inhibited168. Importantly, however, PI3K inhibition
by wortmannin did not alter the enhanced phosphorylation of CD28 observed in TIM-3+
cells, suggesting that this effect is not dependent on PI3K activity. Altogether, the TIM3-dependent increase in CD28 phosphorylation provides some insight into the
mechanism through which TIM-3 promotes T cell activity. Indeed, an effect of TIM-3 on
CD28 phosphorylation would be consistent with the finding in Figure 3.4 that the effects
of TIM-3 expression on TCR activity are greatest when T cells are stimulated with both
aCD3 and aCD28, rather than aCD3 alone.
The intracellular region of TIM-3, like that of many other co-receptors, does not
have catalytic activity, and therefore cannot directly phosphorylate CD28. TIM-3 is
unique in that it does not contain canonical phosphotyrosine-containing motifs that
recruit kinases (as in the case of ITAMs), or phosphatases (as in the case of ITIMs), or
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both (as in the case of ITSMs)169. It therefore remains unclear how TIM-3 promotes
CD28 phosphorylation, and what effector molecules might be involved. Previous work
with peptide screening libraries identified the Fyn SH2 domain and the PI3K adaptor
p85a as effector molecules that can interact with a phosphopeptide corresponding to the
phosphorylated TIM-3 C-tail57. Other immunoprecipitation studies, however, suggest
that both Fyn and p85a associate with TIM-3 only when cells are not activated, and
instead suggest Lck as an effector molecule that binds the TIM-3 C-tail59. Lck and Fyn
are both proposed to mediate phosphorylation of CD2811,170, which requires proximity of
these kinases to CD28. As TIM-3 has been observed in the immunological synapse93,120,
it might facilitate enhanced phosphorylation of CD28 by recruiting Lck (or Fyn) to CD28
in the synapse upon T cell activation. Additional experiments should evaluate this
hypothesis, which remains purely speculative at this point.

3.3.4. Chimeric receptors suggest the importance of the PS-binding extracellular region
for TIM-3 function
Having established a system that displays a TIM-3-dependent effect on T cell activity, I
next aimed to explore how the extracellular ligand-binding region of TIM-3 contributes
to this activity. To this end, I first generated a set of chimeric receptors that swapped the
extracellular regions of TIM-3 with that of PD-1. If the extracellular region is important
for TIM-3 activity in T cells, I hypothesized that replacing it with the extracellular region
of PD-1 should reduce its effect, as expression of PD-1 in Jurkat cells did not modulate
NF-κB activity (Figure 3.3B). I utilized two different constructs containing the
extracellular region of PD-1 and the intracellular region of TIM-3, with either the

119

transmembrane domain of TIM-3 (PTT) or that of PD-1 (PPT) (Figure 3.8A). Both
constructs were expressed on the cell surface after lentivirus transduction of Jurkat
reporter cells (Figure 3.8B). Importantly, these chimeric receptors were expressed at
similar levels to full length TIM-3, as shown by Western blotting with an antibody
targeting the intracellular region of TIM-3 (Figure 3.8C), which is shared between full
length TIM-3 and the PD-1–TIM-3 chimerae. Upon antibody stimulation, TIM-3 Jurkat
reporter cells showed enhanced expression of the NF-κB GFP reporter. However, the
chimeric receptors failed to promote NF-κB activity to the same extent as full-length
TIM-3 (Figure 3.8D,E), supporting the importance of the TIM-3 extracellular region for
its function. Interestingly, the PTT chimera (containing the TIM-3 transmembrane
domain) displayed an intermediate effect, with slightly elevated NF-κB reporter
expression compared to parental, but not to the same extent as intact TIM-3. Recent work
from Kataoka and colleagues has pointed to the importance of the TIM-3 transmembrane
domain in TIM-3 co-stimulatory activity and its localization to the immune synapse93,
which might explain the modest, but statistically significant increase seen here for PTT.
The loss of the effect of TIM-3 in arising from substitution of its extracellular
region suggests that ligand binding might be important for the activity of this receptor –
as is typically true for receptors. As discussed earlier in this thesis, multiple different
ligands have been proposed for TIM-3, including PS, galectin-9, CEACAM1, and
HMGB1. As described in Chapter 2, PS is a shared ligand between TIM-3 and its family
members, whereas galectin-9, CEACAM1, and HMGB1 have never been reported to
bind TIM-1 or TIM-4. I therefore generated a second set of chimeric receptors that
replace the extracellular region of TIM-3 with that from TIM-1 or TIM-4 (Figure 3.9A).
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Figure 3.8) Chimeric receptors that lose the TIM-3 extracellular region fail to
promote T cell activity
(A) Schematic of PD-1–TIM-3 chimerae, with the PD-1 extracellular region, TIM-3
intracellular domain, and the transmembrane domain of TIM-3 (PTT) or PD-1 (PPT).
(B) Expression of chimeric receptors at the cell surface following lentivirus transduction
of Jurkat reporter cells, determined by flow cytometry. Cells were stained with a
fluorescently-labeled antibody for PD-1, which recognizes the PD-1 ECR in the full-length
receptor (blue curve) and in the chimeric receptors, PTT (purple solid curve) and PPT
(purple dashed curve).
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(C) Western blot analysis of full-length TIM-3 and PD-1–TIM-3 chimeric receptors, using
an antibody against the intracellular region of TIM-3 that is expressed in both constructs.
Grb2 is used as a loading control, as previously described. Chimeric receptors are
expressed at similar levels as full-length TIM-3, indicating that any signaling changes do
not reflect loss of receptor expression.
(D) Representative histogram of NF-κB-driven GFP expression in Jurkat reporter cells
after 4 h stimulation and 16 h stimulation with aCD3/aCD28 (1 µg/ml each). TIM-3+
Jurkat cells (red curve) display increased GFP compared to parental cells (black curve),
which is reduced in PTT (purple solid curve) and PPT (purple dotted curve), which lack
the TIM-3 extracellular region.
(E) Quantitation of relative GFP mean fluorescence intensity for parental (black), TIM-3
(red), PTT (purple), PPT (purple, dotted), and PD-1 (blue) Jurkat reporter cells, stimulated
as described in (D). Bars represent mean GFP MFI ± SD for 3 biological repeats, and
statistical analysis was performed with unpaired, two-tailed Student’s test.
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Figure 3.9) Chimeric receptors that retain PS-binding enhance T cell activity
(A) Schematic of TIM chimeric receptors, which replace the TIM-3 ECR with that of TIM1 (TIM-1-3) and TIM-4 (TIM-4-3). Unlike PD-1–TIM-3 chimeric receptors, TIM-1-3 and
TIM-4-3 retain the ability to bind PS (but not other TIM-3 ligands) with their extracellular
regions.
(B,C) Parental Jurkat reporter cells (black) do not express detectable levels of (B) TIM-1
or (C) TIM-4, but TIM-1-3 (teal) and TIM-4-3 (green) are detected at the cell surface
following lentiviral transduction.
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(D) Representative histogram of GFP expression downstream of NF-κB activation
following 4 h starvation and 16 h stimulation with 1 µg/ml aCD3 and 0.5 µg/ml aCD28.
Compared to parental cells (black), cells expressing TIM-3 (red), TIM-1-3 (teal), and TIM4-3 (green) display enhanced GFP expression.
(E) Quantitation of GFP mean fluorescence intensity for parental, TIM-3, TIM-1-3, and
TIM-4-3 NF-κB reporter cells, stimulated as in (E). Data bars represent mean of 5
biological repeats, with standard deviation shown in error bars. p values were determined
with unpaired, two-tailed Student’s t-tests.
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Chimeric receptors in this second set preserve the ability to bind PS but not other TIM-3
ligands, thus allowing me to ask if PS binding is an important property for the effects of
TIM-3 on T cell activation. Following lentivirus transduction, both the TIM-1-3 and
TIM-4-3 chimeric receptors were expressed at the cell surface (Figure 3.9B,C).
Furthermore, both cells expressing TIM-1-3 and TIM-4-3 displayed enhanced NF-κB
reporter expression, to a similar extent as observed for full-length TIM-3 (Figure
3.9D,E). As CEACAM1, galectin-9, and HMGB1 are not ligands for TIM-1 or TIM-4,
these data suggest that the ability to bind PS allows the chimeric receptors to signal like
their wild-type counterpart, and imply that PS is capable of modulating TIM-3 function.

3.3.5. The TIM family ligand PS is exposed in Jurkat culture
To further address the role of PS as a ligand for TIM-3, I next aimed to modulate its
levels in Jurkat cell cultures. I first introduced vesicles containing PS into the Jurkat cell
culture in an attempt to engage TIM-3 in the cells and ask how its function might change.
In these experiments, TIM-3 maintained the ability to increase NF-κB reporter activity
compared with parental cells (Figure 3.10A,B). Introducing PS-containing vesicles did
not modulate NF-κB reporter expression in parental cells. A modest increase in NF-κB
activity in TIM-3+ Jurkat reporter cells was seen upon PS vesicle addition, but it was not
statistically significant (Figure 3.10A,B). In Chapter 2, I showed that inclusion of
phosphatidic acid (PA) enhanced the ability of sTIM-3 to bind PS-containing
membranes. I therefore wondered if adding vesicles containing both PS and PA might be
necessary to fully engage TIM-3 activity. Again, adding PS/PA vesicles did not
significantly impact expression of the NF-κB reporter in parental cells, but nor did it
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Figure 3.10) Addition of PS-containing vesicles does not further increase the effect
of TIM-3
(A) Representative histogram of GFP expression in NF-κB reporter Jurkat cells. After
serum starvation, cells were pre-treated with vesicles (100 µM) containing 0% or 20% PS
in a PC background for 1 h and then stimulated with 1 µg/ml aCD3 and 0.5 µg/ml aCD28
for 16 h. GFP expression was analyzed by flow cytometry for parental cells (black curve),
parental cells with 20% PS vesicles (black dotted curve), TIM-3 cells (red curve), TIM-3
cells with DOPC vesicles (red dotted curve), or TIM-3 cells with 20% PS vesicles (gold
dotted curve).
(B) Quantitation of GFP MFI of cells stimulated as described in (A). Data and error bars
represent mean ± SD for 5 independent experiments, and an unpaired, two-tailed Student’s
t-test was used to determine the p value comparing parental and TIM-3 cells. No
significance was observed when comparing TIM-3 cells with PS-treated TIM-3 cells.
(C) Representative histogram of NF-κB-driven GFP expression in Jurkat reporter cells.
Cells were starved and stimulated as in (A), except that some vesicles contained 25% PS
(dark gold dotted curve) or 20% PS/5% PA (dark blue dashed curve) in a PC background.
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(D) GFP MFI was quantified for 2 independent experiments for parental cells (black),
parental cells with 20% PS vesicles (black dotted), parental cells with 20% PS/5%PA
vesicles (black dashed), TIM-3 cells (red), TIM-3 cells with PC vesicles (red dotted), TIM3 cells with 20% PS vesicles (gold dotted), TIM-3 cells with 25% PS vesicles (dark gold
dotted), or TIM-3 cells with 20%PS/5% PA vesicles (dark blue dashed). Mean ± SD is
shown. Statistical analysis with unpaired, two-tailed Student’s t-test was used to determine
p values, which was significant when comparing TIM-3 and parental cells, but not when
comparing TIM-3 cells stimulated alone or in the presence of 20% PS, 25% PS, or 20%
PS/5% PA vesicles.
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further impact expression of the NF-κB reporter in TIM-3+ Jurkat cells beyond the
modest change seen for vesicles with PS alone (Figure 3.10C,D).
In considering why adding exogenous PS did not substantially impact the function
of TIM-3 as I had expected from the findings with the chimeric receptors, I wondered if
PS might be constitutively exposed in the Jurkat cell culture. PS is known to be exposed
on the cell surface during apoptosis, and also during T cell activation67,107, both of which
likely occur in the Jurkat cell cultures. I therefore used annexin V as a probe to assess PS
exposure in culture. Annexin V is a classical tool used in identification PS on the outer
leaflet of the plasma membrane, and is routinely used to identify apoptotic cells, for
example171,172. I was surprised to find that Jurkat cells in culture were positively stained
with fluorescently-labeled annexin V, indicating exposure of PS on Jurkat cells in
culture. Using flow cytometry, the majority of parental Jurkat reporter cells and virallytransduced TIM-3+ Jurkat reporter cells both were stained with intermediate levels of
annexin V, indicating that PS is present on the outer leaflet of their plasma membranes
(Figure 3.11A). Interestingly, a small population of cells exposed even higher levels of
PS, exceeding 104 on the x-axis, possibly corresponding to dying cells in the culture.
Fischer and colleagues previously showed that, whereas apoptotic cells are stained with
high levels of annexin V, activated T cells display an intermediate level of annexin V
staining107, suggesting that functional T cells are capable of exposing PS on their cell
surface, similar to what is observed here – which may be sufficient to engage TIM-3 as a
T cell co-receptor.
As a complementary approach to confirm this unexpected finding, I also used
widefield fluorescence microscopy to visually detect cells labeled with fluorescently-
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Figure 3.11) PS is exposed on the outer leaflet of the membrane in Jurkat culture
(A) Histogram of PerCP-Cyanine5.5-labeled annexin V staining of parental (black) and
virally-transduced TIM-3+ (red) Jurkat NF-κB reporter cells. Plot is representative of 5
biological repeats.
(B) Widefield fluorescence imaging of parental (top panels) and TIM-3+ (bottom panels)
Jurkat reporter cells labeled with AlexaFluor 647-annexin V (pink in middle, right panels)
to detect PS exposed on the cell surface. DAPI staining in the left panels indicates cell
nuclei.
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tagged annexin V. Importantly, cells were stained prior to fixing and imaging. As
observed by flow cytometry, annexin V-staining was observed on both parental and
TIM-3+ Jurkat cells (Figure 3.11B). These data therefore indicate that PS is expressed on
the outer leaflet of the plasma membrane in the Jurkat cell culture. This does not appear
to result from viral transduction, as annexin V was also detected on uninfected parental
Jurkat cells. If PS is already accessible to TIM-3 in culture, this could explain why
expression of TIM-3 without addition of ligands is capable of modulating T cell
function, and also why adding PS-containing vesicles fails to further modulate the effect
of TIM-3 in this system.

3.3.6. TIM-3 mutants with reduced PS binding fail to promote T cell activity
As shown in Figure 3.10, addition of PS-containing vesicles was not capable of
modulating TIM-3 function in the Jurkat reporter T cells, perhaps because the levels of
PS in culture were already saturating the available TIM-3 receptors. I therefore asked if
reducing the amount of accessible (surface exposed) PS in the culture might reduce TIM3 activity, which would support the importance of PS in modulating TIM-3 activity. I
reasoned that the PS probe annexin V should be capable of binding and sequestering PS
on the cell surface, as shown in Figure 3.11, and should block PS to prevent binding by
TIM-3. Unfortunately, however, upon examining the signaling of cells treated with the
PS probe annexin V, I observed that expression of the GFP NF-κB reporter was
enhanced by annexin V in parental cells, independent of TIM-3 expression (Figure
3.12A,B). I was therefore unable to differentiate between unknown effects of annexin V
itself from effects that it might induce by blocking PS from binding TIM-3.
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Figure 3.12) Treatment with annexin V increases T cell activity independent of
TIM-3 expression
(A) Histogram of GFP expression in parental Jurkat reporter cells following 4 h starvation
and stimulation with aCD3/aCD28. Cells were pretreated with a final concentration of
50 µg/ml annexin V for 30 min before stimulation (dotted line) as previously described.
(B) Quantitation of GFP MFI for parental cell stimulated alone (solid black bar) and
parental cells stimulated in the presence of annexin V (dotted black bar). Data and error
bars represent mean ± standard deviation for n=3.
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I therefore instead tried another – more direct – approach: reducing the PS
binding of TIM-3 using defined mutations. In Chapter 2, I identified two mutated
variants of TIM-3 (TIM-3F40A and TIM-3I96A/M97A) that display substantially reduced PSbinding compared to wild-type TIM-3. I reasoned that, if PS binding is important for the
ability of TIM-3 to promote T cell activity, cells expressing these mutated versions of
TIM-3 that have reduced PS binding capacity should display reduced T cell activity
compared to cells expressing wild-type TIM-3. I first introduced these mutated TIM-3
variants by viral transduction and confirmed their expression on the cell surface, at levels
similar to wild-type TIM-3 (Figure 3.13). Next, I stimulated the Jurkat reporter cells
with aCD3/aCD28 to mimic antigen binding. Cells expressing the mutated variants
TIM-3F40A and TIM-3I96A/M97A displayed a significantly reduced elevation in NF-κB
activity compared with those expressing wild-type TIM-3 (Figure 3.14A,B).
Furthermore, cells expressing mutated TIM-3 variants with reduced PS-binding secreted
significantly less IL-2 compared with those expressing wild-type TIM-3 – and this was
true for cells stimulated with aCD3/aCD28 (Figure 3.14C) or with SEE-activated Raji
B cells (Figure 3.14D) that mimic the formation of an immunological synapse. As
another readout for T cell activity, I also quantified secretion of TNF-a, a proinflammatory cytokine and a marker of T cell activation, from the Jurkat reporter cells
following stimulation with aCD3/aCD28. As observed for other markers of T cell
activity, cells expressing wild-type TIM-3 displayed significantly enhanced secretion of
TNF-a compared to parental cells, whereas those expressing mutated TIM-3 variants
with reduced PS binding secreted significantly less TNF-a (Figure 3.14E). This inability
of mutated variants of TIM-3 with reduced PS binding to promote T cell activity to the

132

Figure 3.13) Mutated variants of TIM-3 with reduced PS binding are expressed at
the cell surface
Expression of TIM-3F40A and TIM-3I96A/M97A detected by (A) flow cytometry, using a
polyclonal antibody against TIM-3 and a fluorescently-labeled secondary antibody, and
(B) Western blot, using an antibody specific for the intracellular region of TIM-3, to ensure
successful recognition of both mutated variants.
(A) Flow cytometry analysis shows that mutated variants of TIM-3 (F40A: dark red dotted
curve; I96A/M97A: dark red dashed curve) were successfully expressed at the cell surface
at similar levels to wild-type TIM-3 (red curve) when introduced by lentivirus transduction.
(B) Bands were detected for the TIM-3 intracellular region in cells transduced to express
wild-type, full-length TIM-3, PD-1–TIM-3 chimera (as shown in Figure 3.8C), TIM-1-3
and TIM-4-3 chimera, and mutated variants of TIM-3, but not in parental Jurkat reporter
cells. Grb2 was used as a loading control.
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Figure 3.14) Cells expressing mutated variants of TIM-3 with decreased PS binding
fail to enhance T cell activity to the same extent as wild-type TIM-3
(A) Representative histogram of GFP expression in NF-κB Jurkat reporter cells following
4 h serum starvation and 16 h stimulation with 1 µg/ml aCD3 and 0.5 µg/ml aCD28. Cells
expressing TIM-3 (red curve) display enhanced GFP expression compared to parental cells
(black curve), which is diminished in the F40A (dark red dotted curve) and I96A/M97A
(dark red dashed curve) mutated variants that have reduced PS binding as shown in Figure
2.8C.
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(B) Quantitation of GFP mean fluorescence intensity for parental (black), TIM-3WT (red),
TIM-3F40A (dark red, dotted), and TIM-3I96A/M97A (dark red, dashed) cells stimulated with
aCD3/aCD28, as in (A). Data bars represent mean of 8 biological repeats, with error bars
showing standard deviation. p values were determined with unpaired, two-tailed Student’s
t-tests.
(C) IL-2 secretion was quantified by ELISA for parental cells (black) TIM-3WT (red), TIM3F40A (dark red, dotted), and TIM-3I96A/M97A (dark red, dashed) cells stimulated as in (A).
Mean ± SD is plotted for n=3, and unpaired, two-tailed Student’s t-tests were used to
compare values for TIM-3WT with TIM-3F40A and TIM-3I96A/M97A.
(D) Analysis of IL-2 released to cell media of Jurkat reporter cells stimulated by SEEloaded Raji B cells. As in (C), bar represent mean ± standard deviation for n=3. Statistical
analysis was performed with unpaired, two-tailed Student’s t-test to determine p values.
(E) Luminex analysis of TNF-a secretion of Jurkat reporter cells stimulated with
aCD3/aCD28 (1 µg/ml each). TIM-3WT cells (red, open bar) displayed increased
production of TNF-a compared to parental cells (black, open bar), and mutated variants of
TIM-3 (F40A: dark red dotted, open bars; I96A/M97A: dark red dashed, gray shaded bars)
failed to enhance TNF-a to the same degree as WT TIM-3. Mean ± SD for n=3 was plotted,
and statistical analysis was completed with unpaired, two-tailed Student’s t-test.
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same extent as wild-type TIM-3 across several readouts indicates a key role for PS as a
ligand of TIM-3 that is capable of controlling its activity as a stimulatory co-receptor in
T cells.

3.3.7. Treatment with a PS-blocking antibody prevents TIM-3 from promoting T cell
activity
One potential caveat with the mutated variants of TIM-3 is that the mutations may cause
misfolding, or might reduce binding to other putative ligands of TIM-3. Therefore, as a
secondary approach, I used a functional TIM-3 antibody, F38.2E2, that was recently
shown to block the PS binding pocket173. Indeed, F38.2E2 targets the CC’ and FG loops
that are involved with PS binding, but did not prevent binding of galectin-9 – allowing
this tool compound to serve as an alternate approach to the mutated variants generated
above. When parental Jurkat reporter cells were treated with F38.2E2, no change in
activity of the NF- κB reporter was observed, as expected (Figure 13.15A,D). TIM-3+
Jurkat cells again displayed enhanced T cell activity compared to parental cells,
increasing NF-κB reporter activity by about 50% (see black dashed line in Figure
13.15E, representing relative NF-κB activity of parental cells). Treatment with F38.2E2
reduced the ability of TIM-3 to promote T cell activity in a dose dependent manner, and
the maximum effect was observed at approximately 1 µg/ml (Figure 13.15B,C,E).
Although the effect of F38.2E2 was modest, it was capable of reducing the stimulatory
effect of TIM-3 on T cell activity by about half, bringing the relative MFI from 1.0 to
approximately 0.7, compared to approximately 0.35 in parental cells (Figure 13.15E).
Similarly, treatment with F38.2E2 reduced the ability of TIM-3+ Jurkat cells to promote
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Figure 3.15) Treatment with F38.2E2 reduces the effect of TIM-3 on T cell activity
(A-C) Representative histograms of GFP expression in (A) parental and (B,C) TIM-3expressing NF-κB Jurkat reporter cells. Cells were serum-starved for 4 h, including a 1 h
pre-treatment with F38.2E2 (0.01 – 10.0 µg/ml) prior to stimulation with 1 µg/ml aCD3
and 0.5 µg/ml aCD28. Histograms for unstimulated cells are shown in (A) gray shaded
and (B) pink shaded curves.
(C) Histograms of GFP expression in TIM-3-expressing Jurkat reporter cells stimulated
alone (red solid curve) or in the presence of 10.0 µg/ml F38.2E2 (blue dotted curve),
indicating reduced activation in cells treated with F38.2E2.
(D,E) GFP MFI from samples in (A) and (B) were quantitated across 3 biological repeats,
and mean ± SD was plotted. Black dashed line indicates relative level of GFP expression
observed in parental cells. Stimulated TIM-3-expressing cells increase NF-κB reporter
expression by about 60%, which is reduced by half in the presence of F38.2E2. Student’s
t-test (unpaired, two-tailed) was used to determine p values.
(F) Levels of IL-2 secreted by parental (black bars) and TIM-3-expressing (red bars)
stimulated as in (A) was quantified by ELISA. Bars represent mean ± standard deviation
for n=3, and p values were determined with unpaired, two-tailed Student’s t-tests.
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IL-2 expression, again by about half (Figure 13.15F). Importantly, treatment with
F38.2E2 did not impact IL-2 production by parental Jurkat reporter cells, as expected
(Figure 13.15F). As either mutated variants or antibody blockade with reduced PS
binding limit the impact of TIM-3 on T cell function, these data suggest that PS does act
as a functional ligand for TIM-3, and in this system, is important for the ability of TIM-3
to promote T cell activity.

3.3.8. Investigating the effect of galectin-9 on TIM-3 function requires additional steps
In addition to PS, galectin-9 has also been proposed as a ligand for TIM-352, and the
majority of TIM-3 studies have used galectin-9 as a modulator in studying TIM-3
effects. A unique property of galectin-9 in the lectin family is its bivalent nature, which
results from it containing two carbohydrate recognition domains connected by a linker
peptide. Other studies in the literature have suggested that galectin-9 can crosslink TIM3 with other proteins, including PD-1121 and CD45120, by binding carbohydrates on both.
Additionally, in Chapter 2, Section 2.3.8 I showed evidence that galectin-9 can crosslink
TIM-3 and enhance its avidity for PS-containing membranes, thus prompting the
question: is the effect of PS-TIM-3 in T cells further impacted by galectin-9
crosslinking? I attempted to address this question using the stable and soluble version of
galectin-9 (ssGal9)131 expressed in Chapter 2 in the Jurkat T cell model. As shown in
Figure 3.16, however, addition of ssGal9 (0.25 µM) resulted in removal of Jurkat cells
from their live, “Jurkat cell” gate, which I interpreted as promoting cell death, a known
function of galectin-9118. Following starvation and stimulation with aCD3/aCD28, the
percentage of parental cells in the “Jurkat cell” gate was approximately 13%, similar to
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Figure 3.16) Stimulating Jurkat cells in the presence of ssGal9 promotes T cell death
(A) Flow cytometry analysis of parental Jurkat reporter cells stimulated with
aCD3/aCD28 (1 µg/ml of each) alone (left panel) or in the presence of 0.25 µM ssGal9WT
(middle panel) or ssGal9R200D (right panel). Initial analysis of all events by forward and
side scatter indicates that treatment with either ssGal9 construct reduces cells in “Jurkat
cell” gate.
(B) As observed in (A), stimulation of TIM-3+ Jurkat reporter cells with aCD3/aCD28
(1 µg/ml of each) alone (left panel) or in the presence of 0.25 µM ssGal9WT (middle panel)
or ssGal9R200D (right panel) results in loss of cells in the “Jurkat cell” gate.
(C) Quantification of the percent of total events in the “Jurkat cell” gate for parental
(black bars) cells or TIM-3+ (red bars) cells stimulated as in (A) alone (open bars), or in
the presence of 0.25 µM wild-type ssGal9 (dark blue shaded bars) or ssGal9R200D (dark
green shaded, dotted bars). Data and error bars represent mean and SD for n=2.
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that of TIM-3+ cells. Upon stimulation in the presence of ssGal9, both parental and TIM3+ cells had less than 1% in the “Jurkat cell” gate (Figure 3.16A-C). Importantly, this
effect of ssGal9 was independent of TIM-3, as it was observed in both parental and TIM3+ Jurkat reporter cells. This finding is in line with previous work in the literature, which
has shown that galectin-9 promotes cell death independent of TIM-3 expression117.
Although this effect of ssGal9 did not appear to involve TIM-3, the ability of ssGal9 to
crosslink other glycosylated molecules may well be important, as the effect of ssGal9
was diminished when one of the carbohydrate recognition domains was mutated (green
plots in Figure 3.16A,B; green filled bars in Figure 3.16C).
In an attempt to explore the effect of ssGal9 on T cell signaling, I reduced the
concentration of ssGal9 until a substantial population of cells remained in the “Jurkat
cell” gate, which occurred at approximately 0.03 µM ssGal9 (Figure 3.17A). However,
the effect of ssGal9 was again independent of TIM-3. Stimulation of Jurkat reporter cells
in the presence of ssGal9 enhanced expression of the GFP reporter downstream of NFκB by about 3.5-fold compared to parental cells stimulated in the absence of ssGal9
(Figure 3.17B,C), in line with previous reports in the literature118. As observed in
Figure 3.16, crosslinking of glycoproteins the sort inferred in Chapter 2 appeared to be
important, as the effect of ssGal9 was substantially reduced when the C-terminal
carbohydrate recognition domain of ssGal9 was mutated (Figure 3.17B,C). Nonetheless,
these data show that ssGal9 impacts T cell function independent of TIM-3, as parental
cells do not express detectable levels of TIM-3. Although one function of galectin-9 may
be to impact the avidity of TIM-3 and PS, galectin-9 appears to have a broad range of
effects on T cells, at least some of which are independent of the effects of TIM-3–PS,
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Figure 3.17) Reduced concentration of ssGal9 promotes T cell activity independent
of TIM-3
(A) Initial flow cytometry analysis of forward and scatter for all events of parental Jurkat
reporter cells that were starved and stimulated (left panel) or starved and stimulated in the
presence of 0.03 µM wild-type ssGal9 (middle panel) or ssGal9R200D (right panel).
Compared to higher concentration of ssGal9 used in Figure 3.16, 0.03 µM preserved some
cells in “Jurkat cell” gate for analysis of GFP expression.
(B) Histogram of GFP expressed downstream of NF-κB activation for parental cell
stimulated alone (black curve) or in the presence of ssGal9WT (0.03 µM, dark blue curve)
or ssGal9R200D (0.03 µM, green dotted curve).
(C) Quantitation of stimulation in (B), plotting mean GFP MFI following stimulation alone
(open bar) or with wild-type (dark blue shaded bar) or R200D ssGal9 (dark green shaded,
dotted bar). Error bars represent standard deviation for n=2.
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and likely reflect the ability of this lectin to bind to a wide range of glycosylated
proteins.

3.4. Discussion
PS, a phospholipid component of the plasma membrane, not only binds to the immune
receptor TIM-3 as shown in Chapter 2, but, as shown here, is also capable of modulating
its activity in T cells. Beyond simply conjugating TIM-3-expressing T cells to surfaces
containing PS, PS binding TIM-3 promotes T cell activity, measured through a GFPbased transcriptional reporter of NF-κB activity, cytokine release, and changes in
phosphorylation of T cell signaling components. Direct addition of PS to the culture did
not substantially modulate TIM-3 activity, as PS was already expressed by the Jurkat
cells in culture. However, blocking PS binding, either with mutations that impair PS
binding or with antibody blockade, reduced the effect of TIM-3, indicating the
importance of this ligand in TIM-3 function in this context.
Interestingly, with either mutations or antibody, TIM-3 retains some – albeit
diminished – ability to increase T cell activity compared to parental cells. The mutated
variants of TIM-3 do not completely abrogate PS binding, as shown in Chapter 2, and
high levels or clustered PS in culture, as observed on activated cells107, could recover
some effect of PS binding. Alternately, the effect retained by the TIM-3 mutants may
reflect a baseline effect of the TIM-3 intracellular domain, which previous groups have
shown retains some function even in the absence of the extracellular domain57, and which
is supported by the residual activity observed with the PD-1—TIM-3 chimera in Figure
3.8. In the case of F38.2E2, the residual activity could result from unsuccessful
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competition with high levels of PS in culture. Alternately, F38.2E2 itself might cluster or
crosslink the receptor in a way that recovers some of TIM-3’s activity, diminishing some
of the effect of PS blocking. A third possibility is that this residual activity may reflect
contributions of galectin-9 or (an)other TIM-3 ligand(s). Several groups have suggested
that TIM-3 might bind multiple ligands simultaneously119,128, although this has not yet
been shown directly (other than by my work in Chapter 2 on PS/Gal9 binding).
CEACAM1 is not expressed in Jurkat cells122,125,174,175, and is thus an unlikely candidate
to explain any residual effect observed in these studies. Binding of galectin-9 to TIM-3,
on the other hand, is not impacted by F38.2E2173 and also should not be impacted by the
mutations made here, as the mutated residues are on the opposite face of the IgV domain
from the predicted glycosylation site of TIM-3 in this domain. Galectin-9 might therefore
crosslink or cluster the receptor to recover the effect of PS binding. Unfortunately, this is
difficult to test directly, as galectin-9 impacts T cells independent of TIM-3, as shown in
Section 3.3.8 and elsewhere in the literature117,153,157. Therefore, understanding the role of
galectin-9, and the effect of its ability to enhance avidity for TIM-3–PS binding will
require additional tools to either enhance its specificity for TIM-3 or mimic its
crosslinking ability.
Despite these limitations, the findings described here provide strong support for
PS as a ligand for TIM-3, and demonstrate the ability of PS to impact the signaling effect
of TIM-3 on T cell activity. Identifying relevant ligands for TIM-3 is especially important
given the recent interest in TIM-3 as a target in immune checkpoint blockade in cancer
therapy128. Indeed, several companies have put forward candidate antibodies targeting
TIM-3 into clinical trials, including MGB453176, Sym023177, BGBA425178,
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LY3321367179, and ICAGN02390180. Like the functional antibody F38.2E2 used here,
most antibodies currently being explored in the clinic share a key feature of blocking PS
binding, and not necessarily binding of galectin-9. The findings described here, however,
suggest that these antibodies should inhibit T cell activation promoted by TIM-3, which
is the opposite of the goal in immune checkpoint blockade. However, as noted above,
TIM-3 has been observed to have an inhibitory effect on T cell activity in Jurkat cells in
some cases, and blocking PS in this context could instead recover T cell function. These
discrepancies highlight the need to better understand which factor(s) dictate the ability of
TIM-3 to act as a co-stimulatory receptor in some cases, as seen here, and as a coinhibitory receptor in other cases. For example, understanding how different ligands of
TIM-3 impact its localization, as well as the phosphorylation of tyrosines in its C-tail,
might provide some insights into the dual function of these receptors. Future studies may
compare changes in C-tail phosphorylation and recruitment of signaling molecules
observed with wild-type versus mutated variants of TIM-3 with reduced PS binding
described here, as a first step towards this goal.
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CHAPTER 4. Conclusions
The overarching goal of my thesis was to improve our understanding of the regulation of
TIM-3 by the ligand phosphatidylserine (PS). Furthermore, I was interested in
understanding how this interaction might modulate the effect of TIM-3 on T cell activity.
TIM-3 is a novel therapeutic target in cancer that is currently being investigated in the
clinic, underscoring the importance of understanding the regulation of TIM-3.

4.1. TIM-3 binds PS with low micromolar affinity, and galectin-9 cross-linking
enhances TIM-3–PS binding
To begin addressing this objective, I first investigated the interaction of human TIM-3
with lipid membrane surfaces containing PS. Using surface plasmon resonance, I
determined that TIM-3 recognizes surfaces containing 10%-20% PS with a low
micromolar affinity, and addition of calcium enhanced PS binding. The binding of TIM-3
to PS-containing surfaces was weaker than that of its relatives TIM-1 and TIM-4, but was
in the range with the affinities of other T cell co-receptors for their ligands, including
CD28 and PD-1154,155. TIM-3 displayed increased binding for surfaces containing PS over
those with phosphatidic acid (PA), and did not bind to surfaces containing
phosphatidylethanolamine (PE). Furthermore, addition of PA to membranes containing
PS enhanced the binding of TIM-3, along with the other TIMs. Therefore, the key
difference between the members of the TIM family appears to be in the affinity of their
interactions with lipid membranes containing PS.
I also identified mutated variants of TIM-3 that displayed reduced PS binding.
These mutated variants were modeled from the co-crystal structure of the murine TIM-3
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IgV domain with a short chain PS. Binding studies performed here indicate that, in
addition to the coordination of the PS headgroup by calcium, hydrophobic interaction
between PS acyl chain and residues in the loops at the edge PS binding pocket are
important for PS binding, as mutation of these residues dramatically decreased binding.
The extracellular domains of mutated TIM-3 were expressed as soluble protein,
indicating they were not aggregated. These variants were thus useful tools in assessing
the impact of PS on TIM-3 activity in cells in Chapter 3.
Lastly, I investigated the role of galectin-9 in modulating the ability of TIM-3 to
bind PS. I confirmed that the bivalent galectin-9 is capable of crosslinking multiple TIM3 molecules. Furthermore, I showed that galectin-9 enhances the avidity of TIM-3 for PS.
This activity of galectin-9 required both of its carbohydrate recognition domains,
suggesting that galectin-9 crosslinking of TIM-3 was responsible for the enhanced PS
avidity. These data support the ability of multiple ligands to coordinately regulate the
activity of TIM-3, which has been proposed by several groups, but has not been explored
biochemically.

4.2. PS promotes the T cell co-signaling activity of TIM-3
Having characterized the binding of PS and TIM-3, I next aimed to understand how this
interaction impacts TIM-3 function. I selected the Jurkat T cell line as a cellular model in
which to study the effect of TIM-3. In this system, I observed that expression of TIM-3
promotes T cell signaling, quantified by enhanced NF-κB activity and cytokine secretion.
These data support the ability of TIM-3 to display co-stimulatory activity in some
contexts. Although minimal changes were observed in many components of the T cell
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receptor (TCR) cascade, cells expressing TIM-3 did display enhanced phosphorylation of
CD28, a co-stimulatory receptor, suggesting one potential mechanism for TIM-3’s costimulatory activity. TIM-3 did not require engagement of CD28 for its co-stimulatory
effect, but the effect of TIM-3 was enhanced when stimulating with αCD28 and αCD3
compared to αCD3 alone.
Having explored the stimulatory role of TIM-3, I next asked if ligand binding, and
specifically PS binding, was important for this function. Studies using chimeric receptors
indicated the importance of ligand binding of TIM-3 for its activity. Furthermore,
chimeric receptors that maintained the ability to bind PS preserved the co-stimulatory
effect of TIM-3. Phosphatidylserine was found to be exposed in Jurkat cell culture, and
thus was present to serve as a ligand for TIM-3, as well as TIM-1-3 and TIM-4-3
chimerae – as it is likely to be in all cell culture studies in the literature. Although
manipulation of PS exposure in culture proved difficult, modifying PS binding indicated
a role for PS in regulating the effect of TIM-3 on T cell activity. Indeed, mutating TIM-3
to reduce its PS binding or blocking the PS binding site pharmacologically (with an
antibody) reduced the function of TIM-3. These data therefore strongly support a role for
PS as a functional ligand of TIM-3 that, in this context, promoted TIM-3’s co-stimulatory
activity.
I also asked whether galectin-9 crosslinking of TIM-3 impacted the effect of PS.
However, as expected, galectin-9 modulated T cell activity even in the absence of TIM-3
expression, making these studies particularly difficult to complete. Additional studies
aiming to explore the impact of the combination of both galectin-9 and PS on TIM-3 will
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need to either enhance the specificity of galectin-9 or utilize another tool to crosslink
TIM-3.

4.3. Understanding TIM-3 ligand regulation to enhance its utility as a therapeutic
target
The work described here shows that PS is an important ligand of TIM-3, and that PS is
capable of modulating the activity of this co-receptor in T cells. The focus T cell function
in the studies described here was motivated in part by the interest in TIM-3 as a target in
immune checkpoint blockade (ICB). In ICB, blocking the interaction of PD-1 with its
ligand reactivates the anti-tumor immune response, pointing to additional T cell cosignaling receptors, such as TIM-3, as targets of interest to enhance patient responses.
Indeed, TIM-3 is co-expressed with PD-1 on the most exhausted and dysfunctional T
cells, and combination targeting of PD-1 and TIM-3 can enhance the activity of these
cells95-97. In the context of a tumor, PS-exposing apoptotic cells or activated T cells107 in
the tumor microenvironment could engage TIM-3 on T cells to reduce their activity.
However, my findings using the Jurkat T cell model support a stimulatory role for the
interaction of TIM-3 with PS, suggesting that blocking this interaction would inhibit,
rather than enhance T cell anti-tumor activity. Conversely, other published studies have
shown that TIM-3 can have an inhibitory effect in some cases, even in the Jurkat cell
line58,59. Since the determinants of the direction of TIM-3 activity remain unclear, we
cannot rule out that PS might contribute to inhibitory effects of TIM-3 in those studies. If
so, blocking the interaction of TIM-3 and PS, a common feature of many tool and
therapeutic antibodies128,173, could promote T cell activity, as is desired in ICB. As future
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studies continue to investigate the specific contexts that permit TIM-3 to both promote
and inhibit T cell activity, it will be important to explore how PS-binding contributes to
the effects of this co-receptor to understand the impact of targeting TIM-3 in cancer.
Enhancing the utility of TIM-3 as a cancer therapy will also involve a better
understanding of which cells respond to immune checkpoint blockade, and the specific
role of TIM-3 in these cells. Combination targeting of PD-1 and TIM-3 enhanced antitumor immunity in mouse models95,96, supporting the notion of targeting other T cell coreceptors expressed on dysfunctional T cells with PD-1 in cancer. However, more recent
work has suggested that it may not be the exhausted, TIM-3+ T cells that respond to PD-1
blockade, but rather a distinct T cell subset that retains some progenitor-like function and
does not express TIM-3181-183. Interestingly, expression of TIM-3 has been reported to
promote differentiation of effector T cells, perhaps at the expense of T cells that permit
long-lived memory101. In this case, blocking TIM-3 might still be able to modulate the
progenitor-like T cell population to enhance anti-tumor immunity. Going forward, it will
be important to understand the role of PS, and possibly other ligands, in regulating TIM-3
activity in these cells to understand how antibodies targeting TIM-3 might be used in the
clinic. Indeed, many of the anti-TIM-3 antibodies proceeding through clinical trials block
the PS binding site176-180, similar to the tool antibody F38.2E2 used here. Although preclinical studies have suggested an effect of anti-TIM-3 antibodies in tumor models as
previously discussed, early clinical trials have not reported strong success of some of
these candidate molecules184,185. These studies are still in early phases with relatively
small numbers of patients with severe disease. Even still, the lack of clear response
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highlights the need to enhance our understanding of how PS regulates TIM-3 in distinct T
cell subsets and what the impact of blocking this receptor-ligand pair might be.
In addition to T cells, TIM-3 is also expressed on other cells in the immune
system, such as NK cells, dendritic cells, and macrophages. On macrophages, expression
of TIM-3 permits phagocytosis of apoptotic cells71,72. The impact of PS on TIM-3
function in other cell types is largely unexplored. However, the ability of PS to modulate
the impact of TIM-3 on T cell signaling motivates additional studies to understand how
TIM-3 function is regulated by its ligand PS in these contexts. Dixon and colleagues
(2021) very recently showed that TIM-3 expression on dendritic cells, but not on T cells,
is responsible for reduced anti-tumor immunity105. Because many of the functional TIM-3
antibodies block the PS-binding site on TIM-3128,173, these findings might also suggest
that PS binding contributes to TIM-3 function in DC cells. Blocking PS binding by TIM3 in the context of DCs could inhibit phagocytosis, but could also impact cell signaling,
as seen here in T cells. Therefore, further studies investigating the effect of PS–TIM-3
across different immune cell types, in addition to T cells, will be important for identifying
which cells should be targeted by TIM-3 blockade to enhance anti-tumor immunity.
Furthermore, such studies might shed light on the determinants of stimulatory versus
inhibitory activity of TIM-3, which still remain unclear.
TIM-3 biology is clearly complex, as this receptor is expressed on multiple types
of immune cells, and might be regulated by several ligands – either independently or in
combination. A systematic understanding of the effect of each ligand, including PS, on
TIM-3 function in each cell type will be important to understanding TIM-3 biology. With
such knowledge, it should be possible to develop a better understanding of the contexts
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where TIM-3 is inhibitory and stimulatory, and therefore, where and when it might be
most effective to target TIM-3 to achieve optimal patient responses in cancer. As TIM-3
antibodies advance in the clinic, the results from clinical trials may also help us to better
understand the biology of this unusual receptor. Across the many cell types where TIM-3
is expressed, understanding the role of PS binding should be considered a priority, as the
findings described here indicate it is indeed a functional ligand of TIM-3.
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